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Abstract 
Osteoarthritis (OA) is a highly disabling pathology which is worldwide investigated by the scientific 
community due to its increasing diffusion. The incidence of this age-related disease is increasing with 
population ageing and worldwide estimates indicate that 9.6% of men and 18% of women with more 
than 60 years present OA-related symptoms.  
Osteoarthritis induces the progressive damage of articular cartilage and subchondral bone and can 
eventually lead to the complete loss of joint functionality. Nowadays, the management of OA includes 
non-pharmacological, pharmacological, and surgical treatments. Non pharmacological approaches 
include exercise, weight loss, and physiotherapy and are used in conjunction with pharmacological 
treatments. The pharmacological management of OA patients is mainly based on the use of anti-
inflammatory drugs for pain control. Hence, the pharmacological approach to OA patients is 
synptomatic, but not resolutive, since it is not able to alter the progression of the disease. These 
therapeutical options are not suitable for late stage OA patients, whereby the severe pain and the 
functional limitations caused by advanced OA degeneration are currently resolved by joint replacement. 
Due to the low self-repair ability of articular cartilage, untreated cartilage lesions can easily degenerate 
into OA. Different strategies have been developed to treat promptly chondral lesions, comprising cell-
based therapies, such as autologous chondrocyte implantation (ACI). These cell-based therapies have 
been recently proposed also for the treatment of early OA patients in order to overcome or at least 
delay the need for a more invasive intervention such as joint replacement.  
However, major issues associated to the clinical use of autologous articular chondrocytes (ACs) are the 
limited number of cell harvestable from a small cartilage biopsy and the de-differentiation process 
occurring during the expansion phase required to achieve a clinically relevant number of cells. 
Furthermore, advanced age and pathological state of joints negatively affect the chondrogenic potential 
of ACs, representing important factors to be considered when applying chondrocyte-based therapies in 
particular categories of patients. In view of a possible use of autologous cell-based therapies for OA 
patients, we analyzed specific features of ACs as cellular yield, cell doubling rates and the dependence 
between these parameters and patient-related data in a set of 211 OA patients undergoing total joint 
replacement (Chapter 3). The patient age was not statistically correlated to the cellular yield, but was 
negatively correlated with the proliferation rate. No significant correlation was observed between the 
level of cartilage degeneration (ICRS score) and cellular yield and proliferation rates. However, in 
samples with the highest degree of cartilage degeneration (ICRS score 4) the cellular yield was lower 
compared to the other three groups (ICRS scores 1-3). In conclusion, we found that age and 
degenerative state of cartilage affect some basic parameter of articular chondrocytes and should be 
considered when evaluating the quality of the cell source to be used in clinical applications. 
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To overcome some of the limitations related to the use of ACs, mesenchymal stem cells (MSCs) present 
in several tissues, such as bone marrow and fat, have been proposed as cell candidate for cartilage 
treatment thanks to their demonstrated chondrogenic ability. When developing treatments for knee 
chondral lesions, infrapatellar fat pad and knee subcutaneous adipose tissue, two fat depots easily 
accessible during knee surgery, can be considered appealing sources for MSCs harvesting. We 
performed a donor-matched comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee 
subcutaneous adipose tissue stem cells (ASCs) obtained from OA patients undergoing total knee 
replacement, analyzing their immunophenotype and multi-differentiative ability, with a focus on their 
osteogenic and chondrogenic potential (Chapter 4). We found that these cell populations share 
common features at the undifferentiated state, such as immunophenotype and clonogenic potential, 
but display a specific commitment towards the osteogenic and chondrogenic lineage. Indeed, 
significantly higher levels of osteogenic markers, as calcified matrix deposition and alkaline phosphatase 
activity, were found in ASCs, highlighting the superior osteogenic commitment of this cell population in 
comparison with IFP-MSCs. Conversely, IFP-MSCs differentiated towards the chondrogenic lineage by 3D 
pellet culture showed greater glycosaminoglycans (GAGs) deposition and higher expression of 
chondrogenic genes as aggrecan (ACAN) and type II collagen (COL2A1) compared to ASCs pellets, 
revealing a superior chondrogenic potential. This result was supported by lower expression of 
hyperthrophic and fibrotic markers, as type X (COL10A1) and type I (COL1A1) collagen, in IFP-MSCs 
pellets compared to ASCs. The observed dissimilarities indicate that populations of adipose-derived 
MSCs harvested from different anatomical sites have specific features that suggest their preferential use 
for specific cell-based applications. 
In the last decade, the co-culture of ACs and MSCs has gained growing interest to investigate the cross-
talk between these cell types and to evaluate the possibility of replacing a fraction of ACs with MSCs, in 
order to reduce the in vitro expansion phase of ACs and subsequently limit their de-differentiation. 
Controversial results have been reported on the possibility to generate cartilage-like matrix by co-
culturing ACs and MSCs, indicating a prominent role for the origin and de-differentiation state of 
chondrocytes as determinants of the outcomes. We evaluated whether the co-culture of IFP-MSCs and 
ASCs with a small fraction of ACs was able to lead to cartilage-like matrix generation and to the 
expression of chondrogenic markers comparable to ACs (Chapter 5). To better resemble a possible 
clinical application of this strategy we performed autologous co-cultures combining IFP-MSCs and ASCs 
with expanded and cryo-preserved donor-matched ACs and we used cells derived from OA patients so 
as not to neglect the impact of the pathological and de-differentiated state of ACs on the outcome of 
the co-cultures. Chondrogenic genes SRY (sex determining region Y)-box 9 (SOX9), COL2A1, and ACAN 
were less expressed in co-cultures compared to ACs mono-cultures. No significant differences were 
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observed for GAGs/DNA in mono-cultures, demonstrating the reduced chondrogenic potential of ACs, 
probably deriving by both their pathological origin and their de-differentiated state. Total GAGs 
content in co-cultures did not differ significantly from values predicted as the sum of each cell type 
contribution corrected for the co-culture ratio, as confirmed by histology. Therefore, a small 
percentage of expanded and cryopreserved ACs did not lead to IFP-MSCs and ASCs chondro-induction. 
Our results suggest that chondrogenic potential and origin of chondrocytes play a relevant role in the 
outcome of co-cultures, indicating the need for further investigations to demonstrate their clinical 
relevance in the treatment of aged osteoarthritic patients. 
As aforementioned, chondrogenic differentiation of both ACs and MSCs is usually performed in 3D 
culture models that partially mimic the 3D environment of cartilagineous matrix such as culture in 
pellets and in 3D scaffolds. Pellet culture is widely used in the field of cartilage tissue engineering to 
test and optimize differentiation protocols. These experiments normally require to prepare replicates 
from a relevant number of donors to investigate different culture conditions. Unfortunately, handling a 
high number of samples in 3D pellet culture is extremely time consuming and is a major issue in 
experiments with many different conditions. To overcome these limitations, we exploited low-cost 
rapid prototyping techniques, such as laser ablation and replica molding, to generate multi-well chips in 
polydimethylsiloxane (PDMS) for the formation and culture of cell aggregates (Chapter 6). Each PDMS 
chip allowed the simultaneous culture of several pellets leading to a significant reduction in the time 
required for pellet seeding and medium refresh operations. Proliferation and metabolic activity were 
comparable between pellets of ACs cultured in PDMS chips and pellets cultured in polypropylene 
tubes, whereas type II collagen deposition was increased in pellets cultured in the PDMS chips. The 
same rapid prototyping approach was applied to generate a patterned scaffold. As a proof of concept, 
we biofabricated a multi-well implantable constructs using clinically approved fibrin glue. We 
demonstrated that regions with different cell densities can be generated within the construct and that 
cells can be distributed in a spatially controlled way. These multi-well implantable scaffolds can be 
seeded with multiple cell types allowing the precise distribution of different cell populations, thus 
representing a useful tool to investigate in vitro and in vivo cell interactions in a 3D environment. 
The introduction of engineered tissue into the clinical practice implies the achievement of high quality 
and safety  standards. The use of automated bioreactor-based manufacturing can significantly increase 
the reproducibility of the results, being minimally affected by operator variability. Furthermore dynamic 
culture systems, such as perfusion bioreactors, represent a smart approach to overcome the limitations 
encountered in the static culture of 3D constructs having clinically relevant dimensions. Indeed, 
perfusion bioreactors have been shown to increase the homogeneity of cell distribution within the 
scaffold compared to static cell seeding. Perfusion culture provides a continuous and homogeneous 
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influx of fresh medium throughout the construct, improving the quality and homogeneity of the 
extracellular matrix. The use of optimized protocols for the expansion and re-differentiation of ACs 
employing clinically approved growth factors is another key step to achieve a successful outcome and to 
grant the clinical translability of the results. Thus, in collaboration with the group supervised by Prof. 
Frédéric Mallein-Gerin (Institut de Biologie et Chimie des Proteines, Lyon, France) we tested the 
combination of a specific cocktail of clinically approved growth factors with a bi-directional perfusion 
bioreactor (OPB, Oscillating Perfusion Bioreactor) with the aim of improving cartilage matrix production 
(Chapter 7). We established a perfusion program including phases of high and low perfusion speeds to 
alternate sequences of cell stimulation and matrix deposition and we compared collagen sponges 
seeded and cultured in dynamic conditions with sponges seeded and cultured in standard static 
conditions. We found that perfusion improved cartilage matrix deposition within the sponges, in 
comparison with static conditions. More precisely, in the sponges cultured in the bioreactor a 
cartilaginous matrix rich in type II and type IX collagen and GAGs, with no signs of hypertrophy, was 
produced. Furthermore, a lower amount of type I collagen was produced in the sponges cultured in 
dynamic conditions, indicating that perfusion limits the risk of fibrocartilage formation. In conclusions, 
the dynamic culture by means of a perfusion bioreactor combined with the use of a cocktail of clinically 
approved growth factors proved to be effective for the generation of engineered cartilagineous grafts, 
improving the homogeneity and quality of the extracellular matrix generated by articular chondrocytes 
seeded within collagen sponges. 
Aged patients with late stage OA involving an extensive erosion of articular cartilage and exposure of the 
underlying subchondral bone cannot be treated with cell-based therapies or standard surgical 
approaches aiming at cartilage restoration. In these patients, joint replacement is currently the only 
clinical option to restore the articular function. The insufficient implant stability is an important 
determinant in the failure of cementless prostheses, leading to an increase in the risk of implant 
mobilization and in the number of revision procedures, with major drawbacks for patients and for 
National Health Systems. With the aim of increasing implant osseointegration, porous metallic materials 
have been developed and applied to cementless implant technology to maximize bone ingrowth and 
bone-implant contact. More recently, the enrichment of porous titanium with growth factors has been 
proposed as a novel strategy to further improve implant osseointegration. We combined a macroporous 
titanium (Trabecular Titanium™, TT), currently used in the clinical practice, with a biocompatible 
hydrogel (amidated carboxymethylcellulose, CMCA) able to encapsulate osteoinductive factors and 
osteoprogenitor cells (Chapter 8). In particular, we chose strontium as osteoinductive factor and bone-
marrow derived MSCs (BMSCs) as osteogenic progenitor cells for implant enrichment. We tested 
different concentrations of SrCl2 to select the optimal concentration to induce BMSCs differentiation. 
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We found that SrCl2 at 5 µg/ml significantly increased calcified matrix deposition, type I collagen 
(COL1A1) expression and alkaline phosphatase activity, being the most effective concentration among 
the ones tested. The enrichment of TT with CMCA (TT+CMCA) significantly increased cell retention 
within the implant, representing an important improvement in view of a future clinical application of the 
bioactive implant. Furthermore, we found that BMSCs cultured in TT+CMCA in the presence of SrCl2 
underwent a more efficient osteogenic differentiation, as demonstrated by higher alkaline phosphatase 
activity and calcium levels. Based on these in vitro results, we performed an in vivo study to evaluate the 
performance of the bioactive implant generated combining the macroporous titanium with strontium-
enriched CMCA and BMSCs (Chapter 9). To mimic implant-bone interaction, an ectopic model was 
developed grafting TT implants into decellularized bone seeded with human BMSCs. TT was loaded or 
not with strontium-enriched CMCA and/or BMSCs and constructs were implanted subcutaneously in 
athymic mice. Osteodeposition at the bone-implant interface was investigated with fluorescence 
imaging, micro-CT, scanning electron microscopy (SEM), histology and biomechanical testing at different 
time points. Micro-CT analysis demonstrated the homogeneity of the engineered bone in all groups, 
supporting the reproducibility of the ectopic model. Fluorescence imaging, histology, SEM and pull-out 
mechanical testing showed superior tissue ingrowth in TT implants loaded with both strontium-enriched 
CMCA and BMSCs. In our model, the synergic action of the bioactive hydrogel and BMSCs increased both 
bone deposition and TT integration, indicating that the generation of bioactive implants able to promote 
bone deposition is a promising strategy for the improvement of implant osseointegration. 
Joint inflammation is an important trait of osteoarthritis, indeed synovitis is observed in various degrees 
in OA patients, with OA synovium showing a mixed inflammatory infiltrate mainly consisting of 
macrophages. The central role of macrophages in OA evolution supports the interest in investigating 
their response to signals typical of OA joints, such as the ones contained in the synovial fluid (SF) of OA 
patients. In collaboration with the Connective Tissue Cells and Repair group supervised by Prof. Gerjo 
J.V.M. van Osch (Erasmus MC, Rotterdam, The Netherlands), we investigated the effect of SF from OA 
patients on the transcriptional expression of anti-inflammatory and pro-inflammatory mediators in 
monocyte-derived macrophages (Chapter 10). SF from donors without any joint pathology was used as 
control, and the effect of the different types of SF was tested on non-activated macrophages (M0) and 
on macrophages activated by IFNγ and TNFα (M1 activation) or IL4 (M2 activation). We found that IL10 
and IL1ra were modulated by the treatment with OA SF in M0 and M2 conditions. The effect on IL10 was 
lost in M1 conditions probably due to the high up-regulation induced by the treatment with IFNγ and 
TNFα. Our results support the idea that arthritic SF is for macrophages a less pro-inflammatory 
environment compared to control SF. This may mimic the macrophage situation in the joint, where 
feedback mechanisms are induced to counteract the ongoing pro-inflammatory processes. 
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 Altogether our findings highlight the complexity and multiplicity of factors that should be considered for 
the development of successful cell based treatments for early and late OA patients. We found that basic 
features of articular chondrocytes were affected by donors age and cartilage degeneration. We also 
found that expanded OA ACs did not exert a significant chondroinductive effect on co-cultured MSCs, 
suggesting that the evaluation of the clinical relevance of this approach in OA patients should strongly 
consider the impact of the de-differentiation state and pathological origin of ACs. Further investigations 
in this field are needed to verify whether it is possible to replicate the results obtained using non-
expanded healthy ACs to co-cultures using expanded ACs from aged patients affected by osteoarthritis. 
These investigations may require the optimization of clinically approved protocols for expansion and re-
differentiation of OA chondrocytes as well as the implementation of three-dimensional and dynamic 
culture systems. We demonstrated that low-cost rapid prototyping techniques are a useful tool to 
develop high-throughput systems for the culture of 3D cell aggregates and to generate patterned 
scaffolds that allow the controlled spatial disposition of different cell types. We also showed that the 
use of perfusion bioreactors for the dynamic culture of 3D constructs can improve the quality of the 
engineered tissue, granting a more homogeneous and efficient distribution of nutrients and cells 
throughout the construct. In order to overcome the limitations related to the use of ACs, MSCs can be 
considered as promising alternative cell candidates. Here, the identification of specific subsets of MSCs 
displaying a peculiar commitment should drive the selection of the most suitable cell source. Indeed, as 
we demonstrated for IFP-MSCs and ASCs, despite common features, specific populations of MSCs 
harvested from different anatomical sites have intrinsic features that make them more or less suitable 
for a specific application.  
Cell-based therapies aiming at cartilage restoration cannot be currently applied to late stage OA 
patients. However, in this category of patients cell-based approaches can be developed to face issues 
that are critical in implant technology, such as poor osseointegration. As we proposed here, 
osteoprogenitor cells, osteoinductive factors, and macroporous metals can be combined to generate a 
bioactive implant with improved osseointegration ability. This approach could be used to generate “off-
the-shelf” implants pre-loaded with osteoinductive factors that can be seeded with autologous BMSCs 
with a fully intra-operative approach.  
Finally, when developing cell-based approaches for OA patients, the inflammatory state of the OA joint 
cannot be neglected. We found that macrophage transcriptional expression was affected by OA synovial 
fluid. This suggests that OA environments may also induce alterations in the re-implanted cells and 
highlights the need for better in vitro models to evaluate the response of cells and engineered tissues to 
a diseased environment.  
In conclusion, to develop novel cell-based approaches for the treatment of OA basic and translational 
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studies should take into account multiple factors that may affect the clinical outcome, such as the 
impaired phenotype of OA chondrocytes, the peculiar commitment of specific populations of MSCs, and 
the impact of inflammatory environment of OA joints.  
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Introduction 
Osteoarthritis (OA) is the most common type of arthritis worldwide and its diffusion is rapidly increasing 
with ageing populations (1). Worldwide estimates report that 9.6% of men and 18.0% of women with 
more than 60 years have symptomatic osteoarthritis, indicating that this pathology is not only a major 
source of pain and disability for patients, but represents also a consistent economic burden for National 
Health Systems (2).  
Osteoarthritis is a highly invalidating disease. Indeed, progressive degradation of articular cartilage and 
subchondral bone often leads to the complete loss 
of joint functionality, compromising patients quality 
of life (3,4). Ideally, the diagnosis of OA should 
occur at a very early stage allowing a prompt 
intervention to restore the damaged articular 
cartilage and to limit the progression of joint 
degeneration and the development of joint 
inflammation. Nowadays, OA is no longer 
considered an exclusively degenerative joint 
disorder, being related to changes in the synovial 
membrane such as the increased infiltration of immune cells, in particular macrophages, which secrete 
pro-inflammatory mediators and participate to cartilage degradation (5,6).  
Age, obsesity, excessive or unbalanced joint load are risk factors for OA development, however articular 
cartilage damage due to excessive "wear and tear" or traumatic events is one of the main determinants 
of OA. In damaged cartilage, a shift in equilibrium between anabolic and catabolic activities occurs, 
compromising the integrity of extracellular matrix (ECM) and subsequently the biomechanical properties 
of articular cartilage. As a result, an unbalanced load is transferred to the underlying bone during joint 
movement, inducing pathological changes in the subchondral bone. Bone overgrowth, leading to 
osteophyte formation, is indeed one of the main features of OA together with joint swelling induced by 
osteophyte formation and/or synovial fluid accumulation.  
A prompt intervention in the early phase of OA is critical to delay the need for joint replacement, which 
so far is the only clinical option available to treat late stage OA. Joint replacement, despite being a 
successful treatment for older patients, is not suitable for young or middle-aged patients who have a 
more active life, as demonstrated by the poorer outcomes of joint replacement procedures in this 
category of patients (7).  
The involvement of articular cartilage damage in the early phase of OA insurgence highlights the 
fundamental role of this tissue for a proper function of joints. Articular cartilage has a highly anisotropic 
Fig. 1. Comparison of healthy and osteoarthritic
knee joint. (Source: http://umm.edu)
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structure composed by multiple layers that differ in terms of matrix composition and organization (Fig. 
2) (8-12). Type-II collagen and proteoglycans are the 
main components of cartilage ECM. Thanks to their 
negative charges, proteoglycans are able to retain 
water molecules within the tissue, allowing the 
load-dependent deformation (8). Lack of 
vascularisation, low cellularity and the limited 
metabolic activity of chondrocytes, which are the 
only resident cell type, are key features of this 
tissue and are related to its low self-repair ability. 
Treatment options for the management of articular 
cartilage lesions include different surgical approaches. A first group of approaches can be defined as 
“marrow-stimulation techniques” and include subchondral bone drilling and microfracture technique 
(Fig. 3). These approaches are based on the recruitment of mesenchymal stem cells from bone marrow 
to the damaged tissue and on their participation to the healing 
process. However, these techniques fail to yield long-term 
solutions, leading to the development of fibrocartilage that 
lacks many of the mechanical properties of the hyaline cartilage 
that covers articular surfaces (13,14). In a second group of 
surgical approaches, the chondral defect is reshaped to a 
standard cylindrical defect and is replaced with osteochondral 
autografts or allografts (Fig. 4). The limited availability of 
autologous osteochondral grafts and the morbidity of the donor 
site are the main limitations of this approach, whereas 
osteochondral allografts are associated with a high risk of 
disease transmission. Furthermore, the implantation of 
osteochondral grafts requires the conversion of a chondral 
lesion into an osteochondral injury to perform the surgical 
procedure, which may negatively affect the functionality of the 
entire bone-cartilage unit (13,15).  
In order to overcome the limitations of the aforementioned 
approaches, cell-based therapies have been proposed for the 
treatment of cartilage lesions. According to the EMA definition 
(Regulation (EC) No 1394/2007), cell-based therapies are 
Fig. 2. Anisotropic structure of articular cartilage.
(Source: http://www.intechopen.com/)
Fig. 3. Microfracture technique.
(Source: http://www.eorthopod.com)
Fig. 4. Osteochondral autograft.
(Source: http://www.eorthopod.com/)
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advanced-therapy medicinal products (ATMPs) defined as “medicines for human use that are based on 
gene therapy, somatic-cell therapy or tissue engineering. They offer groundbreaking new opportunities 
for the treatment of disease and injury”. Articular cartilage has long been considered one of the most 
promising tissues for the application of cell-based approaches since it contains only one cell type, the 
articular chondrocytes (ACs), responsible for the production and deposition of highly specific 
extracellular matrix. Articular chondrocytes were the first cell type used in autologous cell-based 
therapies aiming at cartilage repair. Autologous chondrocyte implantation (ACI), proposed by Brittberg 
et al. for the treatment of knee chondral lesions (16), is a 
two-stage procedure (Fig. 5). During the preliminary 
surgery, a biopsy of articular cartilage is harvested from 
non-bearing areas and autologous chondrocytes are 
isolated and expanded in vitro. During the second 
surgery, expanded chondrocytes are implanted back in 
the damaged area. More recently, other approaches 
based on the use of autologous articular chondrocytes 
have been developed, such as matrix-induced 
autologous chondrocyte implantation (MACI), where a 
three-dimensional matrix is used instead of the periostal 
flap, and co.don chondrosphere®, where 3D spheroids of 
chondrocytes are implanted in the chondral defect. The clinical applicability of these approaches 
depends on the lesion size since the amount of harvestable tissue, and consequently the number of 
autologous chondrocytes that can be isolated, is limited to reduce the risk of generating secondary 
lesions and to minimize donor site morbidity. However, even for the treatment of small focal defects, 
chondrocytes need to undergo in vitro expansion prior to re-implantation to obtain a clinically relevant 
number of cells, which is related to major drawbacks such as chondrocyte de-differentiation (17). This 
limitation is even more relevant when considering the treatment of osteoarthritic patients who present 
extensive cartilage lesions and require a significantly higher number of cells, implying a longer phase of 
in vitro expansion and a deeper impact of the de-differentiation process on chondrocyte phenotype. 
Furthermore, the application of cell-based therapies involving the use of autologous chondrocytes in OA 
patients has to take into consideration that cells derived from aged and/or diseased patients display 
peculiar features that differentiate them from chondrocytes obtained from young and/or healthy 
patients. Indeed, increasing age negatively affects the proliferative and differentiative potential of ACs, 
as shown by the reduced proliferative and chondrogenic potential observed in chondrocytes harvested 
from middle-age and aged patients (18). Different studies have indicated OA chondrocytes as possible 
Fig. 5. Autologous chondrocyte implantation.
(Source: http://www.eorthopod.com/)
Introduction 
14 
candidates for chondral cell-based therapies (19-21), but more recent data have shown that these cells 
show a peculiar form of age- and stress-induced cell senescence, progressing over time due to the 
accumulation of DNA damage and impairing the ability of chondrocytes to participate to tissue 
homeostasis (22). Furthermore, the increased methylation of the promoter of SOX9 found in OA 
cartilage in comparison with healthy cartilage suggests that the cascade of chondrogenic genes induced 
by this transcriptional factor may be down-regulated in OA cartilage (23), thus at least partially 
explaining the differences in cartilage ECM observed between healthy and OA joints. 
To overcome the limitations in the use of articular chondrocytes, mesenchymal stem cells (MSCs) have 
been proposed as an alternative cell source for cartilage cell-based therapies. The presence in the bone 
marrow of non-hematopoietic stem cells was suggested by Friedenstein in 1968 (24). These cells were 
then named “mesenchymal 
stem cells” for their ability to 
undergo the mesengenic 
process differentiating into 
osteoblasts, chondrocytes, 
adipocytes, and myoblasts  
(Fig. 6) (25,26).  
Thanks to their proliferative 
and multi-lineage potential, 
MSCs represent nowadays an 
exceptional tool to design cell-
based therapies aiming at the 
reconstruction of 
mesenchymal tissues. The 
bone marrow is still the main and most investigated source of MSCs, but MSCs have been identified in 
other adult tissues such as adipose tissue. Subcutaneous fat was the first source of adipose-derived 
MSCs (27,28), since this tissue is readily available as waste material after liposuction surgery. More 
recently, the presence of ASCs has been shown in other adipose depots such as visceral adipose tissue 
(29), buccal fat pad (30), and orbital fat tissue (31). Adipose-derived MSCs have been successfully used 
in bone and cartilage applications (32-36), proving to be a relevant cell source for the development of 
musculo-skeletal cell-based therapies. Considering the development of cell-based approaches for the 
treatment of knee chondral defects, the infrapatellar fat pad and the knee subcutaneous adipose tissue 
can be considered appealing cell sources since they can be easily harvested during orthopaedic surgery 
without need to harvest bone marrow from the iliac crest. Despite several studies have demonstrated 
Fig. 6. The mesengenic process. Multi-differentiative potential of
mesenchymal stem cells. (Source: http://stemcellgurus.wordpress.com/)
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the multi-differentiative potential of MSCs from infrapatellar fat pad (37-41) and subcutaneous adipose 
tissue (27,42,43), an extensive and quantitative comparison of their potential as cell candidates for bone 
and cartilage application has not been reported yet. Indeed, in the few studies performing a comparison 
of IFP-MSCs and ASCs (44-46) gene expression data are not present (44,45) and the comparison is 
restricted to very few donors (46), therefore limiting the clinical relevance of the findings and indicating 
the need for a deeper insight in the features of these MSCs populations. 
In the last decade, several groups have focused on the co-culture of ACs and MSCs in order to 
investigate the mutual influences between these cell types and to evaluate the possibility of replacing a 
fraction of ACs with MSCs, in the attempt of reducing the in vitro expansion phase of ACs and its impact 
on the phenotype of ACs. Results from studies evaluating the co-culture of ACs with bone marrow-
derived (47-53) and adipose-derived MSCs (47,48,54,55) have highlighted the potential of this approach 
demonstrating that through the combination of these cell types it is possible to generate cartilagineous 
matrix. However, the studies displaying the most promising results employ either animal chondrocytes 
(50,51,55) or non expanded healthy chondrocytes (48,49), suggesting that the outcome of the co-
culture approach is strongly dependent on the origin and de-differentiation state of articular 
chondrocytes. Considering the application of a co-culture approach to aged OA patients, it is clear that 
the impact of origin and pathological features of chondrocytes cannot be neglected and needs further 
investigation. Indeed, the combination of pathological origin and de-differentiation state of ACs deriving 
from their in vitro expansion has been indicated as a determinant in the outcome of co-cultures 
between OA chondrocytes and BMSCs (53). Furthermore, to resemble the clinical use of autologous co-
cultures, in vitro and in vivo experiments should be performed with donor-matched MSCs and ACs, 
facing practical issues, such as the different proliferation rate and cellular yield of these cell types and 
inter-donor variability, issues that may 
greatly affect the final outcome and that 
are only partially considered in the current 
literature.  
According to one of the paradigms of 
Tissue Engineering, defined in 1993 as “the 
application of principles and methods of 
engineering and life sciences for the 
development of biological substitutes, to 
restore, maintain or improve tissue 
function”, the in vitro development of 
engineered tissues is usually achieved by 
Fig. 7. The Tissue Engineering paradigm. (Source: Ringe et al.,
Nat Rev Rheumatol. 2012)
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the combination of a suitable cell source, growth factors able to promote cell proliferation and/or 
differentiation, and a 3D scaffold that provides the template for tissue development (Fig. 7) (56). This 
paradigm implies the need for efficient three-dimensional (3D) models to investigate cellular cross-talks 
in co-cultured cells and to optimize protocols for cell differentiation. In the field of cartilage tissue 
engineering, 3D culture systems are widely used in basic and translational studies. Indeed, chodrogenic 
differentiation of ACs and MSCs is usually performed by pellet culture (57-61) or by cell culture within 
suitable 3D scaffolds (62,63). Pellet culture, which is traditionally obtained from cell centrifugation in 
polypropylene conical tubes (59), offers a favorable 3D structure for cells, enabling cell-to-cell 
interactions and enhancing the expression of a chondrogenic phenotype (64,65). Articular chondrocytes 
pellets are widely used in this field to test and optimize differentiation protocols. These experiments 
require to prepare replicates from a relevant number of donors to investigate simultaneously different 
culture conditions (66). Unfortunately, handling a high number of samples in 3D pellet culture is 
extremely time consuming and is a major issue in experiments with many different conditions. To 
overcome this limitation, in the last years, attention has been focused on the possibility to develop 
devices able to support the generation and the culture of multiple cell aggregates, which have a broad 
range of applications in the areas of tissue engineering, stem cells research and cancer models (67-70).  
Low-cost rapid prototyping approaches, widely used in 
the fabrication of microfluidics devices (71-75), can be 
exploited to generate these devices. Biofabrication 
technologies can also be applied to the generation of 
implantable scaffolds with a controlled architecture can 
be used as screening devices (Fig. 8) (76,77) as well as 
to mimic anatomical structures (78), with a broad 
range of applications in basic and translational 
research.  
The introduction of engineered tissues into the clinical practice implies high quality standards of the 
product to satisfy safety and efficacy requirements. The use of automated bioreactor-based 
manufacturing (Fig. 8) has been proposed as a way to increase the reproducibility of the result, being 
only minimally affected by operator variability, which has instead a big impact on the outcomes of 
standard cell culture procedures (79). Besides considerations on quality and safety requirements of 
engineered grafts, dynamic culture systems, such as perfusion bioreactors, represent a smart approach 
to overcome the limitations encountered in the static culture of 3D constructs (80-82). A specific 
advantage of direct perfusion bioreactors is the continuous influx of fresh medium and waste removal 
from the construct. Furthermore, the use of perfusion bioreactors increases the homogeneity of cell 
Fig. 8. Multi-well implantable scaffolds (Source:
Higuera et al., Integr Biol (Camb). 2013)
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distribution within the scaffold compared to static cell seeding, favoring the generation of homogeneous 
matrix throughout the scaffold (83).  
As aforementioned, the 
optimization of protocols for cell 
expansion and re-differentiation is a 
key step in the generation of 
engineered tissues. In the last years, 
different protocols have been 
tested in order to reduce the 
negative impact of the in vitro 
expansion on the phenotype of 
articular chondrocytes and to 
improve their re-differentiation 
(59,84,85). These protocols include 
the use of soluble growth factors 
such as transforming growth factor 
beta (TGF-β), basic fibroblast growth factor (bFGF), insulin growth factor (IGF) and members of the bone 
morphogenetic proteins (BMPs) family. If the definition of the optimal combination of growth factors for 
cell expansion and chondrogenic differentiation is complex due to multiple variables in the experimental 
set-up of published studies (i.e. duration of expansion phase, origin of articular chondrocytes, source of 
MSCs, growth factors concentration, basal medium composition), a more general consideration is 
related to the possibility to translate the results obtained in vitro into the clinical practice. Indeed, the 
re-implantation of cells and cell-based products in human beings in naturally correlated to safety 
concerns, that imply the need to use clinically approved growth factors during cell expansion and 
differentiation.  
Promising cocktails of clinically-approved growth factors have been optimized for the expansion (FGF-2 
and Insulin, FI) and re-differentiation of ACs (BMP-2, Insulin and T3, BIT) (86). The sequential addition of 
these growth factors has been shown to induce the production of cartilagineous matrix when ACs were 
re-differentiated within collagen sponges. Nevertheless, matrix deposition was confined in the 
peripheral region of the scaffold, indicating the inefficient perfusion of nutrients and growth factors in 
the scaffold core (86). To overcome the limitations of static culture, combining dynamic culture systems 
with clinically approved protocols for cell expansion and differentiation appears as a promising approach 
to engineer in vitro clinically relevant grafts. Indeed, the use of automated bioreactors may allow to 
overcome major limitations encountered in the static culture of 3D constructs, that are directly 
Fig. 9. (A) Schematic of a standard perfusion bioreactor system with
its imple mentation. (B) Schematic and photograph of an oscillating
perfusion bioreactor exploiting a pump-less perfusion method
(Source: Courtesy of Ske s.r.l.)
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correlated with the increasing size of the engineered graft, and would increase the clinical translability 
of the results thank to improved compliance to quality and safety standards.  
Despite the great potential of cell-based therapies and tissue engineering approaches in the treatment 
of articular cartilage defects, currently these approaches are not clinically relevant when considering 
late stage OA joints, characterized by an 
extensive erosion of articular cartilage and 
exposure of the underlying subchondral bone. 
Cartilage erosion causes the unprotected bone 
to rub directly on the opposing bone, a 
condition associated with high morbidity and 
impaired articular functionailty. So far, in late 
stage OA patients joint replacement (Fig. 10) is 
the only option to restore the articular function 
and to improve patients quality of life. Implant 
technology, however, is not free from 
drawbacks and critical issues. In particular, poor 
osseointegration is a key factor in the 
mobilization of cementless implants, often 
leading to prosthetic failure and to the need for 
re-intervention. Hence, the improvement of 
osseointegration can lead to a reduction in the 
risk of implant mobilization and, consequently, 
in the number of revision procedures (87-89), 
which have major drawbacks such as patients 
morbidity and relevant costs for National Health 
Systems. Porous metallic materials, such as macroporous titanium, have been introduced in cementless 
implant technology to maximize bone ingrowth and bone-implant contact (90-93) and are used to 
produce prosthetic components (Fig. 11) and to fill cavitary and segmental bone defects. Besides surface 
and structure modifications, the implant enrichment with progenitor cells (94,95) and bioactive factors 
(96-103) is a fascinating approach to convert metallic implants from bioinert to bioactive. Autologous 
bone marrow concentrate, obtained with an intra-operative approach, improves bone healing (104). 
Indeed, a recent study has shown that the enrichment of acetabular components with autologous 
BMSCs is able to improve bone formation and bone-implant contact in a caprine animal model (94). 
Since aging and age-related diseases negatively affect bone healing (105), the enrichment of the 
Fig. 10. Representation of OA knee before and after total
joint replacement (Source: http://physioworks.com.au)
Fig. 11. Acetabular cup realized in macroporous titanium
(Source: Limacorporate s.p.a.)
Introduction 
19 
population of osteoprogenitor cells at the implant site may be particularly useful. Considering the 
clinical application of a prosthetic components enriched with autologous MSCs, cell retention into the 
implant may be critical due to the presence of body fluids. The use of biocompatible hydrogels in 
association with macroporous metals can be a promising strategy to overcome this limitation. Recent 
studies have demonstrated that bioactive hydrogels can be combined with metals to enrich implants 
with antibiotics (100,103), VEGF (101) and FGF-2 (102). Exploiting this approach for the simultaneous 
enrichment of progenitor cells and osteoinductive factors could represent a step further in the 
generation of bioactive prostheses with improved osseointegration potential. 
In conclusion, cell-based therapies and tissue engineering strategies have a great potential for the 
treatment of patients affected by osteoarthritis either at early or late stage (106,107). However, when 
considering the re-implantation of autologous cells, being them autologous chondrocytes and/or 
mesenchymal stem cells, the impact of the inflammatory state of OA joints cannot be neglected. 
Nowaday, in contrast to the original view of OA as a simply “wear and tear” disease, it is recognized that 
pro-inflammatory cytokines and mediators play a key role in the onset and progression of this disease 
(Fig. 12) (108-110).  This 
involves the recognition that 
implanted cell-based 
constructs may be subjected to 
the same inflammatory stimuli 
that contributed to the 
degradation of the original 
articular cartilage. In fact, 
inflammatory cytokines such 
as interleukin-1β (IL-1β) and 
transforming necrosis factor-α (TNFα), as well as conditioned medium from OA synovium or OA synovial 
fluid, can interfere with cartilagineous matrix deposition (111-113) and alter the phenotype of 
implanted cells (114,115).  
All these evidences highlight the need to develop in vitro models mimicking the environment of OA 
joint. These models can be exploited to test the performance of tissue engineered constructs in an 
inflammatory environment and should comprise the soluble factors as well as the cell types present in 
OA joints, such as macrophages. Activated macrophages secerning nitric oxide and proinflammatory 
cytokines like IL-1β and TNFα are accumulated in the synovium of early OA patients and drive the 
inflammatory process participating to synovitis (6). Furthermore, macrophages can directly participate 
to cartilage degradation thanks to the expression of catabolic enzymes such as matrix metallo-
Fig. 12. Involvement of synovium in OA pathophisiology. Scheme showing
the involvement of pro- and anti-inflammatory mediators and immune cells.
(Source: Sellam and Berembaum, Nat Rev Rheumatol. 2010)
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proteinases (MMPs) (116,117). Conversely, macrophages also release factors that are important for 
tissue repair and suppression of inflammatory response to tissue damage (118). Hence, OA progression 
might induce and/or be induced by an inappropriate differentiation of resident tissue macrophages, and 
imbalance between functionally distinct phenotype. This suggests that further investigation on the 
influence of stimuli typical of diseased joints on macrophage phenotype is needed to understand their 
role in OA joint and to develop proper models to investigate the applicability of tissue engineered 
products in a diseased environment.  
In order to evaluate basic and translational aspects related to potential cell-based approaches for early 
and late stage OA, in this thesis articular chondrocytes, adipose-derived mesenchymal stem cells, and 
their association were investigated in view of their potential use for the treatment of chondral defects. 
A multi-disciplinary approach was exploited to generate three-dimensional constructs and to develop 
novel strategies for the improvement of prosthetic implants. Finally, to better characterize the OA 
environment, the influence of stimuli typical of OA joint on macrophage phenotype was investigated. 
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Chapter 3 
Characterization of articular chondrocytes isolated from 
211 osteoarthritic patients 
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Abstract 
We analyzed specific features of chondrocytes as cellular yield, cell doubling rates and the dependence 
between these parameters and patient-related data in a set of 211 osteoarthritic (OA) patients 
undergoing total joint replacement. For each patient the data available were joint type, age and gender. 
Knee samples chosen randomly among all biopsies were graded according to ICRS score. Patients' age 
ranged between 30 and 90 years with a mean age of 66 ± 9.7 years. Patients were divided into age 
classes and statistically significant differences in proliferation rate at passage 1 were found between 
chondrocytes derived from young and old donors, with the last ones characterized by a lower 
proliferation rate. A similar trend was observed for proliferation rate at passage 2. For all the samples, 
cellular yields ranged between 0.1 and 5.5 million cells/g of tissue. No significant correlation was 
observed between the level of cartilage degeneration (ICRS score) and cellular yield and proliferation 
rates. However, in samples with a high degree of cartilage degeneration (ICRS score 4) the cellular yield 
was lower compared to the other three groups (ICRS scores 1-3). In this study we performed a 
systematic characterization of basic parameters of chondrocytes originating from a wide group of OA 
patients. Considering the use of autologous chondrocytes in chondral treatments, the characterization 
of cell basic features may represent an important step to determine the quality of the cell source which 
is a major determinant in the outcome of cell-based therapies. 
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Introduction  
Osteoarthritis (OA) is a highly disabling pathology which is worldwide investigated by the scientific 
community due to its increasing diffusion. This age-dependent degenerative disease induces the 
progressive damage of articular cartilage and subchondral bone and can eventually lead to the complete 
loss of joint functionality (1,2). The combination of pharmacological and non-pharmacological therapies 
has been proved to be useful for the treatment of early- and middle-stage OA patients, but a successful 
clinical outcome is not granted when treating late-stage OA patients (3). In this category of patients, the 
severe pain and the functional limitations caused by advanced OA degeneration are currently resolved 
mainly by joint replacement surgery. 
In the last two decades, “advanced therapies” have been intensely investigated in developed countries, 
with the aim to find a biological solution to several degenerative pathologies. In cartilage tissue 
engineering, a possible strategy for an autologous approach would be to isolate cells chondrocytes from 
a cartilage biopsy, to expand the cells and possibly cryopreserve them for future re-intervention. 
Expanded chondrocytes are then seeded on a biomaterial and the cellularized construct is finally 
implanted back to the patient (4). Cartilage tissue engineering applied to OA patients appears to be in 
contrast with the controversial opinion that healthy autologous chondrocytes or mesenchymal stem 
cells are necessary to obtain healthy cartilage in vitro (2,5,6). Recent works, however, have 
demonstrated the possibility to use human OA chondrocytes to obtain autologous engineered cartilage 
with properties similar to those of the constructs obtained from non-OA chondrocytes (7-10). Moreover, 
a recent work (11) on human OA articular chondrocytes characterized their genetic stability during long 
term expansion and demonstrated the safety of this cell type for autologous advanced therapies. Since 
the quality of cells used to generate the engineered tissue greatly influences the outcome, a 
characterization of OA chondrocytes in a wide patient group can help in extending the validity of the 
reported results. 
In this work we analyzed specific features of chondrocytes collected from 211 osteoarthritic patients 
undergoing total joint replacement. The characteristics investigated were cellular yield and cell doubling 
rates, and the dependence between these parameters and some patients-related data. 
 
Materials and Methods  
Chondrocyte isolation, expansion and data collection 
Samples of adult human articular cartilage were harvested from subjects undergoing hip and knee 
routine arthroplasty procedures. With the patient’s informed consent and in respect to the privacy law, 
the patient age, gender and joint type were recorded. Based on evaluation by orthopaedic surgeons, 
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random knee samples were also graded from score 1 to score 4 using the ICRS protocol (12), where 
higher scores indicate higher levels of cartilage degeneration. Minced cartilage fragments (2-3 mm2) 
were weighted and chondrocyte isolation was carried out by cartilage digestion in 0.15% collagenase 
type II (Worthington) performed for 22 h at 37 °C, as previously described (13). 
Viable cells were counted by trypan blue dye exclusion. Freshly isolated chondrocytes (P0) were plated 
for expansion at a density of 1*104 cells/cm2 for the first passage (P1) and cultured  with complete 
proliferation medium (CM) containing Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS, Lonza), 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/ml penicillin, 
100 g/ml streptomycin, 0.29 mg/ml L-glutamine, 1 ng/ml TGFb1, 5 ng/ml FGF-2 (PeproTech) (14). 
Where not otherwise specified, Invitrogen products were used. For the second passage (P2) cells were 
plated at a density of 0.5*104 cells/cm2. Cell doubling rate (d) was calculated as 
 
where N and N0 are the final and initial cell number, respectively, and t is the expansion time. The 
cellular yield was calculated as the ratio between the viable cell number at P0, expressed in millions of 
cells, and the wet weight of the cartilage fragments, expressed in grams.  
 
Data processing and statistical analysis  
The software Graph Pad Prism® was used to order and process the data. For each patient, the available 
data were joint type, patient age, patient gender, ICRS grading, cellular yield, doubling rate at P1 and at 
P2. Mean and standard deviation were calculated for each parameter and relative normalized frequency 
(2) histograms were obtained. The normalized frequency was calculated as  
 
where f is the frequency of the data inside the considered class, Sc is the spacing of the class and Ns is 
the sample size (132 patients for the hip group, 88 patients for the knee group). Relative normalized 
frequency histograms were also obtained for the scored knee cartilage samples. For all the relative 
normalized frequency histograms the Poisson distribution was calculated.  
Non normal distribution of data was determined with a D’Agostino & Pearson normality test. 
Correlation between patients’ age, cellular yield, and proliferation rate at P1 and at P2 was determined 
calculating the Spearman coefficient r and considered significant for p<0.05. To compare independent 
groups, Kruskal-Wallis test followed by Dunn’s multiple comparison test was performed and differences 
were considered significant for p<0.05. 
To better evaluate age-related differences in cellular yield and proliferation rate, patients were grouped 
in the following age classes: ≤60, 65-70, ≥75 years, composed of the same number of patients (n = 47). 
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Four years gaps between classes were left to avoid overlapping.  
Box-plots were used for the visualization of the main parameters of the data statistical distribution both 
for age classes and for ICRS score groups (minimum, 25th percentile, 75th percentile, maximum).  
 
Results 
Patients’ gender distribution showed that 42% of hip arthroplasties were performed on males and 58% 
on females (Fig. 1). For knee arthroplasties the percentage of male vs. female patients was 12% vs. 88%. 
Considering both arthroplasty 
types together, female 
patients were 69% of the 
total. Patients’ age ranged 
between 30 and 90 years and 
the frequency histograms 
showed a mean age of 66 
years, both for knee and hip 
patients (Fig. 2 a-c). The ICRS grading system was applied to samples of knee cartilage randomly chosen 
among the donors, to classify the samples from score 1 (low damage) to score 4 (high damage). The 
mean age of patients did not differ significantly between scores  and ranged from 65 to 69 years, as 
shown in frequency distribution graphs in Fig. 2d. 
Cellular yield values 
ranged between 0.1 
and 5.5 million 
cells/gram of tissue, 
with a mean of 
1.85±1.37 and 1.62 ± 
1.08 million cells/gram 
of tissue for hip and 
knee samples, 
respectively (Fig. 3 a-c). 
For the different ICRS 
scores, mean values of 
cellular yield were 
similar up to score 3 (about 1.4 million cells/gram of tissue), whereas it was lower for highly 
degenerated tissue (score 4, 0.9 million cells/gram of tissue). 
Fig. 1. Frequency distribution of patient gender. The patients, all affected by 
osteoarthritis, were subjected to total hip or knee replacement. 
Fig. 2. Relative normalized frequency distribution obtained for increasing classes of 
patient age for the hip (a), knee (b), total (c) and increasing ICRS scores (d). The 
frequency histograms are approximated by Poisson’s distribution 
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The analysis of the 
correlation between 
patients’ age, cellular 
yield and proliferation 
rate at P1 and at P2 is 
reported in Fig. 4 with 
the corresponding 
correlation coefficients 
(Spearman r).  
Significant correlations 
were observed between 
age and doubling rate at 
P1 (r = -0.223, p<0.01), 
showing a decrease of doubling rate at P1 with increasing age, and between doubling rate at P2 and at 
P1 (r = 0.343, p<0.001), demonstrating a trend between cell growth at both passages. A significant 
correlation was found also between cellular yield and proliferation rate at P2 (r = 0.268, p<0.001), 
suggesting that cells 
deriving from samples 
with a higher cellular 
yield, retain a greater 
proliferation potential 
during expansion.  
Pair wise comparison 
of data, grouped on 
the basis of age 
classes, homogeneous 
in size, are shown in 
Fig. 5.  
The average cellular 
yield did not 
significantly differ between age classes (Fig. 5a). We found statistically significant differences on 
proliferation rates at P1 between the age class ≤60 as compared to the ≥75, which was characterized by 
the lowest proliferation rate (Fig. 5b). Proliferation rates at P2 were higher than at P1, independently 
from the patient age (Fig. 5c).  
Fig. 3. Relative normalized frequency distribution obtained for increasing classes of 
cellular yield for the hip (a), knee (b), total (c) and increasing ICRS scores (d). The 
frequency histograms are approximated by Poisson’s distribution 
Fig. 4. Correlations among individual data groups. (a) cellular yield vs. patient age, (b) 
proliferation rate at P1 vs. patient age, (c) proliferation rate at P2 vs. patient age, (d) 
proliferation rate at P1 vs. cellular yield, (e) proliferation rate at P2 vs. cellular yield, 
and (f) proliferation rate at P2 vs. proliferation rate at P1. Correlation coefficients 
(Spearman r) are indicated in each graph. ** p<0.01, *** p<0.001. 
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No significant correlation was found among ICRS scores, cellular yields and proliferation rates at P1 and 
P2, as shown in Fig. 6. However, as the cartilage damage level increased, the mean cellular yield slightly 
decreased, whereas the proliferation rates did not differ with increasing scores. As already observed for 
data on hip and knee population, proliferation rates at P2 were higher than the rates at P1.  
 
Discussion  
OA is fully recognized as an age-dependent degenerative disease (15). Considering the high and 
increasing life expectancy in developed countries, osteoarthritis is assuming an important social effect. 
Coherently, countermeasures to OA such as cellular therapies are intensely investigated (16). In this 
study, adult human articular chondrocytes were isolated from anatomical specimens discarded during 
total joint replacement, with the aim to characterize them in view of their potential use as source for 
autologous cell therapy. More than two-hundred OA patients were included in this analysis, which 
required, for our institution, a period of four years for data collection. Accordingly with literature (17-19) 
we found that the majority of patients subjected to total joint replacement were postmenopausal 
women. The age of patients in our analysis ranged from 30 to 90 years old, but the frequency 
distributions showed that the highest amount of patients belonged to the range 65-70 years. The pair-
wise analysis of data on cellular yield and proliferation rates showed that the patient age is not 
statistically correlated to the cellular yield, as in (20), but was negatively correlated with the 
proliferation rate at P1, which followed a trend analogue to the proliferation rate at P2. As already 
Fig. 5. Box plots showing pair-wise comparisons of grouped data pertaining to patient age and cellular yield classes 
homogeneous in size. (a) cellular yield vs. patient age, (b) proliferation rate at P1 vs. patient age, (c) proliferation 
rate at P2 vs. patient age. The values delimiting the box in the box plots are the 25th and 75th percentiles of the 
data distribution. * p<0.05. 
Fig. 6. Box plots (a-c) for the ICRS-scored knee cartilage samples. The values delimiting the box in the box plots are 
the 25th and 75th percentiles of the data distribution. 
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reported in the literature (21) for healthy chondrocytes, the most relevant reduction in cellular yield is 
observed between patients younger than 40 years and older patients, then with increasing age this 
feature remains almost constant. 75% of our patients are older than 63 years: this could explain the lack 
of significant influence of patient age on cellular yield. In accordance with previously published data on 
healthy chondrocytes (22), cell proliferation significantly decreased with increasing age at P1, but this 
significant correlation was not found between age and doubling rate at P2. A possible explanation can 
be found in the use of TGFβ1 and FGF2, growth factors able to increase the proliferation rate and to 
maintain the chondrocyte phenotype during the expansion procedures. This property is particularly 
useful when large amounts of cells are needed requiring a long-term expansion (14). Thanks to the use 
of TGFβ1 and FGF-2, chondrocytes started soon to proliferate. The offset difference in cell proliferation 
rates that we found between P1 and P2 is in accordance with previous work (23,24) and can be 
attributed to an initial lag phase where cells recover from isolation procedure. Interestingly, however, a 
relationship between the proliferation rate at P1 and at P2 was found in our data suggesting that cells 
with the lowest proliferation rate at P1 were also less proliferative at P2 and that the cells with high 
proliferation rate at P1 maintained this feature at P2.  
To correlate analyzed cellular parameters with the grade of cartilage degeneration, we evaluated 
random samples scored on the basis of ICRS scale. A lower cellular yield was observed in score 4 
specimens. This result can be attributed to the higher degeneration level of this tissue whereby the 
inflammatory state of the tissue can affect cellularity. The proliferation rates for samples with different 
scores are in accordance with previously reported results (25): score has a slight influence only on the 
initial phase of in vitro expansion, whereas cell proliferation during the subsequent passages was 
independent from the degeneration of the excised cartilage. 
In conclusion, our study allowed a systematic characterization of basic parameters as cellular yield and 
proliferation rates of chondrocytes originating from a wide group of OA patients. This characterization 
could be useful in view of a possible autologous cell therapy approach for osteoarthritis, as it is 
fundamental to determine the quality of the cell source, known to  greatly influence the outcome of 
engineered tissue.  
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Chapter 4 
Donor-matched mesenchymal stem cells from knee 
infrapatellar and subcutaneous adipose tissue of 
osteoarthritic donors display differential chondrogenic 
and osteogenic commitment  
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Abstract 
Cell-based therapies have been recently proposed for the treatment of degenerative articular 
pathologies, such as early osteoarthritis, with an emphasis on autologous mesenchymal stem cells 
(MSCs), as an alternative to terminally differentiated cells. In this study we performed a donor-matched 
comparison between infrapatellar fat pad MSCs (IFP-MSCs) and knee subcutaneous adipose tissue stem 
cells (ASCs), as appealing candidates for cell-based therapies that are easily accessible during surgery.  
IFP-MSCs and ASCs were obtained from 25 osteoarthritic patients undergoing total knee replacement 
and compared for their immunophenotype and differentiative potential.  
Undifferentiated IFP-MSCs and ASCs displayed the same immunophenotype, typical of MSCs 
(CD13+/CD29+/CD44+/CD73+/CD90+/CD105+/CD166+/CD31-/CD45-). IFP-MSCs and ASCs showed similar 
adipogenic potential, though undifferentiated ASCs had higher LEP expression compared to IFP-MSCs 
(p<0.01). Higher levels of calcified matrix (p<0.05) and alkaline phosphatase (p<0.05) in ASCs highlighted 
their superior osteogenic commitment compared to IFP-MSCs. Conversely, IFP-MSCs pellets showed 
greater amounts of glycosaminoglycans (p<0.01) and superior expression of ACAN (p<0.001), SOX9, 
COMP (p<0.001) and COL2A1 (p<0.05) compared to ASCs pellets, revealing a superior chondrogenic 
potential. This was also supported by lower COL10A1 (p<0.05) and COL1A1 (p<0.01) expression and 
lower alkaline phosphatase release (p<0.05) by IFP-MSCs compared to ASCs.  
The observed dissimilarities between IFP-MSCs and ASCs show that, despite expressing similar surface 
markers, MSCs deriving from different fat depots in the same surgical site possess specific features. 
Furthermore, the in vitro peculiar commitment of IFP-MSCs and ASCs from osteoarthritic donors 
towards the chondrogenic or osteogenic lineage may suggest a preferential use for cartilage and bone 
cell-based treatments, respectively. 
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Introduction  
The low self-repair ability of articular cartilage and the lack of treatments that can reproducibly restore 
defects at the bone-cartilage interface provide a major reason for the development of cell-based 
therapies for bone and cartilage repair (1-3). Joint replacement, considered a successful and standard 
procedure in the treatment of elder patients affected by osteoarthritis (OA), is controversial in patients, 
considered too young or active for conventional arthroplasty, who experience higher implant failure 
rates and earlier revisions (4,5). Thus, cell-based therapies have been recently proposed also for the 
treatment of middle-aged early OA patients to alter the progression of degenerative disease, with the 
hope of obviating or at least delaying the need for joint replacement (6). 
Mesenchymal stem cells (MSCs) have been investigated as an alternative to terminally differentiated 
cells to develop novel treatments for bone and cartilage defects, since they can be easily harvested from 
several adult tissues and are able to differentiate towards the osteogenic and chondrogenic lineages 
(7,8). Beside bone marrow MSCs (BMSCs), more recently adipose derived mesenchymal stem cells have 
been successfully used for bone and cartilage applications (9-13). In particular, MSCs resident in the 
infrapatellar fat pad (IFP-MSCs) and knee subcutaneous adipose tissue (ASCs) can be considered 
alternative appealing cell sources for articular cell-based therapies, thanks to their differentiative 
potential and ease of harvesting during knee surgery, which causes minimal additional morbidity to 
patients. Furthermore, the fast protocol employed in their isolation is advantageous in view of a future 
one-step surgical cell-based treatment.  
Beneficial effects have been observed treating animals with induced OA with MSCs derived from 
different adipose depots, with cells playing a key role in the inhibition of OA progression and in the 
restoration of damaged cartilage (14-17). Moreover, it has been demonstrated that intra-articular 
injection of IFP-MSCs leads to relief in pain symptoms and to improvement of knee functions in patients 
suffering from knee OA (18).  
Several studies have characterized the multi-lineage potential and immunophenotype of IFP-MSCs (19-
24), but, to our knowledge, only few studies have reported a preliminary comparison of mesenchymal 
stem cells from infrapatellar fat pad and knee subcutaneous adipose tissue (25-27). Nevertheless, in 
these few comparative studies, the evaluation of osteogenic and chondrogenic potential has been 
performed mainly by qualitative histological stainings, without investigating gene expression profiles 
(25,26), and the comparison was restricted to very few donors (27), limiting the clinical relevance of the 
findings.  
In the present study, to evaluate the different and specific relevance of IFP-MSCs and ASCs for 
orthopaedic cell-based therapies, we compared the features and the multi-differentiative potential of 
cells derived from 25 OA patients undergoing total knee replacement. To eliminate the common issue of 
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inter-donor variability, we performed a donor-matched evaluation, harvesting and comparing both IFP-
MSCs and ASCs from the same patient and focusing on their osteogenic and chondrogenic potential 
through multiple, quantitative analyses, and evaluating also the expression of hypertrophic and 
fibrocatilagineous markers in chondrogenic differentiated cells.  
 
Materials and Methods  
Cell isolation and expansion 
Infrapatellar fat pad and subcutaneous adipose tissue were harvested from the knee of 25 patients 
affected by OA (mean age 70±8 years, range 54-85 years) during total knee replacement, with patients’ 
informed consent and with the approval of the Institutional Review Board. 
Inclusion criteria were: male and female gender, age between 50 and 85 years, grade III and IV knee 
osteoarthritis according to Kellgren-Lawrence grading scale, indication for total knee replacement. 
Exclusion criteria were: rheumatoid arthritis, autoimmune diseases, systemic diseases, tumors, previous 
implant at the same knee and medical contraindication to elective surgery. 
IFP-MSCs were isolated from infrapatellar fat pad (28). Briefly, adipose tissue was carefully separated 
from the synovium and were minced in small pieces. The sample was then enzymatically digested (37°C, 
30 min) by 0.075% type I collagenase (Worthington Biochemical Co, Lakewood, New Jersey, USA). After 
digestion, the sample was centrifuged (1200 g, 10 min) and filtered through a cell strainer (100 μm 
pores) to remove undigested tissue. Cells were counted by Trypan blue exclusion and plated in control 
medium consisting of high glucose DMEM (HG-DMEM, Life Technologies, Carlsbad, California, USA) 
supplemented with 10% fetal bovine serum (FBS, Lonza, Basel, Switzerland), 0.029 mg/ml L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM hepes, 1 mM sodium pyruvate (all from Life 
Technologies) at approximately 104 cells/cm2 (37°C, 5% CO2). The same protocol was used to isolate 
ASCs from knee subcutaneous adipose tissue. Non-adherent cells were removed with the first medium 
refresh. During culture, medium was changed twice a week. When IFP-MSCs and ASCs were about 90% 
confluent, they were detached using 0.05% trypsin/0.053 mM EDTA (Life Technologies) and plated at 
3х103 cells/cm2 for the following passages. 
 
Clonogenic ability assay 
A colony-forming unit–fibroblast (CFU-F) assay was performed to assess the clonogenic ability of IFP-
MSCs and ASCs (29). Cells were plated at different low densities (ranging from 48 cells/cm2 to 1 
cells/cm2) and cultured in control medium with 20% FBS. After 10 days, cells were fixed with 10% 
neutral buffered formalin and stained with Gram’s crystal violet (Sigma-Aldrich, St. Louis, Missouri, USA). 
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CFU-F frequency was established by scoring the individual colonies and expressing them as a percentage 
relative to the number of seeded cells. 
 
Flow cytometry for the assessment of typical MSCs surface markers 
At passage 4 (45-50 days of expansion) surface marker expression was evaluated by flow cytometry. IFP-
MSCs and ASCs were detached using 0.05% trypsin/0.53 mM EDTA and washed twice in cold FACS Buffer 
(PBS w/o Ca2+/Mg2+containing 2% FBS and 0.1% NaN3). For each sample, 2.5x10
5 cells were incubated for 
30 min with the following anti-human primary monoclonal antibodies: CD13-FITC, CD29-biotinylated, 
CD31-FITC, CD34-biotinylated, CD44-FITC, CD45-FITC, CD105-biotinylated, CD106-FITC, CD166-FITC (all 
from Ancell Corporation, Bayport, Minnesota, USA), CD90-FITC and CD73-PE (from Miltenyi Biotec, 
Bergisch Gladbach, Germany), and CD151 (R&D Systems Inc, Minneapolis, Minnesota, USA). After 
incubation, cells were washed with FACS buffer to remove the excess of primary antibody. Cells stained 
with biotinylated antibodies were incubated for 20 min with streptavidin-PE (Ancell Corporation), 
whereas samples stained with anti-CD151 primary antibody were incubated with a FITC-conjugated goat 
anti-mouse secondary antibody (Ancell Corporation). After incubation, cells were washed with FACS 
Buffer and suspended in 500 µl of FACS buffer for analysis. Background fluorescence was established by 
negative controls and data were acquired using a FACSCalibur flow cytometer (BD Biosciences, Franklin 
Lakes,  New Jersey, USA) collecting a minimum of 10.000 events. Analysis was performed using 
CellQuest software (BD Biosciences). 
 
Adipogenic differentiation 
IFP-MSCs and ASCs at passage 4 were plated at 3x103 cells/cm2 and differentiated for 14 days in 
adipogenic medium using a repeated pulsed induction (30) with 3 days of induction in control medium 
supplemented with 1 μM dexamethasone, 10 μg/ml insulin, 500 μM 3-isobutyl-1-methylxanthine and 
200 μM indomethacin (all from Sigma-Aldrich), followed by 3 days of maintenance in control medium 
supplemented with 10 μg/ml insulin.  
The production of lipid vacuoles was quantified by Oil Red O staining. Cells were fixed in 10% neutral 
buffered formalin for 10 min, washed with 60% isopropanol, and stained with 8.5 mM Oil Red O (Sigma-
Aldrich) for 15 min. After rinsing with ddH2O, Oil Red O was unstained with 100% isopropanol and 
absorbance was read at 490 nm (Perkin Elmer Victor X3 microplate reader). 
 
Osteogenic differentiation 
IFP-MSCs and ASCs at passage 4 were plated at 3x103 cells/cm2 and differentiated for 14 or 21 days in 
osteogenic medium (30) consisting of control medium supplemented with 10 mM glicerol-2-phosphate, 
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10 nM dexamethasone, 150 μM L-ascorbic acid-2-phosphate and 10 nm cholecalciferol (all from Sigma-
Aldrich). 
Calcified matrix deposition was measured using Alizarin Red-S staining. Cells were rinsed with PBS, fixed 
with ice-cold 70% ethanol for 1 h and stained with 40 mM Alizarin Red-S (pH 4.1, Sigma-Aldrich) for 15 
min. After washing with ddH2O, samples were unstained for 30 min with 10% cetylpyridinium chloride 
monohydrate (CPC, Sigma-Aldrich) in 0.1 M phosphate buffer (pH 7.0). Absorbance was read at 570 nm 
(Perkin Elmer Victor X3 microplate reader). 
Alkaline phosphatase activity (ALP) was quantified by enzymatic assay (31). Cells were rinsed with PBS 
and lysed in 0.1% Triton X-100 (Sigma-Aldrich). ALP was quantified by incubating cellular lysates at 37°C 
with 1 mM p-nitrophenylphosphate (Sigma-Aldrich) in alkaline buffer (100 mM diethanolamine and 0.5 
mM MgCl2, pH 10.5). The enzymatic reaction was stopped with 1 N NaOH and absorbance was read at 
410 nm (Perkin Elmer Victor X3 microplate reader). ALP activity was normalized on total protein 
content, determined by BCA Protein Assay Kit (Pierce Biotechnology, Rockford, Illinois, USA), and 
expressed as ALP Units per mg of proteins.  
 
Chondrogenic differentiation 
Chondrogenic differentiation was performed by pellet culture. At passage 4, 4x105 IFP-MSCs and ASCs 
were centrifuged (250 g, 5 min) to obtain cell pellets. Pellets were cultured for 14 days in chondrogenic 
medium (32) consisting of HG-DMEM supplemented with 0.029 mg/ml L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin, 10 mM hepes, 1 mM sodium pyruvate, 1.25 mg/ml human serum albumin (all 
from Sigma-Aldrich), 1% ITS+1 (1.0 mg/ml insulin from bovine pancreas, 0.55 mg/ml human transferrin, 
0.5 μg/ml sodium selenite, 50 mg/ml bovine serum albumin and 470 μg/ml linoleic acid, Sigma-Aldrich), 
0.1 µM dexamethasone, 0.1 mM L-ascorbic acid-2-phosphate and 10 ng/ml TGF-β1 (Peprotech, Rocky 
Hill, New Jersey, USA). 
For histological analysis, pellets were fixed for 24 h in 10% neutral buffered formalin, embedded in 
paraffin and sectioned at 4 μm. Sections were stained with haematoxylin-eosin (Sigma-Aldrich) and 
alcian blue (pH 2.5, Sigma-Aldrich) to evaluate extracellular matrix and glycosaminoglycans (GAGs) 
deposition. 
For GAGs quantification, pellets were digested (16 h, 60°C) in 500 µl of PBE buffer (100 mM Na2HPO4, 10 
mM NaEDTA, pH 6.8) containing 1.75 mg/ml L-cystein (Sigma-Aldrich) and 14.2 U/ml papain 
(Worthington). Samples were incubated with 16 mg/l dimethylmethylene blue (Sigma-Aldrich) and 
absorbance was read at 500 nm (Perkin Elmer Victor X3 microplate reader). The same samples were 
used for DNA quantification by CyQUANT Kit (Life Technologies).  
Soluble ALP activity released in culture supernatants was measured by enzymatic assay. At the moment 
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of medium refresh, culture supernatant was collected from each pellet and 50 µl of medium were 
incubated with 1 mM p-nitrophenylphosphate. The release of ALP was determined at early phase (day 0 
to day 3) and late phase (day 11 to day 14) of chondrogenic differentiation. 
 
Gene expression analysis 
After 14 days of adipogenic, osteogenic or chondrogenic differentiation, gene expression was evaluated 
by real time PCR (Rotor Gene RG3000 system, Qiagen). Total RNA was purified from cell lysates using 
the RNeasy Mini kit (Qiagen, Venlo, Netherlands) and reverse-transcribed to cDNA (5 min at 25°C, 30 
minutes at 42°C and 5 min at 85°C) using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
California, USA). 20 ng of cDNA were incubated with a PCR mix (2 min at 50°C, 10 min at 95°C, followed 
by 40 cycles of 15 sec at 95°C and 1 min at 60°C) including TaqMan Universal PCR Master Mix and 
TaqMan® Assays-on-Demand™ Gene Expression probes (Life Technologies) using the following assays: 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Hs99999905_m1), peroxisome proliferator-
activated receptor gamma (PPARG, Hs01115513_m1), leptin (LEP, Hs00174877_m1), runt-related 
transcription factor 2 (RUNX2, Hs00231692_m1), collagen type I alpha 1(COL1A1, Hs01076777_m1), 
aggrecan (ACAN, Hs00153936_m1), SRY (Sex determining region Y)-box9 (SOX9, Hs00165814_m1), 
cartilage oligomeric matrix protein (COMP, Hs00164359_m1), collagen type II alpha I (COL2A1, 
Hs01060345_m1), collagen type X alpha 1 (COL10A1, Hs00166657_m1). The fold change in the 
expression of the different genes was normalized on the housekeeping GAPDH. 
 
Statistical analysis 
Data are expressed as mean±SEM. Normal distribution of values was assessed by Kolmogorov-Smirnov 
normality test. Statistical analysis was performed using Student’s t-test and Wilcoxon test for paired 
data since IFP-MSCs and ASCs were obtained from the same donors; Student's t-test was used for data 
with a Gaussian distribution and Wilcoxon test for data with a non-Gaussian distribution.  (GraphPad 
Prism v5.00, GraphPad Software). Level of significance was set at p<0.05 (* p<0.05, ** p<0.01, *** 
p<0.001). The number of data used for the statistical analyses, indicated in figure legends as “n”, 
corresponds to independent experiments performed with IFP-MSCs and ASCs isolated from “n” 
individual donors, according to Ranstam (33). 
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Fig. 1. Morphology and clonogenic potential of IFP-MSCs and ASCs. (A) 
Cells in culture at passage 4 (scale bars 200 µm). (B) Percentage of 
clonogenic cells from passage 1 to passage 4 (scored colonies were 
normalized on number of seeded cells, n=7, p<0.05) (C) Representative 
pictures of stained CFU-F at P1 and P4. 
Results 
Undifferentiated IFP-MSCs and ASCs share common features and express a similar set of 
cell surface markers  
IFP-MSCs and ASCs displayed a fibroblastoid shape, which was maintained throughout the entire culture 
period, without any difference between the two cell types (Fig. 1A). From passage 1 to 4, both cell 
populations displayed a high 
clonogenic ability (Fig. 1B,C), with a 
significantly higher clonogenic ability 
observed in IFP-MSCs compared to 
ASCs at passage 1 (p<0.05).  
As reported in Fig. 2A, both IFP-
MSCs and ASCs analyzed at passage 
4 showed a similar 
immunophenotype, being positive 
for CD13, CD29, CD44, CD73, CD90, 
CD105, CD166 and negative for CD31 and CD45. For all the tested markers no difference was observed 
between IFP-MSCs and ASCs (Fig. 2B). A variable expression of CD34 and CD106 was found for IFP-MSCs 
and ASCs depending on the donor (10-
35% of positive cells). Both cell types 
expressed CD29, CD90, CD105, CD151 
and CD166 (35-90% of positive cells). A 
very consistent expression of CD13, 
CD44 and CD73 was measured on IFP-
MSCs and ASCs (90-100% of positive 
cells). 
Fig. 2. Cell surface markers expression. (A) 
Expression of the typical MSCs surface 
markers pattern in IFP-MSCs and ASCs 
from the same donor at passage 4 
(markers represented as grey histograms 
and isotype control antibodies represented 
as black histograms). (B) Percentage of 
positive cells for the whole panel of 
surface markers tested (n=6). Ranking was 
established as: - for 0-10%, +/- for 10-35%, 
+ for 35-50%, ++ for 50-90%, and +++ for 
90-100% positive cells. 
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Adipogenic differentiation of IFP-MSCs and ASCs induces a similar upregulation of 
adipogenic markers except for leptin gene expression 
IFP-MSCs and ASCs cultured for 14 days in adipogenic medium showed the progressive loss of the 
fibroblastoid-like shape and the 
production of cytoplasmatic lipid 
vacuoles, as evidenced by Oil Red O 
staining (Fig. 3A, B). The dye 
extraction revealed a significant 
increase in lipid vacuoles content in 
differentiated cells in comparison 
with cells in control medium 
(p<0.001 for IFP-MSCs and p<0.05 
for ASCs) (Fig. 3C). Gene expression 
analysis confirmed the ability of 
both cell types to respond to 
adipogenic induction. Indeed, a 
significant increase of PPARG 
expression was observed in IFP-
MSCs (p<0.05) and ASCs (p<0.01) 
cultured in adipogenic medium in comparison with undifferentiated cells (Figure 3D). Differentiated IFP-
MSCs and ASCs showed also a significant up-regulation of LEP expression, (p<0.05 and p<0.01, 
respectively) compared with undifferentiated cells. Finally, a significantly higher expression of LEP was 
observed in differentiated ASCs in comparison with differentiated IFP-MSCs (+295%, p<0.01). 
 
ASCs respond more efficiently to osteogenic induction in respect to IFP-MSCs 
Both IFP-MSCs and ASCs were able to differentiate towards the osteogenic lineage when cultured in 
osteo-inductive medium, as demonstrated by the upregulation of specific markers such as calcified 
matrix, ALP activity, and transcriptional expression of RUNX2 and COL1A1 (Fig. 4). Our results 
demonstrated that ASCs were more committed towards the osteogenic lineage in respect with IFP-
MSCs. Indeed, after 14 days of culture in osteogenic medium the deposition of calcified matrix was more 
consistent in differentiated ASCs (Fig. 4A) and the quantification of calcified matrix revealed a significant 
difference between the two cell populations (+75% in ASCs, p<0.05, Fig. 4B). Furthermore, after 14 days 
of differentiation, ASCs produced significantly higher levels of ALP in comparison with IFP-MSCs (+66%, 
p<0.05, Fig. 4C). Comparing 14 and 21 days, we observed a significant increase of calcified matrix 
Fig. 3. Adipogenic differentiation. (A-B) Micrographs of IFP-MSCs and 
ASCs differentiated towards the adipogenic lineage during culture and 
after Oil Red O staining (scale bars 200 µm). (C) Quantification of lipid 
vacuoles in undifferentiated (CTRL) and adipogenic-differentiated 
(ADIPO) cells (n=13). (D-E) Gene expression of PPARG and LEP 
normalized to GAPDH (n=7). Red arrow indicates a significant difference 
between IFP-MSCs and ASCs. 
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deposition in IFP-MSCs 
(p<0.05) and ASCs 
(p<0.01) over time. ALP 
levels were increased 
from 14 to 21 days in 
differentiated IFP-MSCs 
(p<0.05), whereas this 
marker remained stable in 
ASCs. After 21 days of 
induction, we did not 
observe any significant 
difference between IFP-
MSCs and ASCs in terms 
of calcified matrix 
deposition and ALP 
activity. 
Higher expression of 
RUNX2 and COL1A1 was 
observed both in 
undifferentiated and 
differentiated ASCs in comparison to their IFP-MSCs counterparts (Fig. 4D, E), with a significant 
difference in the expression of COL1A1 in undifferentiated cells (+53% in ASCs, p<0.05, Fig. 4E). 
 
IFP-MSCs are more committed towards the chondrogenic lineage and express lower levels 
of hypertrophic and fibrocartilagineous markers as compared to ASCs 
After 14 days of chondrogenic induction in pellet culture conditions, no significant difference was 
observed in terms of DNA content, related to cell proliferation, between IFP-MSCs and ASCs pellets, 
even if slightly higher values were measured in IFP-MSCs pellets (Fig. 5A).  
A significantly higher amount of GAGs was observed in IFP-MSCs pellets as demonstrated both from 
histological analysis (Fig. 5B) and biochemical quantification of GAGs (+16%, p<0.01, Fig. 5C). In 
particular, histological sections revealed that IFP-MSCs produced a consistent amount of extracellular 
matrix which was positively stained by alcian blue, confirming the presence of GAGs. On the contrary, 
alcian blue staining was almost absent in ASCs pellets (Fig. 5B). 
Accordingly with data obtained by histological and biochemical analyses, significantly higher levels of 
Fig. 4. Osteogenic differentiation. (A) Micrographs of IFP-MSCs and ASCs 
differentiated for 14 days and stained by AR-S (scale bars 500 µm). (B) 
Quantification of calcified matrix by AR-S staining and extraction in undifferentiated 
(CTRL) and osteogenic-differentiated (OSTEO) IFP-MSCs and ASCs (n=14). (C) ALP 
activity determined by enzymatic assay and normalized by protein content (n=9). 
(D-E) Gene expression of RUNX2 and COL1A1 normalized to GAPDH (n=7). Red 
arrows indicate significant differences between IFP-MSCs and ASCs. 
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ACAN gene expression were observed in IFP-MSCs pellets compared to ASCs pellets (+474%, p<0.001, 
Fig. 5D). Moreover, all the tested chondrogenic markers showed higher expression in IFP-MSCs, with 
significant differences for 
COMP (+127%, p<0.001) 
and COL2A1 (+728%, 
p<0.05) in comparison 
with ASCs. The superior 
chondrogenic potential of 
IFP-MSCs compared to 
ASCs was confirmed also 
by data on hypertrophic 
and fibrocartilagineous 
markers (Fig. 5H, I): 
indeed, expression of 
COL10A1 and COL1A1 was 
significantly higher in ASCs 
in respect to IFP-MSCs 
(+132%, p<0.05 for 
COL10A1; +75%, p<0.01 
for COL1A1).  
Furthermore, in the early 
phase of chondrogenic 
differentiation (day 0 to day 3) ALP released from ASCs pellets was significantly higher in comparison 
with IFP-MSCs pellets (+119%, p<0.05, Fig. 5J).  
 
Discussion 
The main finding of our study was the significantly different commitment of IFP-MSCs and ASCs in terms 
of differentiation ability; in particular, undifferentiated ASCs showed higher osteogenic potential in 
comparison with IFP-MSCs, whereas IFP-MSCs were characterized by a superior chondrogenic ability. In 
our study both cell populations were isolated from the  same knee of each patient,  thus eliminating the 
bias of inter-donor variability and allowing a strict comparison of cell features, giving more consistent 
results. Furthermore, all cells were derived from OA donors undergoing total knee replacement, to allow 
a more reliable prediction of the cell behavior in view of a future clinical application in early OA patients. 
Indeed, in the quest to identify cells able to regenerate bone and cartilage damages and to develop new 
Fig. 5. Chondrogenic differentiation. (A) DNA content in IFP-MSCs and ASCs pellets 
(n=15). (B) Haematoxilin-eosin and alcian blue staining of representative pellet 
sections (C) Quantification of total GAGs in pellets (n=15). (D-I) Gene expression of 
ACAN, SOX9, COMP, COL2A1, COL10A1 and COL1A1 normalized to GAPDH (n=10). 
(J) Soluble ALP activity released in culture supernatants from day 0 to day 3 
(indicated as 3 days) and from day 11 to day 14 (indicated as 14 days) (n=8). Red 
arrows indicate significant differences between IFP-MSCs and ASCs. 
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treatments for early OA patients, a major issue is to establish the ideal anatomical sites for autologous 
MSCs isolation. Both the fat depots investigated in this study are easily accessible during orthopaedic 
surgery and their harvesting causes a minimal discomfort and donor site morbidity, thus being ideal 
sources for the isolation of MSCs. 
Undifferentiated IFP-MSCs and ASCs displayed similar features in terms of cell morphology, typically 
fibroblastoid. Both populations presented a high clonogenic ability, with percentage of clonogenic cells 
ranging between 30 and 40%, with IFP-MSCs forming a higher number of colonies compared to ASCs at 
passage 1, in accordance with previously published data (25). 
After in vitro expansion, the immunophenotype was coherent with the one reported in previous studies 
for IFP-MSCs and ASCs (20,26,27,34,35) and, in accordance with literature, no difference was observed 
between the two populations (26,27). 
Regarding the multilineage potential, both IFP-MSCs and ASCs were able to respond to the adipogenic 
stimuli, showing a similar induction of the characteristic adipogenic markers, but a significantly higher 
expression of LEP was observed in undifferentiated ASCs in comparison with undifferentiated IFP-MSCs. 
Leptin is an inflammatory mediator which is mainly produced and secreted by adipocytes (36,37). This 
adipokine stimulates IL-1β production, increases the effect of pro-inflammatory cytokines and induces 
the expression of matrix metalloproteinases which participate to cartilage matrix degradation in OA 
cartilage (38,39). The significantly superior basal expression of LEP in ASCs in respect to IFP-MSCs is 
coherent published data , reporting a significantly higher production and secretion of this adipokine in 
the subcutaneous adipose tissue of OA patients compared to their infrapatellar fat pad (40). However, 
the same study also reported a superior secretion of IL-6 and its soluble receptor in infrapatellar fat pad 
compared to subcutaneous adipose tissue. The inflammatory profile of MSCs derived from both adipose 
depots would hence need further investigations to better define how these cell populations could react 
to the inflammatory state of OA joints, in view of their possible application in a future cell-based 
therapy. 
Several studies have demonstrated the osteogenic and chondrogenic potential of IFP-MSCs (19-22,24) 
and ASCs (41-43), but without comparing these cell populations.  
In our study, the direct donor-matched comparison between IFP-MSCs and ASCs through quantitative 
analyses allowed to observe important differences in their osteogenic and chondrogenic commitment. 
Significantly higher levels of ALP and calcified matrix deposition in osteo-induced ASCs compared to IFP-
MSCs, together with the superior expression of COL1A1 in undifferentiated ASCs, demonstrated that 
ASCs are more committed towards the osteogenic lineage with respect to IFP-MSCs. These results differ 
from those described in previous studies whereby, on the basis of qualitative stainings, it has been 
reported that IFP-MSCs possess a similar (25) or higher (27) osteogenic potential compared to ASCs. We 
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believe that quantitative analyses and the inclusion of a more appropriate number of donors can 
determine a higher sensitivity compared to qualitative staining, that could have led us to such 
contrasting results compared to the current reported literature. Finally, differently from Mochizuki et al. 
(27) that used as tissue source a mixture of synovium and adipose subsynovium, we carefully selected 
only the adipose fraction of infrapatellar fat pad prior to cell isolation to evaluate solely the 
differentiation potential of  IFP-MSCs, which could also partially explain the different results obtained in 
our study. 
On the other hand, a more pronounced chondrogenic commitment was found in IFP-MSCs compared to 
ASCs, as revealed by the significantly higher transcriptional expression of chondrogenic markers such as 
ACAN, COL2A1 and COMP in IFP-MSCs pellets. This result is in accordance with previously published 
results  (26) where the histological evaluation of pellets revealed that ASCs were characterized by lower 
chondrogenic ability compared to IFP-MSCs that displayed a chondrogenic phenotype more similar to 
the one of BMSCs. A superior chondrogenic potential in IFP-MSCs was observed also described by 
Mochizuki et al. (27) who, however, analyzed expression of chondrogenic genes in pellets obtained from 
IFP-MSCs and ASCs from a single young non-OA donor. Our data, comprising GAGs quantification and 
gene expression analysis of cells derived from a larger number of old OA donors, support these 
literature data, providing an effective demonstration of the superior chondrogenic commitment of IFP-
MSCs compared to ASCs, even when cells are obtained from osteoarthritic donors.  
Furthermore, we investigated the expression of collagen X and alkaline phosphatase which are usually 
associated with the premature development of an hypertrophic phenotype during MSCs chondrogenesis 
(44-47). We found that, in the early phase of chondrogenic differentiation, release of ALP was 
significantly higher in ASCs pellets and that, after 14 days of chondrogenic differentiation, levels of 
COL10A1 and COL1A1 were significantly lower in IFP-MSCs compared to ASCs.  
The dissimilarities found between IFP-MSCs and ASCs may depend on the different anatomical 
localization of infrapatellar fat pad and knee subcutaneous adipose tissue, considering that infrapatellar 
fat pad is in direct contact with synovial membrane and that the local tissue microenvironment could 
affect the commitment of MSCs. Differences in the expression of hypertrophic and fibrocartilagineous 
markers suggest that IFP-MSCs could be more suitable for cartilage applications aiming at the 
generation of specific cartilage-like matrix. However, further investigations after a longer period of 
chondrogenic differentiation are required to confirm the different trend between IFP-MSCs and ASCs in 
developing a hypertrophic phenotype.  
Despite similar surface markers expression in the undifferentiated state, different populations of MSCs 
can display significantly different commitment towards specific cell lineages. This supports the 
importance of introducing more specific and predictive markers to identify which population of MSCs 
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could be more suitable for a specific clinical application. as proposed by recent studies that have 
investigated the differentiation potential of specific subsets of MSCs (48-50). 
It should be highlighted that the differential commitment of IFP-MSCs and ASCs emerged from in vitro 
experiments and should be further confirmed through in vivo studies to better validate the clinical 
relevance of our data. However, our results contribute to show how quantitative analyses on larger 
donor populations are fundamental for a more reliable characterization of primary human cells, 
contributing to build a  more consistent base for cell-based therapies. 
 
Conclusions 
To the best of our knowledge, this is the first study to compare donor-matched IFPs and ASCs from such 
a large number of OA donors, characterizing their osteogenic and chondrogenic potential through 
several quantitative analyses. This provided novel and interesting insights on their specific 
differentiation capabilities, opening to a more rational selection as preferential sources for regenerating 
cartilage and bone tissues or developing osteochondral treatments, aimed at future clinical cell-based 
treatments, also in OA patients. 
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Chapter 5 
Influence on chondrogenesis of human osteoarthritic 
chondrocytes in co-culture with donor-matched 
mesenchymal stem cells from infrapatellar fat pad and 
subcutaneous adipose tissue 
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Abstract 
Co-culture of mesenchymal stem cells (MSCs) and articular chondrocytes (ACs) has been proposed for 
autologous cartilage cell-based therapies, to overcome the issues associated to limited availability of 
articular chondrocytes (ACs).  
To evaluate the potentiality of a co-culture approach in aged osteoarthritic patients, MSCs from 
infrapatellar fat pad (IFP-MSCs) and knee subcutaneous adipose tissue (ASCs) were co-cultured with 
donor-matched osteoarthritic, expanded and cryopreserved, ACs in a 75%/25% ratio. Co-cultures were 
prepared also from nasal chondrocytes (NCs) to evaluate their possible use as an alternative to ACs. 
Pellets were differentiated for 14 days, using mono-cultures of each cell type as reference. 
Chondrogenic genes SOX9, COL2A1, ACAN were less expressed in co-cultures compared to ACs and 
NCs. Total GAGs content in co-cultures did not differ significantly from values predicted as the sum of 
each cell type contribution corrected for the co-culture ratio, as confirmed by histology. No significant 
differences were observed for GAGs/DNA in mono-cultures, demonstrating a reduced chondrogenic 
potential of ACs and NCs. 
In conclusion, a small percentage of expanded and cryopreserved ACs and NCs did not lead to IFP-MSCs 
and ASCs chondro-induction. Our results suggest that chondrogenic potential and origin of 
chondrocytes may play a relevant role in the outcome of co-cultures, indicating a need for further 
investigations to demonstrate their clinical relevance in the treatment of aged osteoarthritic patients.
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Introduction  
Articular cartilage is a highly specialized tissue with a low self-repair ability due to the lack of 
vascularization and to its low cellularity. As a consequence, untreated cartilage lesions can easily 
degenerate and eventually lead to osteoarthritis (OA) and to the loss of joint functionality (1). Different 
strategies have been developed to treat promptly chondral lesions, comprising cell-based therapies 
such as autologous chondrocyte implantation (ACI) (2,3). Major issues associated to the clinical use of 
autologous chondrocytes are the limited number of chondrocytes harvestable from a small biopsy of 
cartilage and the de-differentiation process occurring during their required expansion (4,5). 
Furthermore, advanced age and a pathological state of joints have been demonstrated to reduce the 
chondrogenic potential of articular chondrocytes (ACs) (6-9) and represent important factors that 
should be considered when treating chondral lesions in particular categories of patients. To overcome 
these limitations, other cell sources have been considered as an alternative to ACs. Among terminally 
differentiated cells, nasal chondrocytes (NCs) have been proposed for cartilage tissue engineering (9) 
since their harvesting is associated with a lower site morbidity, their chondrogenic potential is not 
dependent on the donor’s age (10) and they respond better than ACs to inflammatory stimuli (11). 
Beside differentiated cells, mesenchymal stem cells (MSCs) that can be isolated from several adult 
tissues, such as bone marrow and adipose tissue, have been proposed as an alternative to ACs thanks 
to their demonstrated proliferative and chondrogenic ability (12,13). Adipose-derived stem cells (ASCs) 
have been successfully used in several in vivo studies for cartilage generation (14-16). Thus, when 
developing treatments for knee chondral lesions, infrapatellar fat pad and knee subcutaneous adipose 
tissue, that are easily accessible during orthopaedic surgery, can be considered appealing sources for 
MSCs harvesting (17-22). 
Recently, the co-culture of ACs and MSCs has gained growing interest, with the aim of both 
investigating the cross-talk between these two cell types and replacing a fraction of ACs with MSCs to 
reduce the cartilage biopsy size and the time required for chondrocytes expansion, thus limiting their in 
vitro de-differentiation. Controversial results have been reported on the generation of cartilage-like 
matrix and on the chondro-inductive action of chondrocytes in co-culture with ASCs (23-25) or BMSCs 
(25-29). The different origin and de-differentiation state of chondrocytes used in these studies make 
the comparison of their results difficult. In addition, apoptosis of MSCs occuring in chondrogenic pellet 
co-cultures and altering the starting percentages of MSCs and chondrocytes (25) complicates data 
interpretation. 
In the present study we evaluated whether the co-culture of MSCs derived from infrapatellar fat pad 
(IFP-MSCs) and knee subcutaneous adipose tissue (ASCs) with a small fraction of ACs was able to lead 
to cartilage-like matrix generation and to the expression of chondrogenic markers similar to those of 
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ACs. To better resemble a possible clinical application of this strategy we performed autologous co-
cultures combining FP-MSCs and ASCs with donor-matched ACs and we used cells derived from OA 
patients so as not to neglect the impact of a probable pathological state of the cell source on the 
outcome of co-cultures. Furthermore, to test if NCs could be used as an alternative to ACs, co-culture 
experiments were performed combining IFP-MSCs and ASCs with NCs obtained from rinoplasty surgery. 
 
Materials and Methods  
Cell isolation and expansion 
Infrapatellar fat pad, knee subcutaneous adipose tissue and articular cartilage were obtained from 5 
OA patients (mean age 64±10 years, range 54-75 years) undergoing knee replacement. Nasal cartilage 
was obtained from 1 patient (36 years) during rinoplasty procedure. All samples were harvested with 
patients’ informed consent after approval from the Institutional Review Board. 
IFP-MSCs and ASCs were isolated by enzymatic digestion (37°C, 30 min) using 0.075% type I collagenase 
(Worthington Biochemical Co) (30). After digestion, cells were plated in control medium consisting of 
DMEM (4.5 g/l glucose, Gibco) supplemented with 10% fetal bovine serum (FBS, Lonza), 0.029 mg/ml L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM hepes, 1 mM sodium pyruvate (all 
from Gibco) and expanded until passage 4. ACs and NCs were isolated by enzymatic digestion (37°C, 22 
h) using 0.15% type II collagenase (Worthington Biochemical Co) and expanded until passage 2 in 
control medium supplemented with 5 ng/ml fibroblast growth factor-2 (FGF-2, PeproTech) and 1 ng/ml 
transforming growth factor-β1 (TGF-β1, PeproTech) (6). At passage 2, ACs were frozen and successively 
thawed since ACs and the donor-matched IFP-MSCs and ASCs required a different expansion time, 
although they needed to be combined in the same co-culture experiment. NCs were also expanded 
until passage 2 and frozen before use. 
 
Chondrogenic co-culture of IFP-MSCs and ASCs combined with ACs and NCs 
Chondrogenic differentiation was performed by pellet culture technique. Pellets were obtained by 
centrifuging 4x105 cells (250 g, 5 min) in a 1.5 ml conical tube and cultured for 14 days in chondrogenic 
medium containing 0.1 µM dexamethasone (Sigma-Aldrich) and 10 ng/ml TGF-β1 (6). Medium was 
replaced twice a week. Co-cultures were obtained mixing IFP-MSCs and ASCs with donor-matched ACs 
or NCs (ratio 75%/25%) as follows: IFP-MSCs/ASCs, ASCs/ACs, IFP-MSCs/NCs, ASCs/NCs. IFP-MSCs, 
ASCs, ACs and NCs mono-cultures were also prepared. 
 
Analysis of cell distribution in co-culture pellets 
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To analyze cell distribution in co-culture pellets, ACs were stained with the green fluorescent dye 
Vybrant DiO, while IFP-MSCs and ASCs were stained with the red fluorescent dye Vybrant CM-Dil (both 
from Invitrogen) according to the manufacturer’s instructions. Stained cells were mixed as in co-culture 
pellets. One day after pellet formation, pellets were embedded in Tissue-Tek OCT (Sakura), sectioned 
by cryotome (6 μm) and observed through a fluorescence microscope.  
 
Quantification of GAGs and DNA 
Pellets were washed with PBS and incubated in 500 µl of PBE buffer (100 mM Na2HPO4, 10 mM 
NaEDTA, pH 6.8) containing 1.75 mg/ml L-cystein (Sigma-Aldrich) and 14.2 U/ml papain (Worthington) 
for 16 h at 60°C. The amount of GAGs was spectrophotometrically measured using 16 mg/ml 
dimethylmethylene blue (Sigma-Aldrich), with chondroitin sulfate as standard, and DNA content was 
quantified using the CyQUANT Kit (Invitrogen). On the basis of DNA data, the number of cells in each 
pellet was estimated considering an average content of 11.6 pg DNA/cell (25,31). 
 
Histological analysis 
Pellets were fixed for 24 h in 10% neutral buffered formalin, embedded in paraffin and sectioned at 4 
μm. Sections were stained with haematoxylin-eosin (Sigma-Aldrich) or Alcian Blue (pH 2.5, Sigma-
Aldrich) to evaluate pellet morphology and GAGs content. 
 
Gene expression analysis 
Gene expression of chondrogenic markers was evaluated by real time PCR (Rotor Gene RG3000 system, 
Qiagen). RNA was purified from pellets using RNeasy Mini kit (Qiagen) and reverse-transcribed to cDNA 
using iScript cDNA Synthesis Kit (Bio-Rad Laboratories). 20 ng of cDNA were incubated with a PCR 
mixture including TaqMan Universal PCR Master Mix and TaqMan® Assays-on-Demand™ Gene 
expression probes (Life Technologies) using the following assays: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, Hs99999905_m1), aggrecan (ACAN, Hs00153936_m1), collagen type II alpha I 
(COL2A1, Hs01060345_m1), cartilage oligomeric matrix protein (COMP, Hs00164359_m1), SRY (Sex 
determining region Y)-box9 (SOX9, Hs00165814_m1). Expression of chondrogenic markers was 
normalized on GAPDH. 
 
Statistical analysis 
Data are expressed as mean±SEM and statistical analysis was performed by One-Way ANOVA 
(GraphPad Prism v5.00, GraphPad Software). Significance was set at p<0.05. 
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Results 
Quantification of GAGs and DNA content 
Autologous co-cultures were performed combining IFP-MSCs and ASCs with donor-matched ACs. Cell 
distribution within co-culture pellets was evaluated by staining IFP-MSCs and ACs with a fluorescent 
dye. One day after pellet formation, IFP-
MSCs and ACs were homogeneously 
mixed within the pellet (Fig. 1). The same 
behavior was observed in ASCs co-culture 
pellets (data not shown).  
Pellet cell number evaluation revealed 
that, starting from 4x105 cells, a significant 
reduction in cell number occurred in ACs 
pellets (2.9x105, p<0.01). A more relevant 
decrease in cell number was observed in 
IFP-MSCs and ASCs pellets with an average of 1.3x105 and 1.2x105 cells found after 14 days of culture 
(p<0.01 for IFP-MSCs and p<0.05 for ASCs), indicating a lower survival of IFP-MSCs and ASCs compared 
to ACs in pellet culture conditions. A higher number of cells was found in co-culture pellets in 
comparison with 
IFP-MSCs and 
ASCs pellets, 
even though the 
differences with 
respect to ACs 
pellets remained 
significant 
(p<0.01) (Fig. 2a). 
Total GAGs 
content was 2-
fold higher in ACs 
pellets compared 
to IFP-MSCs and ASCs pellets (p<0.001). In co-culture pellets total GAGs content increased only slightly 
compared to IFP-MSCs and ASCs pellets and was significantly lower with respect to ACs pellets 
(p<0.001) (Fig. 2b). Given the higher number of cells present in ACs and co-culture pellets, GAGs 
normalized by DNA was comparable for all the experimental groups (Fig. 2c). 
 
Fig. 1. Representative pictures of macroscopic morphology (a, 
magnification 4X) and cell distribution (b, magnification 10X) of 
IFP-MSCs, IFP-MSCs/ACs, and ACs pellets 1 day after their 
formation. IFP-MSCs are stained red and ACs are stained green. 
Fig. 2. Quantification of DNA content (a), GAGs content (b) and GAGs content normalized by 
DNA (c) in ACs co-cultures after 14 days. Dotted line represents average DNA content after 1 
day of culture. IFP-MSCs, ACs and ASCs mono-cultures were used as a reference. Data are 
expressed as mean±SEM. 
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Similar results were obtained co-culturing IFP-MSCs and ASCs with NCs. After 14 days, a decrease in cell 
number was 
observed in NCs 
pellets (3.1x105 
cells). IFP-
MSCs/NCs and 
ASCs/NCs pellets 
contained a 
significantly 
lower number of 
cells compared 
to NCs (p<0.001), 
even though 
increases were observed with respect to IFP-MSCs and ASCs (Fig. 3a). A small increase in total GAGs 
content was observed in the co-cultures, but differences with IFP-MSCs and ASCs pellets were not 
significant (Fig. 3b). GAGs normalized by DNA was similar in all the experimental groups (Fig. 3c).  
 
Histological analysis 
Histological evaluation revealed consistent differences in terms of matrix quality when comparing IFP-
MSCs and ASCs pellets to ACs and 
NCs ones. Processing of ASCs 
pellets revealed their tendency to 
disaggregate. IFP-MSCs 
performed better than ASCs, 
being characterized by a more 
consistent matrix, however a 
greater amount of matrix was 
found in ACs and NCs pellets (Fig. 
4a) where GAGs were intensely 
stained by alcian blue (Fig. 4b). 
Furthermore, ACs and NCs pellets 
showed the formation of 
structures similar to lacunae that 
were not found in IFP-MSCs and 
Fig. 3. Quantification of DNA content (a), GAGs 
content (b) and GAGs content normalized by DNA 
(c) in NCs co-cultures after 14 days. Dotted line 
represents average DNA content after 1 day of 
culture. IFP-MSCs, NCs and ASCs mono-cultures 
were used as a reference. Data are expressed as 
mean±SEM. 
Fig. 3. Quantification of DNA content (a), GAGs content (b) and GAGs content normalized by 
DNA (c) in NCs co-cultures after 14 days. Dotted line represents average DNA content after 
1 day of culture. IFP-MSCs, NCs and ASCs mono-cultures were used as a reference. Data are 
expressed as mean±SEM. 
Fig. 4. Representative pictures of histological staining with 
haematoxylin/eosin (a) and alcian blue (b) of mono-culture and co-culture 
pellets (magnification 5X) after 14 days. IFP-MSCs, ASCs and ACs 
represented in these pictures were obtained from the same donor. 
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ASCs pellets. IFP-MSCs/ACs and IFP-MSCs/NCs co-cultures showed an increased GAGs content 
compared to IFP-MSCs pellets, increase that was not observed in ASCs co-cultures (Fig. 4b). However, 
the matrix produced by IFP-MSCs co-cultures had structure and composition that was very distant from 
that observed in NCs and ACs pellets. 
 
Gene expression analysis 
Transcriptional expression of different chondrogenic markers was evaluated considering the global 
response of both cell types in co-culture. As expected, ACs expressed higher levels of the tested 
markers in comparison 
with IFP-MSCs and 
ASCs and their 
corresponding co-
culture pellets. 
Increases in COL2A1 
and ACAN levels were 
observed in IFP-
MSCs/ACs compared 
to IFP-MSCs pellets, 
whereas no up-
regulation was 
observed for SOX9 and COMP. On the other hand, the expression of SOX9, ACAN and COMP was 
increased in ASCs/ACs compared to ASCs pellets, whereas COL2A1 was almost undetectable (Fig. 5). 
IFP-MSCs/NCs and 
ASCs/NCs co-cultures 
showed small 
increases in SOX9, 
COL2A1 and ACAN 
expression, but 
except for the 
transcriptional factor 
SOX9, differences in 
gene levels between 
NCs and co-culture 
pellets remained very 
Fig. 5. Gene expression of SOX9 (a), COL2A1 (b), ACAN (c) and COMP (d) in ACs co-
cultures after 14 days. IFP-MSCs, ACs and ASCs mono-cultures were used as a 
reference. Gene levels are normalized to the housekeeping GAPDH and expressed as 
mean±SEM 
Fig. 6. Gene expression of SOX9 (a), COL2A1 (b), ACAN (c) and COMP (d) in NCs co-
cultures after 14 days. IFP-MSCs, NCs and ASCs mono-cultures were used as a 
reference. Gene levels are normalized to the housekeeping GAPDH and expressed as 
mean±SEM 
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consistent (Fig. 6). We found lower levels of COMP in NCs respect to IFP-MSCs and ASCs, which resulted 
in a reduction of its expression in co-cultures (Fig. 6d). 
 
 
Discussion  
The possibility of replacing a fraction of ACs with MSCs has gained growing interest over the last few 
years to reduce the number of ACs required for implantation and to limit ACs expansion and de-
differentiation. Controversial results about the efficacy of ASCs co-culture with chondrocytes have been 
reported. Indeed, besides studies showing that ASCs co-culture with ACs or NCs results in chondro-
induction, seen as the synergistic action of both cell types to generate cartilagineous matrix (24,25), 
another study has reported that ASCs contribution is limited to the transcriptional expression of 
chondrogenic genes (23). Contradictory results have been also reported for co-cultures between 
BMSCs and ACs (25-29) supporting the idea that cell origin and de-differentiation state of ACs as well as 
the MSCs/ACs ratio play a fundamental role in determining the outcome. 
In this study we evaluated whether the co-culture of IFP-MSCs and ASCs with a small percentage of ACs 
could lead to the generation of cartilage-like matrix comparable to that obtained from ACs. To better 
resemble a possible clinical application addressed to treat knee lesion in OA patients, autologous co-
cultures were performed through donor-matched IFP-MSCs, ASCs and ACs using cells derived from old 
OA donors who are known to possess a reduced chondrogenic potential (6-8). Given the growing 
interest for the use of NCs in cartilage tissue engineering, the same experiments were performed using 
NCs. 
As already reported for BMSCs (25,26), cell death of IFP-MSCs and ASCs occurred during chondrogenic 
pellet culture, as demonstrated by a significant decrease in cell number after 14 days. Surprisingly, also 
ACs and NCs underwent cell death, although to a minor extent when compared to IFP-MSCs and ASCs. 
Evaluation of total GAGs content demonstrated that co-culture with ACs did not lead to IFP-MSCs and 
ASCs chondro-induction. Indeed, the measured values did not differ significantly from the ones 
predicted as the sum of the single contribution of ACs and IFP-MSCs or ASCs alone corrected for their 
ratio in co-culture pellets. A recent study has reported that chondro-induction is observed in co-
cultures of ASCs combined with ACs or NCs (25). A major difference between this study and ours can be 
found in the origin of cells used: while Acharya et al. (25) uniquely used non-expanded healthy 
chondrocytes, we used ACs from OA donors undergoing a longer expansion phase known to negatively 
affect ACs chondrogenic phenotype (4). Furthermore, to prepare autologous co-cultures from the same 
patient we had to cryopreserve ACs because of the different time required for ACs, IFP-MSCs and ASCs 
expansion. It has been recently shown that ACs cryopreservation can significantly reduce gene 
expression of SOX9 and COL2 (32), which suggests that the chondrogenic ability of ACs used in our 
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experiments may have been further impaired by this procedure. Considerations about the impact of 
cell expansion and cryopreservation on chondrogenic differentiation can also explain the results 
obtained in NCs co-cultures, in contrast with recently published data (25). Indeed, the low 
chondrogenic ability of ACs and NCs used in our study was confirmed by GAGs normalized by DNA, 
which revealed that the amount of GAGs produced by a single cell by ACs and NCs was similar to that 
observed for IFP-MSCs and ASCs. On the other hand, in accordance with our observations, Giovannini 
et al. (26) have reported that ACs failed to induce BMSCs to chondrogenesis, although BMSCs/ACs co-
culture resulted in significant cartilaginous matrix formation. However, the higher chondrogenic 
potential of BMSCs in comparison with ASCs (33,34), together with a longer period of chondrogenic 
differentiation and healthy origin of ACs (26), could explain why in our experiments only in IFP-
MSCs/ACs and IFP-MSCs/NCs a small increase in GAGs deposition was observed through histological 
evaluation. 
Performing co-culture only between human cells, it was not possible to distinguish the response of 
each single cell type, differently from other studies where animal ACs have been co-cultured with 
human MSCs and specific probes have been used to distinguish the human and bovine genes 
expression (25,29). Thus, we evaluated the global response in terms of gene expression levels 
comparing mono-culture and co-culture pellets. We did not observe a significant up-regulation of 
chondrogenic markers in IFP-MSCs/ACs and ASCs/ACs compared to IFP-MSCs and ASCs pellets and their 
levels remained notably lower compared to those observed in ACs. Our results differ significantly from 
those published by Lee et al. (24) where a significant difference in SOX9 and COL2A1 expression was 
observed between ASCs and ASCs/ACs pellets and levels of these genes were comparable to those of 
ACs. Despite similarities with our study can be found in ACs expansion and cryopreservation, 
differences with our results could be related to the higher percentage of ACs (50% ACs/50% ASCs) and 
to the absence of TGF-β1 during culture (24). Furthermore, in their study ACs were isolated from 
cartilage showing only minimal OA changes and retained a higher ability to produce GAGs, as 
demonstrated by values of GAGs/DNA 2-fold higher than ours even in absence of TGF-β1. These 
dissimilarities could also explain why they obtained the formation of cartilage-like matrix with 
comparable collagen II deposition in ASCs/ACs and ACs pellets, whereas in our study the co-culture of 
IFP-MSCs and ASCs with either ACs or NCs did not lead to cartilagineous matrix generation (24). In 
another study, Hildner et al. (23) analyzed gene expression only in co-cultures performed in a 3D matrix 
(Tisseel or Tissue Fleece). It must be highlighted that in their study ASCs contribution to the expression 
of chondrogenic genes was significant only when small percentages of ACs were used (5% or 10%) (23). 
In our study, results from gene expression analysis of NCs co-cultures were similar to those obtained 
from ACs co-cultures, despite lower levels of SOX9, COL2A1 and ACAN were found in NCs. Surprisingly, 
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COMP expression was lower in NCs than in IFP-MSCs and ASCs which resulted in diminished expression 
of this gene in IFP-MSCs/NCs and ASCs/NCs pellets. In this study we used NCs from a single donor and 
given inter-donor differences the differential expression of COMP in NCs and ACs would need further 
investigations to be confirmed. To our knowledge, no study reporting gene analysis in co-culture of 
ASCs and NCs has been published, which does not permit comparison with our results. 
In conclusion, in our study a small percentage of expanded and cryopreserved ACs and NCs failed to 
induce chondrogenesis in MSCs from infrapatellar fat pad and knee subcutaneous adipose tissue and 
did not lead to the generation of cartilage-like matrix similar to that produced by ACs and NCs. This 
result may depend on several combined factors such as the percentage of chondrocytes used, their de-
differentiation state related to prolonged expansion and cryopreservation as well as the advanced 
donors’ age and the pathological origin of ACs. These considerations suggest that specific attention 
must be given to chondrogenic potential and origin of chondrocytes used in co-culture studies and to 
the experimental design of each study (e.g. MSCs/ACs ratio, use of differentiative factors, 
differentiation time) to better understand their results. However, clinical applicability of the co-culture 
approach still deserves further investigation to extend it also to patients characterized by advanced age 
or degenerative pathologies. 
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Chapter 6 
Rapid prototyping of multi-well devices for pellet 
culture and biofabrication of patterned scaffolds  
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Abstract 
Three-dimensional (3D) cultures are widely used as in vitro models for cell culture in basic and 
translational research. Pellet culture is used in cartilage tissue engineering area to promote in vitro 
chondrogenic differentiation. Unfortunately, handling a high number of experimental replicates in 3D 
pellet culture experiments is extremely time consuming. To overcome this limitation, we exploited low-
cost rapid prototyping techniques, such as laser ablation and replica molding, to generate multi-well 
chips in polydimethylsiloxane (PDMS) able to support the formation and culture of multiple cell 
aggregates. The use of PDMS chips significantly reduced the time required for pellet seeding and 
medium refresh. We found that chondocytes pellets generated with this approach were comparable to 
pellets obtained by standard culture in polypropylene tubes, in terms of proliferation and metabolic 
activity. Type II collagen deposition was increased in pellets cultured in PDMS chips, showing that 
chondrocyte differentiation was improved. The same biofabrication approach was applied to generate 
a patterned fibrin glue scaffold. As a proof of concept, we biofabricated an implantable multi-well 
constructs using clinically approved fibrin glue. We demonstrated that regions with different cell 
densities can be generated within the construct and that cells can be distributed in a spatially 
controlled way. These multi-well implantable scaffolds can be seeded with multiple cell types allowing 
the precise distribution of different cell populations, thus representing a useful tool to investigate in 
vitro and in vivo cell interactions in a 3D environment. 
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Introduction  
Three-dimensional (3D) cultures are widely used as in vitro models for cell culture. Compared with a 2D 
monolayer culture, a 3D model better mimics the in vivo tissue features providing a physiologically 
relevant environment. Multi-well devices have become a viable alternative to standard methods to 
generate and culture multiple cell aggregates, having a broad range of applications in the basic research 
and drug screening on tumor spheroids (1,2) and in tissue engineering basic and translational studies 
(3,4). Rapid prototyping technologies represent an exceptional tool to generate easy-handling platforms 
for 3D cell culture. However, existing lithography-based approaches are often expensive and time 
consuming (5). Indeed, current approaches based on lithographic fabrication require cleanroom facilities 
and minor changes in the design involve an increase in the cost of fabrication and materials. Laser 
fabrication, involving material ablation via beams of infrared light, offers an alternative to lithography-
based approaches for rapid prototyping (6). Recent studies using 3D laser printing (7) or carbon dioxide 
laser (CO2 laser) ablation (8,9) to generate microwells attempted to minimize fabrication complexity. 
In this work we present a rapid, low-cost prototyping method which can be readily available for any 
laboratory to create patterned polydimethylsiloxane (PDMS) chips using polymethylmethacrylate 
(PMMA) CO2 laser ablation for the generation of the master template. Multi-well PDMS chips generated 
with this approach can be used as easy-handling devices for the formation and culture cell aggregates or 
as molds to biofabricate scaffolds with a controlled architecture.  
Articular chondrocytes (ACs) are a widely investigated cell source in the field of cartilage tissue 
engineering (10,11). Their chondrogenic re-differentiation, necessary to re-acquire the original 
phenotype after the in vitro expansion phase (10-12), is performed inducing the cell to form 3D 
aggregates by centrifugation in polypropylene conical tubes (13-16). This type of culture is traditionally 
used in in vitro studies aiming at the characterization of specific cell populations and for the 
optimization of chondrogenic differentiation protocols. This type of studies normally require to prepare 
replicates using cells from different donors, leading to a consistent number of samples. Unfortunately, 
handling a high number of pellets makes routine operations, such as medium refresh, extremely time-
consuming. Furthermore, the simultaneous culture of hundreds of pellets requires a consistent fraction 
of the space available in a standard CO2 incubator and is related to a high risk of contamination.  
Based on the need of user-friendly platforms to implement 3D pellet culture, in the first part of this 
study we applied the laser ablation and replica molding techniques to generate PDMS chips for the 
simultaneous culture of several cell aggregates, comparing the viability and differentiation of ACs pellets 
cultured in the PDMS chips with the one of standard pellets in polypropylene tubes. 
Another major demand in the tissue engineering research is the possibility to generate scaffold with a 
control architecture that allow the control of cell distribution and/or cell orientation by topographical 
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cues (17). A very recent study has shown that implantable multi-well scaffolds can be used to screen in 
vivo the influence of different extracellular matrix components on the chondrogenic differentiation of 
cells seeded within the wells (18), demonstrating the potentiality of this approach. 
In the present study, we applied laser ablation and replica molding techniques to generate multi-well 
implantable constructs where different cell types can be embedded both into the scaffold structure and 
into the wells. Such a scaffold can be used to evaluate the effect of differential cell density areas within 
the scaffold, a parameter that is known to affect specific biological processes such as cartilagineous 
matrix deposition (19,20), and the interaction between multiple cell types distributed into the scaffold 
with a controlled spatial disposition. We used a clinically approved fibrin glue (21-23) to validate our 
biofabrication process. As a proof of concept, we generated a construct with different cell density 
regions and we performed a subcutaneous implantation in nude mice to determine the in vivo behavior 
of the multi-well construct. 
 
Materials and Methods 
Fabrication of PMMA molds 
Drawings of master molds were made by AutoCAD® software (©Autodesk, Inc.) and processed by Corel® 
DRAWTM software (©Corel 
Corporation, 2002) (Figure 1). 
Wells were patterned by laser 
ablation of a PMMA substrate, 
following a protocol described 
elsewhere (8,9), in order to 
yield an array of 2 and 3.4 mm 
wells with a conical cross-
section. After an optimization 
phase to identify the best 
combination of work 
parameters, selected settings 
were: of 22.5 W, write speed of 
0.08 mm/s and focal distance z 
of 17.2 mm. 
 
Fig. 1. Schematic of the PDMS chips fabrication process. A drawing is 
generated in a CAD program (top view with insets showing pitch, diameter 
in x and y direction, taper angles and height of the wells; I) and used as a 
pattern for laser ablation of the PMMA (side view; II). PDMS is poured on 
the patterned PMMA (side view; III). PDMS is peeled off the PMMA after 
polymerization (side view; IV). Rendering of the PDMS devices (IV). 
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Fabrication of PDMS chips and molds 
For PDMS chips and molds, a PDMS mixture (Dow Corning) was prepared at a 10:1 ratio 
(prepolymer/curing agent), degassed, poured on a PMMA mold and baked at 70°C for 2h. Once 
polymerized, the PDMS was carefully peeled off the master template and cleaned with 70% EtOH. After 
rinsing with ddH2O, the PDMS devices were sterilized by autoclave. 
To evaluate the fidelity to the drawing, geometrical characteristics of PDMS devices (A and B) have been 
analyzed using the software Image J (eccentricity; pitch; taper angles, α and β) (Fig. 1). Well diameter 
was 2.0 mm for device A and 3.4 mm for device B. The height of the wells (PA and PB) was 2 mm, The 
fabrication steps and the final devices are shown in Fig. 2. PDMS molds to be used in the biofabrication 
of multi-well scaffolds were plasma treated (Harrick Plasma Instruments, USA) for 8 minutes to increase 
surface hydrophilicity immediately prior to use. 
 
Cell isolation and expansion 
Samples of articular cartilage were harvested from patients affected by osteoarthritis undergoing total 
hip replacement, with patients informed written consent and with the approval of the Institutional 
Review Board. Articular chondrocytes were isolated from cartilage by enzymatic digestion using 0.15% 
type II collagenase (Worthington Biochemical Co) for 22 h at 37°C, according to a previously established 
protocol (15). The cells were plated at a density of 104 cells/cm2 and cultured in expansion medium. 
Expansion medium was composed as follows: High Glucose Dulbecco’s Modified Eagle’s Medium (HG-
DMEM, Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Lonza), 1% HEPES (Gibco), 1% Sodium 
pyruvate (Gibco), 1% Penicillin/Streptomycin/Glutamine (Gibco), 1 ng/mL Transforming Growth Factor 
ß-1 (TGF-ß1, Peprotech) and 5 ng/mL Fibroblast Growth Factor 2 (FGF-2, Peprotech). At subconfluence, 
cells were detached by 0.05% trypsin/0.53 mM EDTA (Gibco) and plated at 5×103 cells/cm2 for further 
expansion. At passage 2 cells were frozen and stored in liquid nitrogen. When needed, cells were 
thawed and expanded for one passage more. To limit the expansion phase required to obtain a suitable 
number of cells, cells from different donors were pooled together to perform the experiments. 
 
Fluorescent cell staining 
To analyze cell distribution in the fibrin glue constructs, cells were stained either with the green 
fluorescent dye Vybrant DiO or with the red fluorescent dye Vybrant CM-Dil (both from Invitrogen) 
according to the manufacturer’s instructions. Briefly, after trypsinization cells were suspended at a 
density of 1x106 cells/mL in serum-free culture medium. Vybrant DiO or Vybrant CM-Dil was added to 
the cell suspension (5 μL/mL). Cells were incubated for 10 min at 37°C and then centrifuged (1500 rpm, 
5 min). Supernatant was removed and the cells were washed twice in expansion medium prior to use. 
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Pellet formation and culture 
Sterile PDMS chips were inserted into the wells of a 12-well multiplate. PDMS chips were then seeded 
with a total number of 2.85x106 cells in order to generate aggregates containing 1.5x105 cells (19 
wells/PDMS chip). Cell seeding was performed by pipetting a volume of cell suspension corresponding 
to 1x105 cells in each single well. The multi-well was then centrifuged 5 min at 230g to favor pellet 
formation and after 4 h, 2.85 ml of chondrogenic medium were added to the multiplate wells. Control 
pellets were prepared in 1.5 ml screw-cap tubes. Briefly, 1.5x105 cells were suspended in 150 μL of 
chondrogenic medium, transferred to 1.5 ml screw-cap tubes and centrifuged 5 min at 230g. 
Chondrogenic medium was composed as follows: HG-DMEM supplemented with 0.029 mg/ml L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM Hepes, 1 mM sodium pyruvate, 1.25 
mg/ml Human Serum Albumin (HSA, Sigma-Aldrich), 1% ITS+1 (containing 1.0 mg/ml insulin from bovine 
pancreas, 0.55 mg/ml human transferrin, 0.5 μg/ml sodium selenite, 50 mg/ml bovine serum albumin 
and 470 μg/ml linoleic acid, Sigma-Aldrich), 0.1 µM dexamethasone, 0.1 mM L-ascorbic acid-2-
phosphate and 10 ng/ml TGF-β1. Samples were cultured for 21 days (37°C, 5% CO2). Medium was 
replaced twice a week during culture.  
 
Generation of multi-well fibrin glue constructs 
The two-component fibrin sealant Tisseel® (Baxter Biosurgery) was used to generate the fibrin glue 
constructs. The kit contained 110,5 mg/ml clottable protein of which 91 mg human fibrinogen and 3000 
KIU/ml aprotinin solution. Thrombin was diluted to 5 U/mL in 40 mM of CaCl2 at pH 7.0.  
In the first phase of the study three different configurations of the bottom layer were tested: (1) 19 
wells, Øwell 1 mm, hwell 1.5 mm; (2) 10 wells, Øwell 1.5 mm, hwell 1.5 mm; (3) 7 wells, Øwell 2 mm, hwell 1.5 
mm. For each construct, 1.15x106 green-stained cells were mixed with fibrinogen and thrombin 
components (1:1). The mixture was poured into the PDMS mold and let polymerize for 1 h at 37°C.  
For cell seeding into the wells, red-stained chondrocytes were suspended at a concentration of 1x105 
cells/μL in chondrogenic medium. In the different configurations a different number of cells was seeded 
in the wells: (1) 1x105 cells in Øwell 1 mm; (2) 2x10
5 cells in Øwell 1.5 mm; (3) 4x10
5 cells in Øwell 2 mm. 
After 15 min, 3 ml of chondrogenic medium were added.  
In the second phase of the study, experiments with either unstained or stained cells were performed 
using the configuration (2) for the bottom layer (Øwell 1.5 mm, hwell 1.5 mm). Two types of fibrin glue 
constructs (Ø 8 mm, h 3 mm) were prepared, each containing a total number of 4x106 cells: (a) multi-
well fibrin glue constructs (Øwell 1.5 mm, hwell 1.5 mm) with 2x10
6 cells dispersed in the fibrin glue 
(bottom layer + top layer) and 2x106 cells seeded into the multi-wells as high density centers; (b) fibrin 
glue scaffold with 4x106 cells homogeneously distributed as control group. 
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The multi-well bottom layer was generated as aforementioned. After polymerization, the fibrin glue 
layer was gently removed from the PDMS mold and transferred into a 12-well multiplate. Custom made 
PDMS rings (Øout 10 mm, Øin 8 mm, h 3 mm) were placed around the bottom layer. Then, 2x10
5 cells 
were seeded in each wells and let adhere for 15 min at 37°C. Finally, a top of fibrin glue was generated 
to ultimate the scaffold. In this phase, the PDMS ring was used to match the bottom layer shape and to 
avoid fibrin glue leaking. For the top (Ø 8 mm, h 1 mm), 8.5x105 cells were mixed with fibrinogen and 
thrombin components (1:1). This mixture was poured on top of the multi-well bottom layer and let 
polymerize for 1 h at 37oC before removing the PDMS ring.  
To prepare fibrin glue scaffolds without wells, the custom-made PDMS rings were placed into a 12-well 
multiplate. Then, 4x106 cells were mixed with fibrinogen and thrombin components (1:1). The mixture 
was poured into the PDMS ring and let polymerize for 1 h at 37oC.  
After complete polymerization, samples were cultured in 3 mL of chondrogenic medium for 1 or 7 days. 
 
In vivo implantation in nude mice of fibrin glue constructs 
To evaluate the maintenance of the scaffold structure in vivo, the fibrin glue constructs seeded with 
green-stained and red-stained cells were subcutaneously implanted in nude mice. The in vivo study was 
approved by the Mario Negri Institute for Pharmacological Research (IRFMN) Animal Care and Use 
Committee (IACUC). Animals and their care were handled in compliance with institutional guidelines as 
defined in national (Law 116/92, Authorization n.19/2008-A issued March 6, 2008, Italian Ministry of 
Health) and international laws and policies (EEC Council Directive 86/609, OJ L 358. 1, December 12, 
1987; Standards for the Care and Use of Laboratory Animals - UCLA, U.S. National Research Council, 
Statement of Compliance A5023-01, November 6, 1998).  
Three 6-weeks-old female athymic mice were obtained from Harlan and maintained in the Animal Care 
Facilities of the IRFMN, under specific pathogen-free conditions with food and water provided ad 
libitum. Animals were anesthetized by intraperitoneal injection of ketamine chloride (80 mg/kg, 
Imalgene, Merial) and medetomidine hydrochloride (1 mg/kg, Domitor, Pfizer). Surgical procedures 
were performed in sterile conditions under a laminar flow hood. Four subcutaneous pockets were 
created on the dorsum of each mouse by blunt dissection through cranial and caudal skin incisions. One 
fibrin glue scaffold was inserted in each pocket, then the skin was sutured with #4-0 Monocryl thread 
(Ethicon). After 28 days, the mice were euthanized by CO2 inhalation and constructs were harvested. 
After the removal of the fibrotic tissue around the explants, stained cells were visualized with a 
fluorescence microscope. 
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Sample analyses  
Measurement of time required for pellet seeding and medium refresh 
For standard pellet culture and culture in PDMS devices, we measured the time required to perform cell 
seeding and medium refresh operations. Independent measures were obtained testing 3 operators with 
different level of skills in cell culture techniques. 
 
Cell viability assay and DNA quantification 
After 21 days of pellet culture in chondrogenic medium, cell viability was evaluated by Alamar Blue 
assay. Briefly, pellets were randomly harvested from different PDMS chips and from the tubes (control 
group) and transferred to a 96-well multiplate. Then, each pellet was incubated with 100 μL HG-DMEM 
supplemented with 10% Alamar Blue (4 h, 37°C). After incubation, the supernatant was harvested and 
fluorescence was measured (540 nm-580 nm) using a Victor X3 Plate Reader (Perkin Elmer). 
The same pellets were lysed for DNA quantification. After washing with Phosphate Buffered Saline (PBS), 
pellets were digested (16 h, 60°C) in 500 µl of PBE buffer (100 mM Na2HPO4, 10 mM NaEDTA, pH 6.8) 
containing 1.75 mg/ml L-cystein (Sigma-Aldrich) and 14.2 U/ml papain (Worthington). DNA 
quantification was performed by CyQUANT Kit (Invitrogen), according to the manufacturer’s 
instructions.  
 
Histological and immunohistochemical evaluation 
For histological analysis, pellets and fibrin glue constructs were fixed for 24 h in 10% neutral buffered 
formalin, embedded in paraffin and sectioned at 3 μm.  
Pellet sections were stained with alcian blue (pH 2.5, Sigma-Aldrich) to visualize glycosaminoglycans 
(GAGs) deposition. For immunohistochemistry, sections were deparaffinized, rehydrated and treated 
with 3% hydrogen peroxide in distilled water for 15 minutes. Mouse monoclonal anti-Collagen II 
(SPM239) (prediluted, Abcam, ab54236) antibody was applied at room temperature for 1 h. The sections 
were labelled by the avidin-biotin-peroxidase (ABC) procedure (24) with a commercial 
immunoperoxidase kit (Vectastain Standard Elite; Vector Laboratories).  
The immunohistochemical reaction was developed with 3.3′ diaminobenzidine (DAB) for 5 min and 
sections were counterstained for 2 min with Mayer's haematoxylin. For morphological evaluation of 
fibrin glue scaffolds, sections were stained with hematoxylin and eosin (HE). 
 
Analysis of structure and cell distribution in fibrin glue constructs 
The macroscopic features of the different bottom layers were evaluated by stereomicroscope (Olympus 
SXZ10). Cell distribution into the scaffold and feasibility of cell seeding into the wells were evaluated by 
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fluorescence microscopy (Olympus IX71) using green- or red-stained cells.  
 
Statistical analysis 
Cell viability, DNA content, and metabolic activity data are presented as mean±SD. Comparison among 
the different experimental groups was performed by One-Way ANOVA with Dunnett’s post-test 
(GraphPad Prism version 5.00 for Windows, GraphPad Software). 
 
Results 
Multi-well PDMS chips support the generation and culture of chondrocyte pellets 
To determine the optimal laser engraving conditions to achieve the three desired well diameters, an 
array of lines was printed on PMMA by varying the laser power and write speed. The following settings 
resulted in uniform wells of the desired sizes. The laser power was set at 22.5 W, the write speed at 0.08 
mm/s, and z = 17.2 mm.  
Optical images of the fabricated wells can be seen in Fig. 2. PMMA microwells exhibited an irregular 
edge and debris distributed 
over the edges (Fig. 2a).  
PDMS multi-well arrays 
demonstrated fidelity to the 
original design. The pitch in 
the well array (center to-
center distance) was 2 mm. 
The inner surface revealed 
cone-shaped walls (Fig. 2b). 
Articular chondrocytes were 
used to test the multi-well 
PDMS chips in order to evaluate their ability to support the formation of cell pellets.The PDMS chips 
were designed to fit the wells of a 12 multi-plate, allowing the simultaneous culture of a high number of 
samples and of different experimental conditions in the same plate,as shown in Figure 3a where PDMS 
chips immediately after cell seeding are depicted.. The use of these devices significantly reduced the 
time required for cell seeding and medium refresh operations compared to standard pellet culture, 
representing a technical amelioration in terms of work efficiency (Fig. 3b). The PDMS chips, thanks to 
the transparency of the material, also allowed to monitor the samples through microscopy throughout 
the entire period of culture and to measure basic parameter such as pellet area.  
Fig. 2. PDMS chips fabrication process. (a) Ablated PMMA molds (I). PDMS 
casting for replica molding (II). Device A (Øwell 2 mm) (III). Device B (Øwell 3.4 mm) 
(IV). (b) Optical images of device A (right) and B (left). Scale bars: 1 mm except 
where noted. 
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As shown in Fig. 3c, cell aggregates started to form already 24 hours after cell seeding and, after 21 days 
of culture, pellets were well-formed in both types of PDMS chips. Pellets area increased from 7 to 21 
days of chondrogenic culture due to matrix deposition (Fig. 3b). At the end of culture, we compared the 
Fig. 3. Validation of PDMS chips for seeding and culture of chondrocyte pellets. (a) Picture of the two PDMS chips 
positioned in a 12- multiplate immediately after cell seeding. (b) Measurements of the time required to perform cell 
seeding and medium refresh (* p<0.001, PDMS chips vs standard pellet culture). (c) Micrographs of a representative 
well of the two PDMS chips seeded with chondrocytes at different time points. (d) Average area of pellets cultured in 
the PDMS chips over time (* p<0.05, 21 days vs 7 days). (e) DNA content and cell viability measured in pellets 
cultured in 1.5 ml tubes (control group, Ctrl) or in PDMS chips after 21 days of culture. Metabolic activity calculated 
as the ratio between cell viability and DNA content of each single pellets. (f) Histological evaluation of GAGs and type 
II collagen deposition in control pellets and in pellets cultured in PDMS chips after 21 days of culture.  
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cell viability of pellets cultured by standard technique and pellets cultured in PDMS chips (Fig. 3d). No 
significant difference in cell viability was observed among the different experimental groups. In the 
same way, the DNA content and the metabolic activity of pellets cultured in tubes and in PDMS chips did 
not differ, showing that pellets cultured in PDMS chips were viable and active as standard pellets. 
Histological evaluation revealed that GAGs deposition, which is a key marker of chondrogenic 
differentiation, was comparable in Ctrl pellets and in pellets cultured in multi-well PDMS chips (Fig. 3e). 
Lacunar structures, similar to those found in native hyaline cartilage, were observed in all the 
experimental groups. Analysis of type II collagen deposition by immunohistochemistry revealed a more 
intense staining in pellets cultured in PDMS chips compared to standard pellets, indicating the 
production of highly specialized extracellular matrix in these samples (Fig. 3f).  
 
PDMS molding allows the generation of multi-well fibrin glue scaffold with differential cell 
density regions  
Multi-well fibrin glue constructs were prepared according 
to the scheme depicted in Fig. 4a. The easiness of the 
biofabrication process allowed us to prepare a maximum 
of 65 samples simultaneously.  
PMMA and PDMS molds with the three different tested 
configurations are shown in Fig. 4b. The PDMS molding 
was used to produce fibrin glue constructs with different 
multi-well pattern as shown in Fig. 5a. We noticed that 
the configuration with 10 wells (Øwell 1.5 mm) was the 
easiest to produce and manipulate. Indeed, the 
configuration with larger wells (Øwell 2 mm) had a very 
thin outer border that did not allow the easy removal of 
the scaffold from the PDMS mold. The peripheral border 
of these constructs tended to break during this operation, 
resulting in lateral leaking of the cells seeded into the 
wells. On the other hand, the configuration with smaller 
wells (Øwell 1 mm) was quite easy to manipulate since 
stiffer, but small imperfections in the fibrin glue bottom 
layer resulted in a dramatic reduction of the volume of 
the wells, making the cell seeding not reproducible.  
Cell embedding in the bottom layer resulted in a 
Fig. 4. Schematic of the multi-well fibrin glue 
construct biofabrication. (a) PMMA molds and 
PDMS counter-molds were generated. Cell-
loaded fibrin glue was poured into the PDMS 
mold to generate the multi-well bottom layer. 
After polymerization, the wells were seeded 
cells. Cell-loaded fibrin glue was then poured on 
the the bottom layer. (b) Picture of PMMA 
molds (left) and PDMS counter-molds (right). 
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homogeneous distribution of cells throughout the scaffold (Fig. 5b, upper row, green-stained cells). The 
seeding of cells in the multi-wells proved also to be effective (Fig. 5b, middle and lower row). As 
aforementioned, the incomplete formation of the outer border in the scaffold with Øwell 2 mm, was 
associated to inefficient cell retention into the wells as shown in Fig. 5b (lower row), where the well in 
the right corner in the image does not contain any red cell after 24 h of culture.  
Thus, we selected the configuration with Øwell 1.5 mm for the prosecution of the study. The central 
section of the bottom layer shows the cell deposition on the bottom side of each well (Fig. 5c), 
demonstrating that in this configuration red-stained cells were confined into the wells and that 
differential cell density regions were generated within the scaffold.  
Using the selected configuration of bottom layer (10 wells, Øwell 1.5 mm, hwell 1.5 mm) the construct was 
completed by adding the top layer. In Fig. 6a macroscopic pictures of fibrin glue scaffolds without wells 
and with wells immediately after complete polymerization are shown. The pattern of multi-wells was 
still visible under the top layer (Fig. 6a, right image). Morphological evaluation by HE staining showed 
that the multi-well structure was maintained after 7 days of in vitro culture (Fig. 6b). In control scaffolds 
Fig. 5. Biofabrication of multi-well 
fibrin glue constructs. (a) Micrographs 
showing the different configurations 
designed for the fibrin glue bottom 
layer (scale bar 1 mm). Insets 
represent the entire bottom layer. (b) 
Cell distribution in the multi-well 
constructs. The upper row shows 
green-stained cells in the bottom 
layer, the middle row shows red-
stained cells in the wells, and the 
lower row shows the merged picture 
of the bottom layer with the cell-
seeded wells (scale bar 1 mm). (c) Side 
view of the fibrin glue scaffold section 
(Øwell 1.5 mm, h 1.5 mm, scale bar 1 
mm). 
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cells were homogeneously dispersed into the fibrin glue (left column), whereas the borders of single 
wells were clearly visible in multi-well scaffolds 
(right column). Indeed, in multi-well constructs a 
multi-layer of cells was visible inside the wells 
demonstrating that differential cell density areas 
were present into the scaffold. Finally, we evaluated 
the behavior of multi-well constructs after in vivo 
subcutaneous implantation in nude mice. After 5 
weeks of implantation the dimensions of the 
scaffolds were dramatically reduced. The pictures 
reported in Fig. 7 represent the same scaffolds 
photographed prior and after implantation with the 
same microscope magnification and show the 
reduction of the diameter from 8 mm to 1.5-2 mm. 
Surprisingly, despite the reduction in the construct 
dimensions, the multi-well structure was 
maintained, as shown in the post-implantation 
pictures where the high density seeding areas in the 
wells are still clearly visible. 
 
 
 
 
 
 
Fig. 6. Histological evaluation after 1 and 7 days of 
culture. (a) Representative pictures of fibrin glue 
scaffold. (b) Histological pictures of scaffold stained by 
H/E showing the borders of a single well and the 
distribution of cells on the bottom side of the well.  
 
Fig. 7. Evaluation of scaffold structure maintenance after in vivo implantation in nude mice. Micrographs showing 
the dramatic shrinking of the scaffold and the maintenance of the multi-well structure after in vivo implantation 
(upper row: top and bottom layers seeded with red-stained cells, wells seeded with green-stained cells; top layer, 
bottom layer and wells seeded with a mix of red- and green-stained cells) (fluorescence microscopy, scale bar 1 
mm). 
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Discussion 
The primary purpose of this study was to exploit low-cost rapid prototyping techniques to generate 
multi-well devices for pellet culture and to biofabricate patterned fibrin glue scaffolds. 
The use of the PDMS devices significantly reduced the time required for pellet seeding and medium 
exchange operations, which are highly time-consuming factors when handling several replicates and 
experimental groups. Furthermore, the possibility to culture simultaneously a maximum of 228 pellets in 
a single 12-multiplate allowed to reduce significantly the space required for samples culture in the CO2 
incubator. The high hydrophobicity of PDMS (25), related to the low cell adhesion on this material, led 
to the formation of well-defined chondrocyte pellets and the optical transparency of the PDMS chips 
allowed to monitor the process of pellet formation and the changes occurring during culture. The 
comparison between pellets generated and cultured in PDMS chips with pellets in polypropylene tubes 
did not reveal any significant difference in terms of DNA content, cell viability, and metabolic activity. 
Deposition of GAGs was similar in the different experimental groups, whereas type-II collagen was more 
present in pellets cultured in the PDMS chips compared to standard pellets. These results indicate that 
the generated system was able to support very well both cell viability and chondrogenic differentiation, 
thus representing an appealing option for 3D cell culture. A similar approach has been used in a very 
recent study to generate and culture chondrocyte micro-pellets (166 cells each) (4). In this study, the 
PDMS insert surface required a chemical surface treatment to avoid cell spreading all over the well. 
Differently, in our PDMS devices we did not need to perform any surface treatment since, probably due 
to the higher ratio between the number of cells and the surface available for cell adhesion, 
centrifugation was sufficient to trigger the formation of pellet in the wells. The generated PDMS chips 
can be also exploited to perform the indirect co-culture of cell aggregates obtained from different cell 
types. Indeed, thanks to the possibility to precisely seed each single well with a specific cell population 
and to retrieve pellets from selected wells this system would allow to evaluate the effect of paracrine 
factors in each cell type, representing a complementary alternative to the trans-well system.  
In the second part of the study we applied the same rapid prototyping approach to produce an 
implantable multi-well fibrin glue scaffold. It has been shown that cell density affects the capability of 
chondrocyte to generate specific cartilagineous matrix. In particular, several studies have shown that a 
high cell density in a 3D scaffold improves cartilagineous matrix deposition (19,20). However, this 
consideration needs to take in account the limitations related to the great number of chondrocytes 
required to seed the scaffolds with such a high cell density. This requirement is particularly critical 
considering the limited size of the harvestable biopsy of autologous cartilage that is related to the need 
to expand in vitro articular chondrocytes to achieve a relevant number of cells, implying major 
drawbacks such as chondrocytes de-differentiation (10-12,26). The generation of high cell density areas 
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within a scaffold may represent a successful approach to overcome this issue, leading to the formation 
of “chondrogenic centers” that drive the differentiation process and positively influence the 
differentiation of regions with lower cell density. Similar approaches have been proposed by other 
groups that have used chondrocytes aggregates of different dimensions to seed 3D scaffolds (3,27). 
Here, we did not generate the chondrocyte aggregate before scaffold seeding, but thanks to the ability 
of cells to adhere to the fibrin glue, regions with high cell density were created by seeding a confluent 
cell multilayer within the wells. However, the proposed scaffold configurations could be seeded with 
pre-formed aggregates, being the dimensions of the wells compatible with the dimensions of 
chondrocyte pellets obtained through standard techniques (1.5x105 - 5x105 cells/pellet).  
As hypothesized for the PDMS chips, a multi-well scaffold like the one generated in this study can be 
used to evaluate the effects of the co-culture between different cell types, such as chondrocytes and 
mesenchymal stem cells that are usually investigated through standard 3D culture models which do not 
allow the spatially controlled distribution of cells, such as pellet culture (28-30) and scaffolds (31,32). 
The controlled distribution of mesenchymal stem cells and bovine chondrocytes has been performed in 
a very recent study demonstrating that implantable multi-well scaffolds can be used to screen 
simultaneously the effect of several extracellular matrix components on the chondrogenic ability of 
MSCs in co-culture with bovine articular chondrocytes (18). Differently from this screening platform 
where cells are seeded uniquely into the wells, in our multi-well construct cells can be seeded both into 
the scaffold structure and inside the wells, allowing to evaluate the interaction among multiple cell 
population distributed in different regions of the scaffold.  
The implantation in nude mice revealed that the architecture of the construct was very stable. Indeed, 
after 5 weeks of in vivo subcutaneous implantation, despite the dramatic shrinking of fibrin glue that has 
been reported also by other groups (33,34), we found that the multi-well structure was maintained, 
indicating that our fibrin scaffolds underwent poor remodeling over time. However, since lower 
concentrations of fibrinogen are compatible with the biofabrication of fibrin glue scaffolds with a 
controlled architecture (35), this parameter can be modulated in order to increase or decrease the 
stability of the constructs, depending on the desired application.  
 
Conclusions 
We have presented a simple and economical method, employing technologies and instruments 
accessible at most of the tissue engineering labs, for the generation of devices for the culture of multiple 
cell aggregates and for scaffold prototyping, which could have a broad range of applications in several 
research fields.  
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Chapter 7 
The use of a bi-directional perfusion bioreactor for 
cartilage engineering promotes the reconstruction of 
hyaline cartilage rather than fibrotic cartilage  
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Abstract 
We previously reported that a cocktail of bone morphogenetic protein (BMP)-2, insulin and 
triiodothyronine (BIT) could trigger re-differentiation of human chondrocytes after their amplification on 
plastic, with cartilage-characteristic matrix reconstruction when the chondrocytes were seeded in 
collagen sponges. However, this matrix was not homogenously distributed in the scaffolds, most likely 
because the collagen sponges were cultivated in static conditions. With the aim of enhancing cellular 
access to nutrients and the soluble factors, bi-directional flow was tested to perfuse the scaffolds during 
cartilage reconstruction.  
After 3 weeks of amplification on plastic, ACs were seeded then cultivated for 21 days in collagen 
sponges under bi-directional flow, by using a prototype of OPB (Oscillating Perfusion Bioreactor). We 
established a program of perfusion including phases of high and low perfusion speeds to alternate 
sequences of cell stimulation and matrix deposition. For comparison, cultures of ACs in collagen sponges 
were performed in static conditions. The status of the chondrocyte phenotype and the nature of the 
matrix synthesized in collagen sponges were evaluated by real time PCR, Western Blotting and 
immunohistochemistry analyses. The viability and cell proliferation were also monitored.  
The results clearly indicate that perfusion improved cartilage matrix deposition within the sponges, in 
comparison with static conditions. More precisely, in the sponges cultured in the bioreactor, 
redifferentiated and metabolically active ACs produced a cartilaginous matrix rich in type II and type IX 
collagens and in glycosaminoglycans, with no sign of hypertrophy. Interestingly, a much lower amount 
of type I collagen was produced in the sponges cultivated in dynamic conditions, indicating therefore 
that bi-directional perfusion limits the risk of fibrocartilage formation. 
The combination of ACs, collagen sponges, and the BIT cocktail with the bi-directional perfusion 
bioreactor favors the reconstruction of hyaline cartilage. Importantly, bi-directional perfusion abolishes 
the spatial concentration gradients routinely observed in scaffolds in static culture. This study also 
demonstrates the value of a multi-factorial approach for the design of cell-based grafts for cartilage 
repair. 
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Introduction  
Population aging leads to an increasing number of symptoms related to degenerative lesions in articular 
cartilage. Among the younger population, traumatic cartilage lesions also have an increasing incidence 
given the importance of intensive sport practice in our society. Articular cartilage is an avascular tissue 
that has poor intrinsic healing capacities. Consequently, cartilage focal lesions are irreversible and often 
lead to osteoarthritis (OA), causing pain and disabilities for the patients. Several surgical approaches 
such as mosaicplasty or microfracture have been developed to repair damaged cartilage and avoid total 
joint replacement. However, these treatments remain unsatisfactory with the formation of a 
fibrocartilage rich in type I collagen which has different biomechanical properties from the hyaline 
cartilage, rich in type II collagen. 
Consequently, articular cartilage is a good candidate for cell therapy and tissue engineering approaches. 
The first cell therapy used in orthopaedic surgery was the Autologous Chondrocyte Implantation (ACI) 
developed by Brittberg et al. (1). ACI is now performed worldwide for the treatment of articular 
cartilage focal lesions. Briefly, chondrocytes are collected from a small biopsy of non-bearing healthy 
cartilage and amplified in vitro. The cell suspension is then implanted in the focal lesion of the same 
patient under a periosteal flap for the first generation of ACI or under a collagen membrane for the 
second.  
During chondrocyte expansion in vitro, it is well known that a dedifferentiation process occurs (2). This 
dedifferentiation is characterized by the loss of type II collagen expression in favor of fibrotic type I 
collagen expression (2,3). Thus, several studies demonstrated that the tissue produced during ACI was a 
fibrocartilage rich in type I collagen. Despite improvement in the quality of life of the patients, health 
agencies that survey ACI now agree that the method should be improved by the use of biomaterials and 
growth factors in order to deliver well differentiated chondrocytes and to broaden ACI clinical 
application to larger defects and developing OA lesions.  
In the context of matrix associated ACI (MACI), we previously demonstrated the reconstruction of a 
cartilage-characteristic matrix in collagen sponges by sequential addition of soluble factor cocktails 
during chondrocyte amplification (FGF-2 and Insulin, FI) and their culture in collagen scaffolds (BMP-2, 
Insulin and T3, BIT) (4). The FI-BIT combination allows a strong increase of cell reservoir, the 
chondrocyte redifferentiation and an enhanced matrix synthesis in collagen sponges. However, matrix 
deposition occurred only on the periphery of the scaffold, suggesting that nutrients and growth factors 
did not access the core of the sponge. 
Perfusion bioreactors are known to improve the homogeneity of the matrix produced in biomaterials (5) 
(6). In this study, a bidirectional interstitial perfusion bioreactor prototype, the Oscillating Perfusion 
Bioreactor (OPB) (7), was selected to perfuse the collagen sponges, with the view of improving cellular 
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access to nutrients and growth factors. The OPB was first used to enhance the formation of tissue 
engineered cardiac grafts independently and interactively with insulin-like growth factor (8). In another 
study, Valonen et al. used the OPB to engineer cartilage constructs in polycaprolactone scaffolds (9). 
They demonstrated that the culture of human mesenchymal stem cells in polycaprolatone scaffolds in 
the OPB prototype led to higher total collagen content and more homogenous matrix deposition in a 
chondrogenic medium. These exciting results prompted us to investigate the effects of bidirectional 
perfusion to stimulate human articular chondrocytes in collagen sponges, in combination with the BIT 
cocktail, in the context of MACI procedure. Special attention was given to the newly synthesized matrix 
in the collagen sponges through a careful analysis of its deposition and its protein composition.  
 
Materials and Methods  
Cell amplification  
Primary cultures of human chondrocytes were prepared from macroscopically healthy zones of 
osteoarthritic hip joints obtained from 12 donors (age range: 33-74) undergoing total hip replacement. 
The study was carried out in full accordance with local ethics guidelines and cartilage samples were 
collected after obtaining written informed consent of the donors and with the approval of the Institute 
Review Board. Chondrocytes were extracted as previously described (10). Briefly, small slices of cartilage 
were sequentially digested in culture medium consisting of DMEM/Ham’s F12 (Gibco-Invitrogen) with 
0.2 % trypsin (Sigma) for 30 min at 37°C, followed by 0.15 % bacterial collagenase A (Roche Applied 
Science) overnight. The cells were then seeded at a density of 0.8×104 cells/cm2 in culture medium 
supplemented with 10 % Newborn Calf Serum (NCS) (Hyclone), 50 µg/ml streptomycin (Panpharma) and 
2 µg/ml amphotericin B (Bristol Myers Squibb). At this stage, cells were designated P0. 36 h after 
seeding (P0-36h), medium was changed and was supplemented with 5 ng/ml FGF-2 (R&D Systems) and 
5 µg/ml insulin (Umuline rapide, Lilly). The cocktail of FGF-2 and insulin was designated FI. The culture 
medium was replaced 3 times a week until cells reached confluence. The cells were then trypsinized and 
replated at the same density for another passage (P1). After each trypsinization, cells were stained with 
Trypan blue and the ones excluding the dye were counted with a hemocytometer.  
 
The Oscillating Perfusion Bioreactor (OPB) 
The Oscillating Perfusion Bioreactor was used as previously described (8). In brief, each scaffold was 
press-fitted into the base of a specimen holder. Then, the specimen holder was closed, resulting in a 
collagen sponge immobilized in a 6.35-mm-diameter by 8-mm-long chamber within a loop of gas-
permeable silicone rubber tubing (1/32 inch wall thickness, Cole Parmer Vernon Hills, IL). Each loop was 
Perfusion bioreactors for cartilage tissue engineering 
82 
mounted on a 12.5-cm-diameter supporting disc (Fig. 1). 18 closed-loop chambers were mounted on an 
incubator-compatible motorized frame that slowly oscillated the chambers around their central axis (Fig. 
1). Interstitial fluid flow was ensured by fixing the construct within the specimen chamber to avoid fluid 
flow around the construct.  
 
Fig. 1. Oscillating Perfusion Bioreactor (OPB). The scaffold is fixed into a sample holder (asterisk) which is 
connected to a silicon tube forming the culture chamber. The chamber rotates around the central axis following an 
oscillatory movement, allowing the bi-directional interstitial perfusion through the scaffold full-thickness. A 
maximum of 18 independent chambers can be simultaneously positioned in the OPB frame. The left picture shows 
the OPB in the incubator with the PC-based control. 
 
Cell culture in collagen sponges  
Collagen sponges composed of native (90-95%) type I collagen and (5-10%) type III collagen were 
prepared from calf skin by Symatese Biomatériaux (Chaponost, France). They were crosslinked to 
increase their stability by using glutaraldehyde and sterilized by 25 kGy β-radiation. They were sized 
with a skin biopsy punch (Laboratoires Stiefel, France) as discs with 8 mm diameter and 2 mm thickness, 
which corresponds to a volume of 0.1 cm3. Their pore size was around 100 nm.  
Static conditions 
Passaged P1 chondrocytes contained in 15 ml of culture medium were seeded onto the sponges with 
13×106 cells/cm3  (750 000 cells per sponge) and the sponges were placed in 6-well culture plates and 
incubated at 37°C for 2 h. Ten milliliters of culture medium containing 10 % NCS and supplemented with 
50 µg/ml 2-Phospho-L-ascorbic acid (trisodium salt, Fluka) was then added to the wells. After 48h, 
medium was replaced by culture medium containing 10 % NCS and supplemented with 50 µg/ml 2-
Phospho-L-ascorbic acid in the absence or presence of 200 ng/ml of recombinant human BMP-2 
(Dibotermine-alpha, drug form of BMP-2 contained in the kit InductOs, Wyeth), 5 mg/ml insulin (Umulin, 
Lilly) and 100 nM thyroxin T3 (Sigma). The cocktail of BMP-2, insulin and T3 was designated BIT. The 
medium containing 10 % NCS and ascorbate was referred as control medium for the culture in scaffold. 
Medium was replaced twice a week over a culture period of 21 days.  
Dynamic conditions 
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Passaged P1 chondrocytes were dynamically seeded onto the sponges with 13×106 cells/cm3. More 
precisely, three milliliters of cell suspension were added to 7 ml of culture medium in each OPB 
chambers. The OPB worked at 1000 µm/s for 24h and was slowed down at 300 µm/s for the following 
24 h.  
After 48 h, medium was replaced by six milliliters of culture medium containing 10 % NCS, 50 µg/ml 
streptomycin (Panpharma) and 2 µg/ml amphotericin B (Bristol Myers Squibb) and supplemented with 
50 µg/ml 2-Phospho-L-ascorbic acid (trisodium salt, Fluka), in the absence or presence of 200 ng/ml of 
recombinant human BMP-2 (Dibotermine-alpha, drug form of BMP-2 contained in the kit InductOs, 
Wyeth), 5 mg/ml insulin (Umulin, Lilly) and 100 nM thyroxin T3 (Sigma). The cocktail of BMP-2, insulin 
and T3 was designated BIT. The culture medium containing 10 % NCS and ascorbate was referred as 
control medium for the dynamic culture in scaffold. Medium was replaced twice a week over a culture 
period of 21 days.  
Program 1: After the seeding phase, and during the whole culture period, the OPB worked at a constant 
speed of 100 µm/s. 
Program 2: After the seeding phase, during 72 h, the OPB worked at a constant speed of 5 µm/s. Then, a 
progressive increase of perfusion speed from 5 µm/s to 20 µm/s was applied in 7 days. During the last 9 
days, cycles with variations of perfusion flow rate were planned as followed: 8 h at 5 µm/s followed by a 
quick increase to 20 µm/s in 16 h.  
The programs of dynamic culture are indicated as prog 1 and prog 2 in the text.  
 
In vivo subcutaneous implantation  
The in vivo study was approved by the Mario Negri Institute for Pharmacological Research (IRFMN) 
Animal Care and Use Committee (IACUC). Animals and their care were handled in compliance with 
institutional guidelines as defined in national (Law 116/92, Authorization n.19/2008-A issued March 6, 
2008, by the Italian Ministry of Health) and international laws and policies (EEC Council Directive 86/609, 
OJ L 358. 1, December 12, 1987; Standards for the Care and Use of Laboratory Animals - UCLA, U.S. 
National Research Council, Statement of Compliance A5023-01, November 6, 1998).  
6-weeks-old female athymic mice were obtained from Harlan and maintained in the Animal Care 
Facilities of IRFMN, under specific pathogen-free conditions with food and water provided ad libitum. 
Animals were anesthetized by intraperitoneal injection of ketamine chloride (80 mg/kg, Imalgene, 
Merial) and medetomidine hydrochloride (1 mg/kg, Domitor, Pfizer) and surgeries were performed 
under a laminar flow hood, in sterile conditions. Unconnected subcutaneous pockets were created on 
the dorsum of each mouse by blunt dissection through cranial and caudal skin incisions. After in vitro 
culture for 21 days, one collagen sponge was inserted per pocket, then the skin was sutured with #4-0 
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Monocryl thread (Ethicon). 
After 6 weeks, the mice were euthanized by CO2 inhalation. At explantation, all constructs were 
dissected free from the nude mice, weighed and processed for histological analysis. 
 
Gene expression analysis by reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was isolated from the chondrocytes cultured in monolayer or in collagen sponges after 21 
days of culture by using the NucleoSpin RNA II kit (Macherey-Nagel), according to manufacturer’s 
instructions. Total RNA was then reverse transcribed as previously described (11).  
Real-time PCR amplifications were performed in a 20 µl reaction mix containing 10 µl Fast Start 
Universal SYBR green master (Roche), 4 µl RT aliquot diluted at 1:5 in sterilized water, 300 nM each 
primer and 4 µl water. Amplification was performed in a Rotorgene (Qiagen). Thermal cycling conditions 
consisted of an initial denaturation step of 95°C for 2 min, 40 cycles of 95°C for 15s and annealing and 
extension at 60°C for 30s. The sequences of the primers used in this study have been previously 
described (12). Fluorescence thresholds (Ct) were determined automatically by the software with 
efficiencies of amplification for the studied genes ranging between 90% and 110%. GAPDH Ct value was 
substracted from the target sequence Ct value to obtain Ct. The level of expression was then calculated 
as 2-Ct and expressed as the mean of duplicate samples. 
 
Antibodies 
Polyclonal rabbit antibodies to human type II collagen (Ref 20211) were kindly provided by D. J. 
Hartmann (13). Polyclonal rabbit antibodies to type I collagen were from Novotec (Ref 20111) and to 
actin from Sigma (Ref A5060). Monoclonal antibody to type IX collagen (23-5D1) was kindly provided by 
B. R. Olsen (14). Secondary antibodies were: alkaline phosphatase-conjugated anti-rabbit or anti-mouse 
IgG (Bio-Rad) and horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Cell signaling for Western 
blotting assays and Vector kit Immpress for immunohistochemistry experiments). 
 
Western-blot analysis 
After 21 days of in vitro culture, collagen sponges were frozen in liquid nitrogen. After thawing, they 
were rinsed with phosphate-buffered saline containing 2 mM EDTA and 0.2 mM PMSF, refrozen, then 
ground with a mortar and pestle into a fine powder finally resuspended and boiled in Laemmli buffer.  
For Western-blot analysis, equivalent amounts of proteins were separated by SDS-polyacrylamide gel 
electrophoresis on 4-12 % gradient gels for sponge samples, and on 6 % gels for culture medium 
samples. After transfer, membranes were probed with primary antibodies, washed and incubated with 
alkaline phosphatase-conjugated IgG for types I, II and IX collagens or with HRP-conjugated IgG for actin 
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detection. After multiple washes, bound antibodies were detected on X-ray films using an Immun-star 
AP or HRP chemiluminescent substrate (Bio-Rad). Membranes were re-probed with antibodies after 
striping (Re-Blot Plus Strong, Chemicon). 
Densitometry analyses were performed for type I and type II collagen on the western blotting data from 
every experiment with the ImageJ software. The values were calculated as the total of each collagen 
forms, namely the mature collagen chains, the unprocessed chains (pro) and the processing 
intermediates of the procollagen containing the aminopropetide (pN) or the carboxypropetide (pC), and 
normalized to the actin. 
 
Histological and immunohistochemical analysis  
Histological examinations of the collagen sponges seeded with chondrocytes were performed after 21 
days of in vitro culture and after subsequent 6 weeks of in vivo implantation in nude mice. The collagen 
sponges were rinsed in phosphate-buffered saline and fixed for 24 hours with 4 % neutral-buffered 
formalin. After dehydration in a graded series of ethanol baths, samples were embedded in paraffin, 
sectioned at 5 μm and stained with Mayer's hematoxylin. For histochemical detection of sulfated 
proteoglycans, sections were stained with 0.5% safranin-O in 0.1 M sodium acetate at pH 7.4 for 10 min. 
Safranin-O is a cationic dye that binds GAGs and stains orange in an aqueous mounting medium (15).  
Hematoxylin-eosin counterstaining and immunohistochemical analysis were performed on 4-5 µm 
sections. Incubation with type II collagen antibodies was followed by incubation with HRP-conjugated 
secondary antibodies. Sections were revealed with diaminobenzidine and observed with a DM 750 
microscope (Leica) with an integrated color camera (ICC50 HD). Image acquisition was achieved with Las 
Ez software (Leica). 
 
Statistical analysis 
Differences in relative gene expression between experimental groups were analyzed using the Mann-
Whitney U-test for non-parametric analysis. A p-value  0.05 was considered as significant. The number 
of experiments carried out is noted in the figure legends. 
 
Results 
Topography of the neosynthesized matrix in the collagen sponges  
Chondrocytes were amplified in monolayer and then seeded on collagen sponges for a three-week 
culture period in static or in dynamic conditions. The metabolic activity of the chondrocytes was verified 
during monolayer expansion and at the end of the culture in collagen sponges (data not shown). 
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Haematoxylin eosin stainings were realized to assess the repartition of the matrix synthesized by 
chondrocytes in collagen sponges. The proteoglycan content was evaluated by safranin O staining. In 
static culture conditions, as expected, a peripheral deposition of matrix rich in proteoglycans was 
evidenced (Fig. 2).  
 
Fig. 2. Deposition of cartilage-
characteristic matrix under static 
and dynamic conditions. Human 
articular chondrocytes were 
cultured in collagen sponges for 21 
days in static or dynamic conditions 
(prog 1), in the presence of BIT 
cocktail. Haematoxylin Eosin 
staining shows the matrix 
distribution in the sponges (Scale 
bars 100µm). Inserts show the Safranin O staining of the scaffold periphery (top right) and core (bottom left) at 
higher magnification. Images shown are representative of the experimental results (n=6).  
 
 
No matrix production was detected in the core of the collagen sponges. On the contrary, under bi-
directional perfusion, we observed a homogenous deposition of matrix within the scaffold. The 
produced matrix was characteristic of cartilage with the presence of proteoglycans both in the core and 
at the periphery of the scaffold. 
 
Characterization of the matrix synthesized by chondrocytes in the collagen sponges  
To further characterize the matrix produced by chondrocytes in the collagen sponges, we realized 
immunohistochemical analyses for type II and type I collagens that are markers of hyaline cartilage and 
fibrocartilage respectively. 
 
Fig. 3. Immunostaining of type II and type I collagen neo-synthesized by chondrocytes in collagen sponges in static 
or dynamic conditions. The chondrocytes were cultured for 21 days in collagen sponges in presence of the BIT 
cocktail in static or dynamic conditions (prog 2). The pictures show the scaffold core and are representative of 
experiments performed with cells isolated from six donors. (A) Dynamic culture conditions led to the formation of 
matrix production units rich in collagens (Scale bar: 10µm) (B) At the cellular level (dotted line), under dynamic 
culture conditions, the chondrocyte cytoplasm (white arrow head) is stained for type II but not for type I collagen 
(Scale bar: 10µm). 
 
 
In static culture conditions, in the scaffold core, chondrocytes were isolated and had a fibroblastic-like 
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shape characteristic of dedifferentiated chondrocytes (Fig. 3A). Regarding the collagen sponges cultured 
under bidirectional perfusion, well-defined matrix production units were homogeneously distributed in 
the scaffolds. Those units were constituted of several chondrocytes surrounded by newly synthesized 
matrix. Dynamic culture conditions also promoted a round morphology of the chondrocytes, typical of 
differentiated chondrocytes, whether the perfusion flow was constant (supplementary data S1) or not 
(Fig. 3A).  
At the cellular level, in static culture conditions, chondrocyte cytoplasms were stained for both type I 
and type II collagens, indicating an active production of those collagens after 21 days of culture (Fig. 3B). 
Very interestingly, under bidirectional perfusion, close examination revealed that type II collagen, but 
not type I collagen, was present in the cytoplasm, suggesting that, after three weeks of culture, the 
production of type II collagen was still active whereas type I collagen was no more synthesized. 
 
Dynamic culture conditions promote selectively type II collagen content over type I 
collagen 
To determine the biochemical composition of the newly synthesized matrix in the collagen sponges, 
western blotting analyses were performed on the hyaline cartilage markers, type II and type IX collagen, 
and on the fibrocartilage matrix marker, type I collagen. Type II and type IX collagen were detected in 
both static and dynamic culture conditions (Fig. 4).  
Fig. 4. Analysis of type I and type 
II collagen production by 
western blot analysis. A 
representative western blot 
analysis of the type II, type IX 
and type I collagen after 21 day 
of culture in collagen sponges in 
static (Sta) or dynamic 
conditions (Dyn) (prog 2) is 
shown in the left panel. The 
mature collagen chains, the 
unprocessed chains (pro) and 
the processing intermediates of 
the procollagen containing the 
aminopropetide (pN) or the carboxypropetide (pC) are indicated for type II and type I collagen. The upper band 
represents the dimers of collagen molecules (β). The immunoblotting for actin is shown as a loading control. These 
results are representative of six different experiments. The right panel shows the ratio of type II and type I collagen 
at the protein level after 21 days of culture. Densitometry analysis was performed on the western blotting data 
from all the experiments. The values were calculated as the total of each form, and normalized to the actin. The 
results are indicated as mean±SD (n=6). 
 
Covalently cross-linked dimers of type II collagen were also evidenced suggesting the presence of a 
fibrillar network. Very strikingly, a lower production of type I collagen was evidenced in dynamic culture 
conditions. This results was observed in the two dynamic culture conditions tested in this study, 
whether the perfusion velocity was constant (supplementary data S2) or not (Fig. 4). Therefore, the ratio 
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of type II / type I collagen production is favored in dynamic culture conditions (Fig. 4). The health 
agencies commonly use the ratio of type II/type I collagen gene expression as an index of chondrocyte 
differentiation and of tissue engineering construct quality. In our study, at the mRNA level, this 
differentiation index was increased by dynamic culture conditions (supplementary data S3). Considering 
that tissue engineering requires protein level evaluation, we went further in assessing the quality of the 
synthesized matrix by measuring this ratio at the protein level via a densitometry analysis of the western 
blotting data (Fig. 4). It showed that dynamic culture conditions favored hyaline cartilage matrix 
production over fibrocartilage matrix synthesis. Besides, at the end of the in vitro culture, a more 
detailed analysis of the different forms of type I and type II collagens corresponding to the different 
steps of collagen maturation indicated that equivalent amounts of procollagen and mature form of type 
II collagen were synthesized in both static and dynamic culture conditions, whereas equivalent amounts 
of procollagen and mature forms of type I collagen were produced only in static conditions. Indeed, 
dynamic culture conditions led to a very low amount of type I procollagen, suggesting that type I 
collagen was no longer synthesized.  
This result was further supported by the analysis of the engineered constructs at different time-points of 
culture. We monitored the expression and 
deposition of type I and type II collagens 
in the scaffolds, at 7, 14 and 21 days of 
culture. After 7 days of culture, 
chondrocytes still showed a fibroblastic-
like shape, characteristic of 
dedifferentiated chondrocytes, whereas, 
from day 14, a round morphology, typical 
of fully differentiated chondrocytes, was 
observed. Immunohistochemical analyses 
showed that pericellular matrix rich in 
type II collagen was detected from 14 
days of culture and the matrix production 
units were defined only after 21 days of 
culture (Fig 5). A strong type II collagen 
staining was observed in chondrocyte 
cytoplasms at every time-point, whereas, for type I collagen, it was observed only at 7 days of dynamic 
culture (Fig. 5). This suggests that the type I collagen was produced early in the culture period, which is 
in accordance with the previous results. 
Fig. 5. Analysis of the type II and type I collagen deposition in the 
collagen sponges at different time points. Collagen sponges 
seeded with chondrocytes were cultured in static or dynamic 
(prog 1). Samples were analyzed after 7 days (D7), 14 days (D14) 
or at the end of the culture (D21) by immunohistochemical 
analyses to evaluate the type II and type I collagen deposition. 
The pictures shown are representative of the experimental results 
(n=2). Scale bar: 10µm. 
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At the gene expression level, COL2A1 mRNA steady-state levels in collagen sponges gradually increased 
over 21 days of culture both in static and dynamic 
conditions (Fig. 6). These results were coherent with the 
western blotting analysis showing an active production of 
type II collagen during the whole culture. On the other 
hand, COL1A1 mRNA level was lower at each time point in 
dynamic culture conditions, which is consistent with the 
western blotting results at the end of the culture. Type I 
collagen expression remained steady during the whole 
static culture. On the contrary, after 7 days of dynamic 
culture, a strong decrease of COL1A1 mRNA level was 
observed, confirming the arrest of type I collagen 
expression during the 3D culture. Yet, the ratio of type 
II/type I collagen synthesis was enhanced in dynamic 
culture conditions as soon as 14 days of culture (Fig. S4). 
This highlights that the combination of the BIT cocktail and 
bidirectional perfusion allowed the deposition of a hyaline 
cartilage matrix in collagen sponges by promoting type II 
collagen production over type I collagen. Interestingly, this 
reconstructed cartilage appeared stable after 6 weeks of in 
vivo implantation (Fig. S5). 
 
Discussion 
The present study was performed to develop a tissue engineering strategy for the reconstruction of 
articular cartilage using human chondrocytes, a collagen scaffold and a bidirectional bioreactor 
prototype. This bioreactor system considered features of significance not only to tissue culture, but also 
to clinical translation (asepsis, scale-up, automation, and ease of use) (16). Previous studies have shown 
the potential of perfusion bioreactor to allow a homogenous matrix deposition in biomaterials (17-19). 
In accordance with these results, in our study bidirectional perfusion of collagen sponges seeded with 
human articular chondrocytes led to the deposition of an homogenous cartilaginous matrix within the 
scaffolds in the presence of the BIT cocktail.  
After chondrocyte monolayer expansion and seeding in collagen sponges, two different perfusion 
programs were performed in this study. A constant perfusion with a flow speed of 5 µm/s was selected 
for program 1. Wendt et al. (17) have demonstrated that similar perfusion speed allows to obtain a 
Fig. 6. Analysis of the type II and type I 
collagen gene expression in dynamic and static 
conditions. Collagen sponges seeded with 
chondrocytes were cultured in static or 
dynamic (prog 1) conditions. After 7 (D7), 14 
(D14), and 21 (D21) days, samples were 
analyzed by real time PCT to evaluate the 
transcriptional expression of type II and type I 
collagen Data were normalized on GAPDH. The 
values are presented as mean±SD.  
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defined oxygen tension and a homogeneous matrix deposition. Flow speeds used in program 2 were 
selected according to previous studies on perfusion bioreactors (20-22). Davisson et al. (20) and Shahin 
and Doran (21) demonstrated that a slow perfusion speed during the first days of culture, respectively 
10 µm/s and 7 µm/s, was required to protect the early matrix deposition in porous scaffolds in 
comparison with high perfusion speed, respectively 170 µm/s and 19 µm/s. Shahin and Doran (21) also 
proved that type II collagen and proteoglycan synthesis was enhanced with a slow increase of perfusion 
flow speed from 7 to 19 µm/s. In the present study, the lowest flow speed was applied at 5 µm/s on the 
basis of a previous study showing that a similar flow speed increased matrix synthesis and deposition 
(22). No major differences were detected between the two programs in terms of matrix deposition, 
suggesting that the advantages of the bidirectional perfusion were more important than the variations 
induced by the different flow speeds. 
Special attention was given to the nature of the extracellular matrix synthesized by chondrocytes, with a 
view of cartilage matrix reconstruction. Our results demonstrated that hyaline cartilage markers were 
produced both in static or dynamic conditions. Besides, in dynamic culture conditions, the typical round 
morphology of chondrocytes was restored. The role of cell shape was demonstrated to be a key factor in 
the re-expression of the chondrocyte phenotype (23,24). More precisely, the actin cytoskeleton 
organization influences the expression of the chondrogenic transcription factor Sox9 (25,26) that 
promotes especially type II collagen expression. After monolayer amplification, chondrocytes showed a 
fibroblastic-like shape that was maintained until 7 days post-seeding. After 21 days of dynamic culture in 
collagen sponges, we observed a restoration of the round morphology typical of differentiated 
chondrocytes. In this study, the chondrocyte morphological changes from fibroblastic-like to round 
shape was observed after 14 days of dynamic culture, simultaneously with the decrease in type I 
collagen expression. Perfusion without the BIT cocktail was not sufficient to promote the change of cell 
shape after 21 days of culture (data not shown). On the other hand, in static culture conditions, BIT 
cocktail treatment was not sufficient to induce changes in cell morphology within the sponge core, but 
round chondrocytes were found in the matrix produced at the periphery of the scaffold, as shown in a 
previous study (4). These results suggest that the combination of perfusion with the BIT cocktail induces 
the cell rounding and the deposition of cartilage characteristic matrix in the core of the collagen sponges 
and allows an homogeneous distribution of engineered cartilage.  
Other studies using perfusion have shown an increase in the collagen content (9,21). In our study, no 
dramatic increase in collagen content was noticed between dynamic and static culture conditions. Type 
II collagen expression was even favored in static culture conditions. This result is consistent with the 
ones of Mizuno et al. that showed that perfusion leads to a decrease in the synthesis of hyaline cartilage 
markers by calf’ chondrocytes in collagen sponges (27). Yet, in the present study, the combination of the 
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perfusion in the OPB with the BIT cocktail treatment improved the chondrocyte phenotype as it favored 
the ratio of type II/type I collagens both at the gene expression and the protein synthesis levels. Thus, 
even though the quantity of the engineered cartilage was not increased, its quality was improved by the 
combined use of the OPB bioreactor and the BIT cockatil. 
Our data showed that type I collagen was produced after 7 days of dynamic culture, but decreased 
dramatically for the rest of the culture period. This is an important result since we seeded the collagen 
sponges with fully dedifferentiated chondrocytes. Indeed, chondrocytes after monolayer amplification 
are known to undergo dedifferentiation (2) which is characterized by a loss of type II collagen expression 
in favor of type I collagen. This phenomenon is enhanced by the FI cocktail treatment (4, 28). Therefore, 
the chondrocytes seeded in the collagen sponges had a strong COL1A1 expression explaining the type I 
collagen production at early stage of culture in both dynamic and static conditions. Thus, the 
combination of the BIT cocktail and the bioreactor culture led to an arrest of type I collagen expression 
and synthesis. It is consistent with the study of Raimondi et al. that showed that perfusion of human 
chondrocytes cultured in pellets inhibits the type I collagen expression observed when the pellets are 
cultured in static conditions (29). The same type I collagen synthesis inhibition was made in perfused 
human articular cartilage explants in comparison with explants cultivated in static conditions by Strehl et 
al. (19, 30).  
The type II/type I collagen ratio was favored not only at the gene but also at the protein level in dynamic 
culture conditions. It evidences the specific expression of the differentiated phenotype of chondrocytes 
especially since, in other cell types like osteoblastic cell lines (31) or gingival cells (32), culture under 
perfusion triggers an induction of type I collagen production. So, the decrease in type I collagen 
production observed in dynamic culture conditions is part of the redifferentiation process triggered by 
the combination of the perfusion culture and the BIT cocktail treatment. Therefore, our data suggest a 
specific differential control of type I and type II collagens in chondrocytes under perfusion. The exact 
nature of molecular mechanisms are still to be determined, but it is known that perfusion exert 
mechanical forces such as fluid shear stress (18) and that chondrocyte phenotype and especially 
cartilage matrix proteins expression are sensitive to mechanical forces (33). 
In our model, culture of chondrocytes under perfusion in the presence of 10% of serum only was not 
sufficient to induce the matrix production and the chondrocyte redifferentiation (data not shown). Thus, 
the combination of the BIT cocktail with the perfusion culture triggered a synergistic response in favor of 
chondrocyte differentiation. Therefore, we can hypothesize that signaling cross talks between soluble 
and biomechanical factors enhanced cell differentiation. In human osteoblasts seeded in collagen 
scaffolds, Kopf et al. demonstrated that a direct cross talk between BMP-2 and mechanotransduction 
signaling occurred (34). Such cooperative regulation of the BMP pathway can be partially responsible of 
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the synergistic response of chondrocytes to the fluid shear stress and BIT cocktail in our study. 
Other molecular mechanisms triggered by perfusion have been identified such as the activation of the 
mitogen-activated pathway kinase (MAPK) pathway, as reviewed by Chiquet et al. (35). Interestingly, the 
cytoskeleton organization has also been found to be under the influence of perfusion (36) and this could 
also contribute to the rounding of cell shape observed in our study. 
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Supplementary Figures  
 
Fig. S1. Immunostaining of type II and type I collagens neo-synthesized by chondrocytes in collagen sponges in 
static or dynamic culture conditions. Chondrocyte-seeded collagen sponges were cultured for 21 days in presence 
of the BIT cocktail in static or dynamic conditions (prog 1). The pictures are taken in the scaffold core and are 
representative of chondrocytes isolated from six donors. (A) Dynamic culture conditions led to the formation of 
matrix production units rich in collagens (Scale bars 10µm). (B) At the cellular level, under dynamic culture, the 
chondrocyte cytoplasm is stained for type II but not for type I collagen (Scale bars 10µm). 
 
Fig. S2. Bi-directional perfusion 
favors the differentiation index at 
the protein level. A representative 
western blotting analysis of the type 
II, type IX and type I collagen after 
21 day of culture in collagen sponges 
in static (Sta) or dynamic conditions 
(Dyn) (prog 2) is shown in the left 
panel. The mature collagen chains, 
the unprocessed chains (pro) and 
the processing intermediates of the 
procollagen containing the 
aminopropetide (pN) or the 
carboxypropetide (pC) are indicated 
for type II and type I collagen. The upper band represents the dimers of collagen molecules (β). The 
immunoblotting for actin is shown as a loading control. These results are representative of six different 
experiments. The right panel shows the ratio of type II and type I collagen at the protein level after 21 days of 
culture. Densitometry analysis was performed on the western blotting data from all the experiments. The values 
were calculated as the total of each form, and normalized to the actin. The results are indicated as mean±SD (n=6). 
 
Fig. S3. Ratio of type II and type I collagen 
transcriptional expression in different conditions of 
dynamic culture. Chondrocyte-seeded collagen 
sponges were cultured  in static or dynamic culture 
conditions using two different perfusion programs 
for the dynamic culture (prog. 1, n=6; prog. 2, n=4) 
The transcriptional expression of COL2A1 and 
COL1A1 was evaluated by real time PCR. Data were 
normalized on GAPDH The ratio values are indicated 
as mean±SD. 
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Fig. S4. Ratio of type II and type I collagen expression at different 
time points during culture. Collagen sponges seeded with 
chondrocytes were cultured in static or dynamic (prog. 1) 
conditions. After 7 (D7), 14 (D14), and 21 (D21) days, samples were 
analyzed by real time PCT to evaluate the transcriptional expression 
of type II and type I collagen Data were normalized on GAPDH. The 
ratio of type II/type I collagen gene expression was determined 
using the values measured in the experiments reported in Fig. 5. The 
values are presented as mean±SD.  
 
 
 
 
 
Fig. S5. Immunohistochemistry of type II collagen in the collagen 
sponge after 6 weeks of subcutaneous implantation in nude mice 
Chondrocyte-seeded sponges were cultured for 21 days in static or 
dynamic (prog 2) conditions and then implanted into the 
subcutaneous pockets of nude mice. The picture shows the  
immunostaining of type II collagen in the core of a scaffold cultured 
for 21 days in dynamic conditions prior to implantation in nude mice 
(Scale bar 10µm). 
 
 
 
Cell-hydrogel enriched titanium for orthopedic implants 
96 
Chapter 8 
Orthopedic bioactive implants: hydrogel enrichment of 
macroporous titanium for the delivery of mesenchymal 
stem cells and strontium 
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Abstract 
Insufficient implant stability is an important determinant in the failure of cementless prostheses. To 
improve osseointegration, we aim at generating a bioactive implant combining a macroporous titanium 
(TT) with a biocompatible hydrogel to encapsulate osteoinductive factors and osteoprogenitor cells. 
Amidation and cross-linking degree of an amidated carboxymethylcellulose hydrogel (CMCA) were 
characterized by FT-IR spectrometry and mechanical testing. Bone marrow mesenchymal stem cells 
(BMSCs) from osteoarthritic patients were cultured on CMCA hydrogels, TT and TT loaded with CMCA 
(TT+CMCA) with an optimized concentration of SrCl2 to evaluate cell viability and osteo-differentiation. 
Amidation and cross-linking degree were homogeneous among independent CMCA batches. SrCl2 at 5 
µg/ml significantly improved BMSCs osteo-differentiation increasing calcified matrix (p<0.01), type I 
collagen expression (p<0.05) and Alkaline Phosphatase activity. TT+CMCA samples better retained cells 
into the TT mesh, significantly improving cell seeding efficiency respect to TT (p<0.05). BMSCs on 
TT+CMCA underwent a more efficient osteo-differentiation with higher Alkaline Phosphatase (p<0.05) 
and calcium levels compared to cells on TT. 
Based on these in vitro results, we envision the association of TT with strontium-enriched CMCA and 
BMSCs as a promising strategy to generate bioactive implants promoting bone neoformation at the 
implant site. 
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Introduction  
Joint replacement is widely used to recover articular functionality in joints compromised by 
degenerative pathologies or severe traumas. The integration between bone and implant is crucial in 
cementless prostheses where bone ingrowth is required to grant fixation. The achievement of an 
optimal osseointegration can lead to a reduction in the risk of implant mobilization and, consequently, 
in the number of revision procedures (1-3), which have major drawbacks such as patients’ morbidity and 
relevant costs for National Health Systems. With this aim, cementless implant technology has evolved 
with the introduction of porous metallic materials to maximize bone ingrowth and bone-to-implant 
contact (4-7). Among the different types of porous titanium, Trabecular Titanium™ (TT) is currently 
clinically used in acetabular cups and to fill cavitary and segmental bone defects. This macroporous 
titanium is characterized by multiple layers of hexagonal pores with a 640 µm diameter (8), 
macroporosity that facilitates cell migration and bone deposition (9). It has been shown that porous 
titanium implants can be enriched, either directly (10-12) or by association with biocompatible 
hydrogels (13-16), with antibiotics (14) , VEGF (15) and FGF-2 (16). To improve implant osseointegration, 
osteogenic factors can used for implant enrichment. Strontium is a low cost ion and is easier to handle 
compared to osteoinductive proteins, such as BMP-2, being therefore an ideal candidate to enrich off-
the-shelf materials for bone tissue engineering, as proposed for hydroxyapatite (17,18) and, more 
recently, for titanium (19,20). Indeed, strontium ranelate is a drug used for the treatment of 
osteoporosis thanks to its ability to increase bone neoformation and to reduce bone resorption (21-23). 
Furthermore, strontium has a positive effect on osteogenic differentiation of bone marrow 
mesenchymal stem cells (BMSCs) (24-28) which are resident at the implant site and are characterized by 
an intrinsic osteogenic potential (29-31). It has been demonstrated that the use of autologous bone 
marrow concentrate, obtained by an intra-operative approach, improves bone healing (32). Thus, 
loading BMSCs into the implant may represent a promising approach to increase the population of 
osteogenic progenitor cells (33,34) at the implant site, especially when aging and age-related diseases 
negatively affect bone deposition (35).  
We envision that autologous BMSCs can be isolated and seeded into a titanium prosthesis pre-loaded 
with a strontium-enriched hydrogel with a completely intra-operative approach. The implantation of a 
bioactive prosthesis, delivering cells and osteogenic signals, could result in higher implant stability and 
faster osseointegration, reducing recovery time and improving patients’ quality of life. In this study we 
combined TT with an amidated carboxymethylcellulose hydrogel (CMCA), previously used for 
chondrocyte culture (36). We evaluated if cell seeding efficiency and osteogenic differentiation were 
improved when TT was enriched with CMCA (TT+CMCA) as compared to normal TT that represents a 
clinical standard reference. To better resemble a possible clinical application, BMSCs were obtained 
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from OA patients. 
 
Materials and Methods  
Substrates preparation 
CMCA polymer synthesis 
A water-based synthesis was developed to obtain amidated carboxymethylcellulose (CMCA) from 
carboxymethylcellulose (CMC, CEKOL® 30000, CP Kelko), in alternative to organic synthesis (37). CMC 
was solubilized in ddH2O (1.5% W/V) with N-hydroxysuccinimide (Fluka) at a molar ratio 1:1. 
Methylamine (Merk) was added to CMC solution, at a molar ratio 1:1 with CMC. pH was adjusted to 4.7 
with HCl (Sigma-Aldrich) and finally, amidation of CMC was obtained by adding 1-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide (EDC, Ubichem) at a molar ratio 1:1 with CMC. After 3 h at r.t., purification 
was performed by ultrafiltration (Millipore Cogent M1, 100 kDa membrane). Purity was controlled by 
FT-IR spectrometry (Spectrum 400 FT-IR FT-NIR, Perkin-Elmer). Purified CMCA was freeze-dried for 
storage. 
Validation of CMCA polymer functionalization by FT-IR spectrometry 
FT-IR spectrometry was used for a semi-quantitative evaluation of amidation degree. Since bands for 
COO- (1590 cm-1) and amidic group (1640 cm-1) were too near to allow a clear distinction between them, 
an acidification step with Dowex resin (Sigma-Aldrich) was performed to convert COO- groups into COOH 
groups. As a result, the absorption peaks of amidic groups (1640 cm-1) were clearly distinguished from 
those of the groups that did not react (1730 cm-1) and the percentage of amidic moieties introduced was 
calculated. 
CMCA hydrogel cross-linking 
Freeze-dried CMCA polymer was solubilized (1.7% W/V) in ddH2O together with N-hydroxysuccinimide 
at molar ratio 1:1 with CMCA. 1,3-diaminopropane (Merk) was added in a ratio of 1:2 with CMCA and pH 
was adjusted to 4.7 with HCl. Finally, the activator EDC was added at a molar ratio 1:1 with CMCA. Cross-
linking reaction took 3 h and hydrogel purification was performed by washing in ddH2O. To verify cross-
linking reproducibility, 5 min after the addition of EDC 6 ml of reaction blend were sampled with a 10 ml 
syringe without needle and kept at r.t. to let the cross-linking reaction end. Since cross-linking degree 
affects hydrogel mechanical properties, LFPlus digital testing tensile machine (Amestek) was used to 
measure the injection force needed to extrude the hydrogel from the syringe. 
CMCA hydrogel loading into Trabecular Titanium™ mesh 
Trabecular Titanium™ (Ti6Al4V, Ø 8 mm, h 3 mm, pore Ø 640 µm) was obtained by electron beam 
melting (8). Hydrated CMCA was injected into TT mesh through a syringe. The amount of hydrated 
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CMCA loaded was determined by weighing (analytical balance Ohaus, Adventurer Pro AV2101C). 
Constructs were oven-dried at 50°C and sterilized by EtO. 
 
BMSCs culture and osteogenic differentiation 
BMSCs isolation and expansion 
Bone marrow was harvested from the femoral compartment of 9 OA patients (mean age 59±4 years) 
undergoing total hip replacement, after written consent. Bone marrow was centrifuged and plated in 
control medium consisting of HG-DMEM (High Glucose, Gibco) with 10% Fetal Bovine Serum (FBS, 
Lonza), 0.029 mg/ml L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM hepes, 1 mM 
sodium pyruvate (all from Gibco) supplemented with 5 ng/ml FGF-2 (Peprotech). BMSCs were selected 
for plastic adherence and expanded. Cells were frozen at passage 2 and, at need, thawed and expanded 
until passage 4. 
Selection of SrCl2 concentration to improve BMSCs osteogenic differentiation 
Cells were seeded at 3x103 cells/cm2 and cultured for 14 days in osteogenic medium consisting of 
control medium supplemented with 10 nM dexamethasone, 10 mM glycerol-2-phosphate, 150 μM L-
ascorbic acid-2-phosphate and 10 nM cholecalciferol (all from Sigma-Aldrich) (38) in the presence of 0, 
1, 5, 10 and 20 μg/ml SrCl2 (Sigma-Aldrich). 
Culture of BMSCs on CMCA hydrogel 
Hydrated CMCA was dispensed a 24-multiplate (0.75 ml/well), and then oven-dried at 50°C and 
sterilized in EtO. 24 h before cell seeding, CMCA samples were hydrated with 0.75 ml of medium. 
7.5x105 BMSCs were suspended in 1 ml of medium, seeded on CMCA and cultured up to 21 days in 
different media: control, osteogenic or osteogenic with 5 µg/ml SrCl2. 
Osteogenic differentiation of BMSCs on TT and TT+CMCA 
7.5x105 BMSCs were suspended in 75 µl of medium and seeded on normal TT or on TT+CMCA samples. 
After 3 h, 1 ml of medium was added. TT and TT+CMCA samples were cultured up to 21 days in 
osteogenic medium with 5 µg/ml SrCl2. 
 
Evaluation of cell behavior on biomaterials 
Cell seeding efficiency 
Seeding efficiency on TT and TT+CMCA was determined by DNA quantification 24 h after seeding 
(CyQuant kit, Invitrogen) and calculated as percentage of the number of seeded cells. 
Cell viability 
Cell viability was determined by Alamar Blue assay (Invitrogen). 800 µl of 10% Alamar Blue in HG-DMEM 
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w/o phenol red were added to each sample and incubated for 4 h at 37°C. Fluorescence (540 nm-580 
nm) was read using a Victor X3 Plate Reader (Perkin Elmer). 
Calcified matrix deposition 
Calcified matrix was quantified by Alizarin Red-S (AR-S, pH 4.1, Fluka) staining. After washing, each 
sample was unstained with 10% cetylpyridinium chloride monohydrate (CPC, Sigma-Aldrich) in 0.1 M 
phosphate buffer (pH 7.0) and absorbance was read at 570 nm (39).  
Gene expression of type I collagen 
Expression of type I collagen (COL1A1) was evaluated by real time PCR (Rotor Gene RG3000 system, 
Qiagen). RNA was purified with RNeasy Mini kit (Qiagen)and reverse-transcribed to cDNA with iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories) (5 min at 25°C, 30 min at 42°C, 5 min at 85°C). 20 ng of cDNA 
were incubated with a PCR mixture including TaqMan Universal PCR Master Mix and TaqMan® Assays-
on-Demand™ Gene expression probes (Life Technologies) (2 min at 50°C, 10 min at 95°C, 40 cycles of 15 
sec at 95°C, 1 min at 60°C). COL1A1 expression was normalized on glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH).  
Alkaline Phosphatase activity 
Alkaline Phosphatase (ALP) activity was determined by enzymatic assay incubating cell lysates at 37°C 
with 1 mM p-nitrophenylphosphate in 100 mM diethanolamine and 0.5 mM MgCl2 (pH 10.5, Sigma-
Aldrich) (40). Absorbance was read at 405 nm. ALP was normalized on protein content, determined by 
BCA Protein Assay Kit (Pierce Biotechnology). 
Calcium quantification 
Calcium quantification was performed by Randox assay (Randox Laboratories Ltd). Samples were 
incubated with 0.5 M HCl for 6 h at 4°C on a rotating plate. Supernatants were incubated with the 
Randox working solution. Absorbance was read at 570 nm.  
Scanning Electron Microscopy analysis 
BMSCs adhesion and matrix production were evaluated by SEM. Samples were fixed for 1 h in 
glutaraldehyde (1.2% in 0.1 M sodium cacodylate buffer), washed with 0.1 M sodium cacodylate buffer 
and fixed for 1 h in OsO4 (1% in 0.1 M sodium cacodylate buffer). Samples were dehydrated through 
graded EtOH, submitted to critical point drying with CO2, sputter-coated with gold and analyzed with 
Sigma Scanning Electron Microscope (Zeiss, 10 kEV). 
 
Statistical Analysis 
Data are expressed as mean±SEM, unless differently specified. Statistical analyses were performed using 
Student’s t-test to compare two groups and Two-Way ANOVA to compare groups at different time 
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points (Graph Pad Prism, v 5.0). Significance was set at p<0.05. 
 
Results and Discussion 
Substrates preparation 
Validation of CMCA hydrogel amidation and cross-linking 
Hydrophilicity of CMC was increased introducing amidic groups in the polymer backbone. To avoid the 
use of dimethylformamide, a very toxic reagent (41-43) used for the organic synthesis of CMCA (37), a 
water-based synthesis was developed. FT-IR 
spectra (Fig. 1a) allowed the quantification of 
amidic groups introduced and, as shown in 
Fig. 1b, we observed that the amidation 
degree was homogeneous among 
independent samples (39.4±2.3%). Different 
CMCA batches were homogeneous for cross-
linking degree as demonstrated by similar 
values of injection force (258.5±12.8 N) 
measured by a mechanical extrusion test (Fig. 
1c). To demonstrate the reliability of this 
method, cross-linking was performed starting 
from different CMCA concentrations. When 
CMCA concentration was lower (1.6% W/V) 
injection force was reduced, whereas when it 
was higher (1.8% W/V) we observed an 
increase in this parameter. This method, 
easier and less expensive compared to 
titration and NMR (37,44), can be used as a 
routine quality control to evaluate the 
homogeneity of cross-linking among different 
batches of production and can reveal small 
differences in the starting conditions of the cross-linking reaction. Nevertheless, quality controls should 
include further analyses to grant the spatial homogeneity of hydrogel cross-linking. 
 
 
Fig. 1. CMCA amidation and cross-linking degree. (a) FT-IR 
spectra of CMCA before and after the acidification step 
(CMCA_H). Inset represents COOH and amidic group 
peaks. (b) Amidation degree calculated on the basis of FT-
IR spectra (mean±SD, n=12). (c) Cross-linking validation by 
mechanical testing starting from 1.7% CMCA (W/V, 
mean±SD, n=12). Control samples were prepared starting 
from 1.6% and 1.8% CMCA (W/V). 
Cell-hydrogel enriched titanium for orthopedic implants 
103 
CMCA hydrogel loading into TT mesh 
CMCA loaded within the TT mesh through a syringe was homogeneously distributed in TT pores (Fig. 2a). 
CMCA loading was reproducible as demonstrated by the low variability in the amount of hydrogel 
loaded among different samples (Fig. 2b). In our approach the interaction between CMCA and TT was 
granted by the increase of volume of CMCA that, 
once rehydrated with the cell suspension, 
remained entrapped within TT structure without 
any loss of hydrogel during culture. As an 
alternative, phosphonate derivatives of CMC can 
be developed to generate a chemical bound 
between titanium and hydrogel (45). 
 
Selection of SrCl2 concentration to improve BMSCs osteogenic differentiation 
Aiming at the future incorporation of SrCl2 within CMCA hydrogel, BMSCs were cultured in the presence 
of different amounts of SrCl2 to select a suitable concentration for the improvement of their osteogenic 
differentiation. Since these in vitro tests are oriented towards our aim to implant a bioactive device 
made from TT and CMCA directly into the bone, all the experiments were performed in osteogenic 
medium, mimicking the differentiative signals that in vivo would be provided by the adjacent bone. 
The evaluation of osteogenic markers in BMSCs cultured with different concentrations of SrCl2 revealed 
that the best one to improve BMSCs osteogenic differentiation was 5 µg/ml (Fig. 3). 
 
Fig. 3. Selection of SrCl2 concentration to improve BMSCs osteogenic differentiation. (a) Quantification of calcified 
matrix after AR-S staining (ABU, arbitrary units; n=6, ** p<0.01). (b) Micrographs of BMSCs stained with AR-S. (c) 
Type I collagen (COL1A1) expression normalized to GAPDH (n=3, * p<0.05). (d) ALP activity (ALP Units/µg of 
proteins, n=6). 
 
Fig. 2. CMCA loading into TT. (a) Section of TT+CMCA 
(scale bar 5 mm, CMCA stained red). (b) Weight of 
hydrated CMCA loaded into TT mesh (mean±SD, n=47). 
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Indeed, a statistically significant increase in calcified matrix deposition was observed in cells in 
osteogenic medium with 5 µg/ml SrCl2, compared to osteogenic medium without SrCl2 (p<0.01, Fig. 3a). 
Representative micrographs showing calcified matrix stained by AR-S are reported in Fig. 3b. The 
osteoinductive effect of SrCl2 was evident also on type I collagen gene expression, with cells cultured in 
osteogenic medium with 5 µg/ml SrCl2 showing the highest expression of this marker (p<0.05, Fig. 3c). 
Even ALP activity was increased by the presence of SrCl2, but differences were not significant (Fig. 3d). 
Our results demonstrated that a low concentration of SrCl2 (5 µg/ml) improved BMSCs osteogenic 
differentiation, accordingly with data by Sila-Asna et al. (24). Strontium has a positive effect on bone 
metabolism (21) and on MSCs osteogenic differentiation (26,28). Furthermore, it has been 
demonstrated to improve osseointegration when delivered at the implant site by direct incorporation 
within titanium (19), or inclusion in a hydroxyapatite coating (20) and in bone graft extenders (46). Since 
the in vivo effect of strontium on bone metabolism is associated with increased BMSCs osteogenesis 
(27), we believe that the simultaneous inclusion of BMSCs and strontium in a hydrogel loaded into 
titanium may promote bone ingrowth by a dual action on host progenitor cells resident at the implant 
site and on cells encapsulated into the hydrogel. 
 
BMSCs culture and osteogenic differentiation in CMCA hydrogel 
BMSCs viability in CMCA without titanium was determined during culture in the presence of different 
media: control, osteogenic and osteogenic supplemented with 5 µg/ml SrCl2. BMSCs viability was 
maintained during 
culture in all the tested 
conditions (Fig. 4a). ALP 
activity was quantified 
after 14 and 21 days as 
marker of osteogenic 
differentiation (Fig. 4b). 
To confirm our data on 
the osteoinductive 
effect of SrCl2, BMSCs were cultured in CMCA and differentiated either in normal osteogenic medium or 
in osteogenic medium with 5 µg/ml SrCl2. Cells cultured in CMCA maintained their osteogenic potential. 
Indeed, at 14 days a significant increase in ALP was observed in cells cultured in osteogenic medium with 
SrCl2 compared to cells in control and osteogenic medium (+274% and +62% respectively, p<0.05). The 
difference between this group and control cells remained statistically significant even at 21 days (+80%, 
p<0.05). The same trend was observed in calcium levels but increases were not significant due to the 
Fig. 4. Viability and osteogenic differentiation of BMSCs on CMCA hydrogel. (a) 
BMSCs viability in different culture media (ABU, arbitrary units, n=6, * p<0.05). (b) 
ALP activity (ALP Units/µg of proteins, n=4, * p<0.05). 
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great inter-donor variability (data not shown). 
Accordingly with data by Leone et al. (36), who used CMCA for chondrocyte differentiation, we did not 
observe any cytotoxic effect of CMCA. Culture on CMCA did not impair the ability of BMSCs to respond 
to the osteogenic stimuli provided by culture medium. These results, together with the already 
demonstrated lack of inflammatory response in rabbits treated with CMCA (36), support the potential 
clinical use of this hydrogel in bone applications. 
 
Improvement of TT-BMSCs interaction by enrichment with CMCA hydrogel 
Cell seeding efficiency and cell adhesion 
The presence of CMCA inside TT pores significantly increased cell seeding efficiency (+21% compared to 
TT without CMCA, p<0.05, Fig. 5a). This increase was probably due to the ability of CMCA to immobilize 
cells inside TT. In view of a clinical application, it should be highlighted that the difference in cell 
retention between TT and TT+CMCA would be even more crucial since cells would not be allowed to 
adhere to TT for 3 
hours before 
being in contact 
with body fluids, 
as we let them in 
our experiments 
before adding 
culture medium.  
We believe that 
prostheses made 
of Trabecular 
Titanium™ pre-loaded with dry CMCA could be easy-to-handle devices for the orthopedic clinical 
practice. CMCA loaded in these devices could be hydrated intra-operatively with a suspension of 
autologous BMSCs obtained by bone marrow and directly implanted. After 21 days of culture, SEM 
showed that BMSCs colonized both TT and TT+CMCA samples, covering the surface of titanium samples 
(Fig. 5b-c) and the inner surface of pores (Fig. 5d-e) and displaying cell attachment to TT and TT+CMCA 
through the formation of cell protrusions (Fig. 5 f-g). These observations are coherent with recent 
results proving the ability of TT to support the growth of human adipose derived stem cells (47,48). No 
difference was observed between TT and TT+CMCA demonstrating that CMCA did not impair the ability 
of cells to colonize and fill with matrix TT pores. 
 
Fig. 4. Cell seeding efficiency and cell adhesion on TT and TT+CMCA. (a) Seeding efficiency 
expressed as percentage with respect to the initial number of seeded cells (n=5, * p<0.05). 
(b-g) SEM analysis after 21 days of culture. BMSCs adhesion on TT and TT+CMCA outer 
surface (b-c, scale bar 500 µm). Magnification of a titanium pore covered by cells and 
extracellular matrix (d-e, scale bar 200 µm). Adherent cells inside the inner surface of 
titanium pores (f-g, scale bar 50 µm). 
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BMSCs viability and osteogenic differentiation 
Viability and osteogenic differentiation of BMSCs on TT and TT+CMCA were assessed to compare their 
osteoconductivity. As shown in Fig. 6a, no difference in cell viability was observed between TT and 
TT+CMCA. After 14 days, ALP activity was significantly increased in TT+CMCA samples (+91%, p<0.05, 
Fig. 6b) supporting the idea that TT combined with CMCA is more osteoconductive than TT. The same 
trend was observed 
in calcium 
quantification, with 
higher values for 
BMSCs cultured on 
TT+CMCA with 
respect to TT (Fig. 
6c).  
Matrix characterized 
by a fibrillar 
structure was found 
to be deposited by 
cells inside titanium 
pores in both TT and 
TT+CMCA (Fig. 6d). 
The observed 
increases in 
osteogenic markers demonstrated that the association of TT and CMCA lead to a construct with 
improved osteoconductivity compared to TT. Further improvement of this feature by the association of 
TT with a hydrogel enriched with an osteoinductive factor appears a very promising strategy to improve 
implant osseointegration that grants prosthetic stability (1-3). Recently, factors such as VEGF and FGF-2 
have been incorporated in hydrogel coatings to obtain bioactive titanium (15,16). Preliminary 
experiments demonstrated that SrCl2 can be included in the CMCA hydrogel and subsequently released 
(data not shown). In this study we found that SrCl2 at 5 µg/ml is able to improve osteogenic 
differentiation of BMSCs. This data will guide us in the selection of the initial amount of SrCl2 that should 
be incorporated into CMCA to obtain a similar final concentration released to the cells in the implant, at 
least in the initial phase of healing process. It is possible to speculate that, in vivo, strontium will be 
gradually eluted from CMCA included in a TT mesh creating a gradient of strontium concentrations that 
may vary with time and distance from the implant. Nevertheless, the presence of an optimal 
Fig. 6. BMSCs behavior on TT and TT+CMCA. (a) Cell viability of BMSCs (ABU, 
arbitrary units, n=8). (b-c) ALP activity (b) and calcium quantification (c) (n=4, * 
p<0.05, ** p<0.01). (d) Fibrillar structure of extracellular matrix produced by BMSCs 
after 21 days of culture (SEM analysis, scale bar 1 µm). 
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concentration of strontium within implant will provide BMSCs seeded into TT with signals triggering 
their initial osteogenic differentiation. In view of a future clinical application, CMCA would be enriched 
with SrCl2, loaded within TT mesh and oven-dried to generate off-the-shelf devices that can be easily 
seeded with autologous cells during surgery. In these bioactive implants, the hydrogel would play a key 
role retaining of progenitor cells at the bone-implant interface and delivering an osteogenic signal in 
addition to physiological signals from bone. 
 
Conclusions 
Faster and improved bone ingrowth into a porous titanium implant may confer better stability during 
the healing process. Our results demonstrate that the association of a biocompatible hydrogel, such as 
CMCA, with a macroporous titanium may represent a suitable approach to effectively immobilize 
autologous BMSCs within the implant. The enrichment with strontium and osteoprogenitor cells would 
convert the prosthesis from inert to bioactive, promoting osseointegration and consequently reducing 
the risk of mobilization and the number of revision procedures. This strategy could be exploited also in 
revision surgery, where macroporous titanium can be used to fill void bone spaces and to provide an 
anchorage point for revision components, helping the surgeon to manage bone loss at implant interface. 
Based on these considerations, we envision that the generation of bioactive implants that can deliver to 
the implant site both progenitor cells and osteogenic signals would represent a significant step forward 
respect to the current clinical practice. 
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Chapter 9 
In vivo evaluation of bone deposition in macroporous 
titanium implants loaded with mesenchymal stem cells 
and strontium-enriched hydrogel 
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Abstract 
Bone-implant integration represents a major requirement to grant implant stability and reduce the risk 
of implant loosening. This study investigates the effect of progenitor cells and strontium-enriched 
hydrogel on the osseointegration of titanium implants. To mimic implant-bone interaction, an ectopic 
model was developed grafting Trabecular Titanium™ (TT) implants into decellularized bone seeded with 
human bone marrow mesenchymal stem cells (hBMSCs). TT was loaded or not with strontium-enriched 
amidated carboxymethylcellulose hydrogel (CMCA) and/or hBMSCs. Constructs were implanted 
subcutaneously in athymic mice and osteodeposition was investigated with micro-CT, SEM, and pull-out 
at 4, 8 and 12 weeks. Fluorescence imaging was performed at 8 and 12 weeks, histology at 4 and 8 
weeks. Micro-CT demonstrated the homogeneity of the engineered bone in all groups, supporting the 
reproducibility of the ectopic model. Fluorescence imaging, histology, SEM and pull-out mechanical 
testing showed superior tissue ingrowth in TT implants loaded with both strontium-enriched CMCA and 
hBMSCs. In our model, the synergic action of the bioactive hydrogel and hBMSCs increased both the 
bone deposition and TT integration. Thus, we suggest that using prostheses pre-loaded with strontium-
enriched CMCA and seeded with BMSCs could represent a valid single-step surgical strategy to improve 
implant osseointegration. 
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Introduction  
Titanium is widely used to produce prosthetic implants because of its biocompatibility, high strength-to-
weight ratio and low elastic modulus (1,2). In cementless prosthesis, primary implant stability is 
achieved by passive mechanical fixation within the bone, then secondary stability is achieved through 
osseointegration (3). Osseointegration and implant stability are essential to reduce the risk of implant 
loosening (4,5) and consequently the revision surgeries. Since the bone-implant interface is the weakest 
point during the initial healing (6), porous metal materials have been developed for cementless implants 
to maximize bone-to-implant contact and bone ingrowth (7-9). Furthermore, surface coatings have been 
developed to activate the bio-inert surface of metallic implants, as the combination of titanium with 
hydrogels (10,11). Strontium (Sr) is a promising candidate for implant enrichment, as recently proposed 
for bone scaffolds (12) and titanium (13,14). Indeed, the anabolic and anticatabolic effects of strontium 
on bone (15), together with its ability to promote osteogenic differentiation of bone marrow 
mesenchymal stem cells (BMSCs) (16,17) are believed to support implant bone ingrowth. It has been 
shown that BMSCs seeded into titanium implants or transplanted in the peri-implant site are able to 
improve osseointegration (18-20). This approach could be particularly useful in elderly patients, where 
age and age-related pathologies can deplete the population of BMSCs or impair their osteogenic ability 
(21). Among porous metals developed for prosthetic implants, Trabecular Titanium™ (TT) is clinically 
used for acetabular cup and revision components. This macroporous titanium has a structure 
resembling the trabecular bone that has been optimized to improve bone ingrowth (22). Previously, we 
have demonstrated that a low concentration of strontium can induce hBMSCs osteogenic differentiation 
and that the association of TT with an amidated carboxymethylcellulose (CMCA) hydrogel significantly 
improves cell retention and hBMSCs differentiation (23). Based on these promising results, we suggest 
that TT implants preloaded with a Sr-enriched CMCA hydrogel could be loaded with autologous BMSCs 
and implanted in a one-step approach to improve osseointegration. Ectopic models have been used to 
evaluate bone formation and to highlight the pristine effects of bioactive factors and transplanted 
heterologous/xenogenic cells, avoiding the complex interactions of native bone environment (24). 
However, only a recent study has proposed a subcutaneous ectopic model of osseointegration, using 
titanium screws and ceramic scaffolds (25).  
In our in vivo study, to evaluate if the association of TT with Sr-enriched CMCA and hBMSCs could 
ameliorate bone deposition, we developed an ectopic model of osseointegration, where athymic mice 
acted as “living bioreactors” and a bone scaffold seeded with osteogenic pre-differentiated hBMSCs and 
cultured prior to implantation was used to mimic bone.  
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Materials and Methods  
Experimental design 
This study used a full factorial design testing the association of TT with two factors (Sr-enriched CMCA, 
here on called CMCA, and hBMSCs), resulting in four groups: TT (absence of CMCA and hBMSCs); 
TT+CMCA (presence of CMCA, absence of hBMSCs); TT+BMSCs (absence of CMCA, presence of hBMSCs) 
and TT+CMCA+BMSCs 
(presence of CMCA 
and hBMSCs) (Fig. 1A). 
TT group was used as 
control for data 
normalization, since it 
represents the current 
clinical practice. 
Samples from each 
group were analyzed 
as follows: 
fluorescence imaging 
(n=3, 8 and 12 weeks); 
micro-CT (n=3, 4, 8 and 
12 weeks); histology 
and histomorphometry (n=2, 4 and 8 weeks); SEM at (n=1, 4, 8 and 12 weeks); pull-out at (n=3, 4 and 8 
weeks; n=4, 12 weeks).  
 
Materials description 
Trabecular Titanium™ was provided as disks (Ø 8mm, h 3mm, Ti6Al4V, Limacorporate s.p.a.) with a 
compact head (Ø 8mm, h 1mm) and a trabecular structure (22) (Ø 8mm, h 2mm) CMCA was 
synthetized(23) and enriched with SrCl2 (Sigma-Aldrich) prior to loading into TT. TT+CMCA samples 
consisted in TT disks loaded with CMCA (wet weight 0.07g/sample.).  
 
Cell culture and osteogenic pre-differentiation 
Human BMSCs were isolated from 5 osteoarthritic patients undergoing total hip replacement (mean age 
57±6 years) under informed written consent and approval of the Institutional Review Board. Bone 
marrow was centrifuged (400g, 10 min) and plated in complete medium: high glucose Dulbecco’s 
Fig. 1. Experimental design. (a) Implantation scheme (12 mice per time point): 6 
animals received TT and TT+CMCA, 6 animals received TT+BMSCs and 
TT+CMCA+BMSCs. (b) Construct scheme: grey structure represents engineered bone 
(Ø 14 mm x h 5 mm), black structure represents the TT compact head (Ø 8 mm x h 1 
mm), and the grid structure represents the trabecular structure of TT disk (Ø 8 mm x h 
2 mm). (c) Side-view picture of the assembled construct. (d) Construct assembling by 
press-fit. 
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Modified Eagle Medium (Gibco), 10% fetal bovine serum (Lonza), 1mM sodium pyruvate, 100mM hepes, 
2mM L-glutamine, 100µg/mL streptomycin, 100U/mL penicillin (all from Gibco), 5ng/mL bFGF 
(Peprotech). Cells were expanded until passage 2 and frozen. When needed, cells were thawed and 
differentiated in osteogenic medium (26): complete medium with 0.15mM L-ascorbic acid, 10nM 
dexamethasone, 10nM cholecalciferol, and 10mM β-glycerophosphate (all from Sigma-Aldrich). 
 
Construct model assembling 
The constructs were composed of TT or TT+CMCA, unseeded or seeded with hBMSCs, grafted in cell-
seeded bone scaffolds [Figure 1(B)]. Decellularized bovine cancellous bone (Tutobone®, Tutogen Medical 
GmbH) was cut in cylinders (Ø 14mm, h 5mm) and centrally holed (Ø 8mm, h 3mm) to insert TT or 
TT+CMCA. After 3 weeks of differentiation, 8.5x105 hBMSCs were seeded on bone scaffold and cultured 
for 1 week in osteogenic medium. The day before implantation, 7.5x105 hBMSCs pre-differentiated for 4 
weeks were seeded on TT and TT+CMCA. On the implantation day, TT and TT+CMCA, unseeded or 
seeded with hBMSCs, were grafted in the bone scaffold [Figure 1(C)].  
 
In vivo subcutaneous implantation 
Animals were handled under the approval of the Institutional Animal Care and Use Committee of Mario 
Negri Institute for Pharmacological Research. Procedures and animal care were conducted in conformity 
with institutional guidelines in compliance with national (Law 116/92, Authorization n.19/2008-A issued 
March 6, 2008, by the Italian Ministry of Health) and international laws and policies (EEC Council 
Directive 86/609, OJ L 358. 1, December 12, 1987; Standards for the Care and Use of Laboratory Animals 
- UCLA, United States National Research Council, Statement of Compliance A5023-01, November 6, 
1998).  
Thirty-six 6-weeks-old female athymic mice (from Harlan) were maintained under specific pathogen-
free conditions with food and water provided ad libitum. Twelve animals per time point (4, 8, 12 weeks) 
received two implants/each inserted subcutaneously in dorsal pockets with the compact head of TT 
facing the skin. Surgeries were conducted under general anesthesia by intraperitoneal injection of 
ketamine chloride (80 mg/kg, Imalgene, Merial) and medetomidine hydrochloride (1 mg/kg, Domitor, 
Pfizer). A blunt dissection was conducted to create a pocket between the aponeurosis and the 
subcutaneous tissue for construct placement, then the skin was sutured with #4-0 Monocryl thread 
(Ethicon). After 4, 8 and 12 weeks mice were euthanized by CO2 inhalation and implants were removed 
for investigations.  
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Bone deposition analysis by fluorescence imaging  
Imaging of bone deposition within the constructs was performed using the fluorescent bisphosphonate 
agent OsteoSense™750 (VisEN Medical) (27,28). This analysis was performed at 8 and 12 weeks, because 
at 4 weeks there was an high risk of inflammatory response and poor uptake of the fluorescent agent in 
the construct area. Mice were intravenously injected with 2 nmol/subject OsteoSense™750. After 24 
hours, optical scans were acquired on living mice and ex vivo on explanted constructs. For the in vivo 
scan, animals were anesthetized with a continuous flow of 2% isoflurane. The fluorescent signal was 
detected using the Explore Optix System equipped with a fixed pulsed laser diode as illumination source 
(734nm excitation - 770nm emission, ART Advanced Research Technologies). Fluorescence was recorded 
as pseudo-color images showing the distribution of detected photon counts. Overlay of the grey-scale 
(body reference photograph) and pseudo-color images allowed the localization of fluorescent signal in 
the animal. Ex vivo imaging was performed on explants on both dorsal and ventral side defining a region 
of interest (ROI). Optiview software (version 2.02.00; ART Advanced Research Technologies) elaborated 
the data and the intensity of the Fluorescence Lifetime Imaging (FLI) signal was shown as pseudo-color 
scale bars. In explanted constructs, the photon counts emitted from each ROI-related pixel of dorsal side 
were coupled with those of ventral side. Values were normalized respect to TT.  
 
Micro-CT analysis 
At 4, 8 and 12 weeks, explanted constructs were scanned with an Explore Locus micro-CT scanner (GE 
Healthcare) using 80 kV voltage, 450 μA current with 400 msec exposure time per projection and 400 
projections over 360°. The isotropic resolution was 27μm and the reconstructed 3D images were 
analyzed using MicroView software (version 2.1.2; GE Healthcare). A volume of interest (VOI) comprising 
the whole construct was designed and a histogram, depicting the distribution of voxel along the scale of 
density expressed in Hounsfield units, was computed. Based on the histogram, the different regions of 
each construct were separated using a global thresholding procedure. Isosurface volume rendering 
function was applied to determine the volume of each region.  
 
Histological analysis and histomorphometry 
Samples were histologically investigated at 4 and 8 weeks. The death of one mouse of the 12-weeks 
group reduced the number of samples designed for histology, thus the remaining samples were 
investigated by pull-out test. Explants were fixed in 10% formalin, dehydrated in a graded series of 
ethanol and embedded in methyl-metacrylate (Technovit®7200). Middle cross-sections were ground to 
about 60-90µm (Exakt Apparatebau) and stained with toluidine blue. The software ImageJ1.45s® was 
used to detect the various components of the construct (titanium, bone scaffold, newly formed tissue) 
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and to perform the histomorphometric analysis. Tissue ingrowth was calculated as the percentage of 
the space available for tissue ingrowth occupied by newly formed tissue and represented as relative 
increase respect to TT.  
 
Scanning electron microscopy (SEM) 
After 4, 8, and 12 weeks, explants were fixed in 2.5% paraformaldehyde and 2.5% glutaraldehyde in 0.1 
M Na-Cacodylate buffer (pH 7.4), then rinsed with Na-Cacodylate buffer and fixed for 1 h in OsO4 (1% in 
Na-Cacodylate buffer). Samples were dehydrated in ethanol and hexamethyldisilazane (Sigma-Aldrich), 
mounted on aluminum stubs and sputter-coated with gold (E5100 Polaron Instruments). Observations 
were performed with Sigma Scanning Electron Microscope (Zeiss) fitted with secondary (SE) and 
backscattered electrons (BSE) detectors, and images were acquired at 10 kV at working distance of 
7mm. 
 
Mechanical pull-out tests 
Pull-out tests were performed to determine the interfacial shear strength of the implanted constructs 
after 4, 8, and 12 weeks. Tests were performed on a mechanical testing bench (servo-hydraulic universal 
MTS MiniBionix 858, load range 25 KN Load cell class 0.5 - Calibration certified 2010_002) using a 
custom-made pull-out system and support jigs. Samples were centered over the support jig and a screw 
was glued on the titanium compact head. Samples were then placed on a flat surface and secured onto 
a vise. The pull-out test was performed applying a constant crosshead speed of 0.5 mm/min on the 
constructs and recording the resulting pull-out force trend. Peak force values were normalized respect 
to the average value measured in TT after 4 weeks and expressed as relative increase. 
 
Statistical Analysis 
Statistical analysis was performed using the One-Way ANOVA with Bonferroni’s post-hoc test (Graph 
Pad Prism v5.00, Graph Pad software) to compare the experimental groups within the same time point. 
Data are presented as meanstandard error (SE) unless differently specified. Level of significance was 
set at p0.05.  
 
Results 
Gross appearance  
All animals survived the surgery and post-operative period without complications, with the exception of 
one mouse, which showed local infection and skin ulceration after 8 weeks and was removed from the 
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study. The implanted constructs evoked an initial inflammatory response, which receded during time. At 
the time of sample harvesting, no signs of infection and/or foreign body reaction were observed and the 
implants were easily dissected from subcutaneous tissue. Gross appearance of the explants revealed the 
formation of a vascular network throughout the constructs already after 4 weeks (Fig. 2A). 
 
Bone deposition analysis by fluorescence imaging 
Osteosense™750-related signal, visualized by in vivo imaging, was clearly detectable in regions subjected 
to active bone turnover (skull, scapula, spine, hind limbs) (Fig. 2B). The signal in the implanted 
constructs was 
partially masked by 
the stronger signal 
coming from active 
bone remodeling 
regions of mice. To 
overcome this 
limitation, we 
analyzed ex vivo the 
distribution of 
Osteosense™750 
scanning the samples 
with the TT compact 
head upward (dorsal) 
or downward 
(ventral) (Fig. 2C). At 8 
weeks, TT+BMSCs and 
TT+CMCA+BMSCs 
signals were higher 
compared to TT and TT+CMCA samples, that displayed comparable FLI photon counts. After 12 weeks, 
FLI photon counts in TT+CMCA and TT+BMSCs samples were 1.5-fold higher compared to TT. More 
interestingly, the signal of TT+CMCA+BMSCs constructs was higher compared to all the other groups 
[Figure 2(D)]. 
 
Micro-CT analysis 
Micro-CT was performed to obtain information on volumetric appearance of the constructs and to 
Fig. 2. In vivo and ex vivo fluorescence imaging of osteodeposition (a) Gross 
appearance of explanted constructs in dorsal and ventral view. (b) Representative FLI 
images before and 24h after injection of Osteosense™750 in a living mouse. (c) 
Representative images FLI images of Osteosense™750 uptake in explanted constructs 
in dorsal (left column) and ventral (right column) view. (d) Quantification of 
Osteosense™750-related FLI signal. Photon counts emitted from dorsal and ventral 
side of each construct were coupled and normalized respect to TT value at the 
corresponding time point (TT=1, red line).   
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analyze the matrix deposition. The 3D rendering of the implanted construct is shown in Fig. 3(A). Within 
each assembled construct we identified different regions on the basis of their different ability to 
attenuate X-rays. Fig. 3(B) shows the different attenuation peaks associated with void space (A), matrix 
deposited within bone (B), bone trabeculae (C), matrix deposited within titanium (D), and titanium 
structure (E) and the spatial distribution of voxel with the same attenuation coefficient. For all the 
groups, the volume of engineered bone, corresponding to the sum of bone matrix and bone trabeculae 
(B+C), was homogeneous after 4 weeks from implantation (Fig. 3C).  
The same result was obtained comparing the volume of engineered bone in the different groups after 8 
and 12 weeks (data not shown). For each implant, we tried to determine the bone mineral density 
(BMD) to evaluate the ongoing mineralization process (data not shown). Despite our efforts, we were 
not able to precisely quantify the density of newly formed bone matrix, since titanium caused a high 
scattering of x-rays both in the TT disk and in the surrounding bone region.  
 
Histological analysis and histomorphometry 
After 8 weeks, Toluidine Blue staining of explanted constructs revealed that poor integration occurred 
between TT and engineered bone in TT and TT+CMCA groups (Fig. 4A,B). A more consistent amount of 
newly formed tissue was found at the bone-TT interface in TT+BMSCs and TT+CMCA+BMSCs groups (Fig. 
4C,D). Upon close inspection at higher magnification, fibrovascular tissue was observed in TT+BMSCs 
group (Fig. 4E). Only in TT+CMCA+BMSCs samples, we observed areas with concentric whorls of spindle 
shaped cells with matrix deposition reminiscent of early bone formation (Fig. 4F). Representative 
histomorphometric analysis of tissue ingrowth within the constructs is shown in Fig. 4G.  
Fig. 3. Micro-CT analysis. (a) 3D rendering of the implanted construct (top image) and 3D rendering of the TT disk 
within the bone scaffold displayed in the background as 2D shaded image (bottom image) (b) Representative 
intensity histogram of tomogram data. The vertical lines indicate the threshold-based phase separation of air (A), 
matrix within bone (B), bone trabeculae (C), matrix within titanium (D) and titanium trabecular structure (E). 
Below, the resultant 2D ROIs (yellow) of the different construct compartments (A-E) superimposed on micro-CT 
sections. (c) Volume of engineered bone comprising matrix and bone trabeculae (B+C) in the different groups at 4 
weeks. Volume measures (mm
3
) are graphed as mean±SD. 
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Fig. 4. Histological and 
histomorphometric analysis of the 
constructs. Histology at 8 weeks after 
implantation: (a-d) interface between 
titanium and engineered bone in TT (a), 
TT+CMCA (b), TT+BMSCs (c), and 
TT+CMCA+BMSCs (d) (Scale bars 200 
µm); (e) bundles of fibrovascular tissue 
at bone-TT interface in TT+BMSCs (Scale 
bar 100 µm); (f) concentric layers of 
spindle cells interspersed with ECM in 
TT+CMCA+BMSCs (Scale bar 100 µm). 
Titanium (T) and engineered bone (B) 
are specified in the images. (g) 
Representative image used for 
histomorphometric analysis. TT and bone trabeculae are represented in green and newly formed tissue is 
represented in pink. (h) Quantification of tissue ingrowth at 4 and 8 weeks after implantation. Data were 
normalized respect to TT value at the same time point and expressed as fold increase (TT=1, red line).   
 
At 4 weeks, tissue ingrowth in TT, TT+BMSCs, and TT+CMCA+BMSCs samples was similar, whereas at 8 
weeks TT+BMSCs and TT+CMCA+BMSCs showed a greater tissue ingrowth compared to TT and 
TT+CMCA samples (Fig. 4H).  
 
Scanning electron microscopy (SEM) 
After 4 weeks, SEM analysis highlighted striking differences between experimental groups where TT was 
enriched with hBMSCs in 
comparison with groups where TT 
was unseeded. Indeed, matrix filled 
the space at the bone-implant 
interface in TT+BMSCs and 
TT+CMCA+BMSCs, whereas empty 
space was clearly visible in TT and 
TT+CMCA samples (Fig. 5A).  
At all the tested time-points, 
TT+CMCA+BMSCs showed a 
superior matrix content at the bone-
TT interface. A clear increase in 
quantity and organization of newly 
formed matrix was observed in this 
experimental group over time (Fig. 
5B). 
 
Fig. 5. SEM evaluation of new matrix deposition. (a) SEM images of the 
bone-TT interface (yellow arrows) 4 weeks after implantation. 
Titanium (T) and engineered bone (B) are respectively on the left and 
right side of pictures (Scale bars 500 µm). (b) SEM images of 
TT+CMCA+BMSCs at 4, 8 and 12 weeks after implantation showing the 
progressive increase in matrix organization (Scale bars 100 µm). Insets 
represent the same areas at a higher magnification (Scale bars 5 µm).  
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Mechanical pull-out tests 
Pull-out test was carried out by means of a customized apparatus (Fig. 6A,B). A representative curve of 
pull-out force is shown in Fig. 6C, 
where the maximum value 
corresponds to the maximum 
load achieved before failure 
following a mixed fracture mode 
(cohesive and adhesive). After 4 
weeks, pull-out peak force in all 
the experimental groups was 
comparable to that measured for 
TT alone. At later time points, 
the association of TT with Sr-
enriched CMCA and hBMSCs 
resulted in higher pull-out peak 
force values compared to all the 
other experimental groups. 
Furthermore, in TT+BMSCs and 
TT+CMCA+BMSCs groups, pull-
out peak force increased from 4 to 12 weeks, whereas values measured in TT+CMCA group remained 
more stable during time (Fig. 6D).  
 
Discussion 
Osseointegration, achieved through the matrix deposition at the bone-implant interface, significantly 
contributes to the success of implanted devices (3,5). In our previous in vitro study (23), we 
demonstrated that the association of TT and CMCA significantly increases cell retention within TT and 
hBMSCs osteogenic differentiation in the presence of strontium, suggesting that hBMSCs and Sr-
enriched CMCA could be combined to generate bioactive TT implants.  
In this in vivo study, we generated an ectopic model of osseointegration in athymic mice by 
subcutaneous implantation of constructs composed of engineered bone and TT, loaded or not with Sr-
enriched CMCA and hBMSCs. To evaluate the influence of these factors on implant integration, we used 
a multimodal approach combining imaging techniques, mechanical testing and histological analysis. A 
recent study by Park et al. (25) employed a subcutaneous model of osseointegration. In this proof-of-
concept study, a synthetic scaffold was loaded with BMP-2 to induce bone differentiation of the rat host 
Fig. 6. Evaluation of bone-TT integration through pull-out biomechanical 
testing. (a) Pull-out servo-hydraulic machine scheme. (b) Custom made 
construct holder. (c) Representative curve of pull-out peak force. (d) 
Quantification of pull-out peak force. For each group, the mean values of 
peak force (N) were normalized respect to the value of TT at 4 weeks, used 
as baseline (TT=1, red line). 
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cells and coupled with a compact titanium dental implant. Differently, we firstly engineered in vitro a 
construct using a decellularized bone scaffold enriched by osteogenic pre-differentiated hBMSCs, then 
we inserted a porous TT disk loaded or not with a bioactive hydrogel and human cells. In our 
subcutaneous model of osseointegration, engineered bone scaffolds were filled with high-density 
connective tissue, in accordance with results from  Park et al. (25). The formation of a vascular network 
throughout the constructs after 4 weeks suggests that, although other ectopic implant sites provide 
more efficient vascularization (24), in our model vascularization was achieved even at an early time 
point. Bone deposition was monitored by in vivo and ex vivo imaging using a fluorescent bisphosphonate 
agent (27,28). The higher signal observed in TT+CMCA+BMSCs constructs suggests that the association 
of TT with Sr-enriched CMCA and hBMSCs stimulates bone remodeling, as confirmed by the high near-
infrared fluorescence signal measured in this experimental group. Micro-CT technology is a non-
destructive technique used for the evaluation of bone regeneration and bone-implant bonding (29,30). 
In our study, micro-CT was used to verify the homogeneity of the engineered bone. We found that the 
engineered bone was homogeneous in all the experimental groups, indicating that dissimilarities among 
groups were not a consequence of differences in the surrounding engineered bone. Given the 
impossibility to evaluate the bone deposition within TT by micro-CT due to the high scattering of x-rays 
induced by titanium (29,31), we performed histological and histomorphometric analyses obtaining 
results coherent with the ones of fluorescence imaging. These data were sustained by SEM results that 
showed a superior matrix deposition in TT+CMCA+BMSCs constructs, supporting, once again, the 
hypothesis that hBMSCs and Sr cooperate in generating a stable interaction between TT and bone. Pull-
out tests were used to evaluate osseointegration (31-34). The lack of data from histological analysis at 
12 weeks did not allow us to correlate the pull-out data with the bone deposition occurring at the 
implant interface. In our experiments, pull-out peak force for TT achieved values of 15 N, being 
comparable to values reported in literature for titanium implants inserted in rat tibiae (32,33) and 
demonstrating the validity of our model. Thus, an immediate outcome of this study is the development 
of an ectopic model which could be used to analyse the effects on implant osseointegration of surface 
treatments or bioactive factors loading, as well as the influence of implanted cells, avoiding the complex 
interaction of host cells and endogenous factors that act as incontrollable variables in orthotopic models 
(24). Noticeably, the use of athymic mice is useful to test the effect of heterologous cell sources, 
allowing the use of human cells as we did here, where only cells from aged osteoarthritic patients were 
used to resemble the possible clinical application of TT implants. However, the ectopic model has 
limitations related to the absence of a native bone response and, since our results were achieved with a 
limited number of animals, a further evaluation in an orthotopic model will be performed. 
In this in vivo study, we showed that the synergic effect of osteogenic progenitor cells and Sr-enriched 
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CMCA loaded into TT enhanced matrix deposition at the bone-implant interface. Other studies have 
demonstrated that the strontium-enrichment of titanium increases bone apposition on implant surface 
and leads to greater osseointegration in orthotopic animal models (13,14). In our study, where an 
ectopic model was used, the enrichment of implant with the cellular component was crucial to achieve a 
better bone-implant integration. Indeed, the most striking differences in terms of osteodeposition and 
integration were observed between unseeded groups (TT and TT+CMCA) and groups where TT and 
TT+CMCA were enriched with hBMSCs, demonstrating the key role of osteogenic progenitor cells. 
Considering that prostheses are usually applied in aged patients, where the number and osteogenic 
potential of resident BMSCs can be diminished (21), we believe that loading the implant with autologous 
progenitor cells can be a good strategy to increase the population of bone-forming cells at the implant 
site, as reported in recent studies (18-20). In our previous in vitro study (23), we demonstrated that the 
enrichment of TT with CMCA results in significantly higher cell retention . This would ensure the 
maintenance of hBMSCs in implanted TT+CMCA prostheses, preventing cells from being washed away 
by body fluids. Autologous BMSCs have been proved safe even in the long-term period (34). We believe 
that the enrichment of TT implants with Sr-enriched CMCA and autologous BMSCs obtained with an 
intra-operative approach, would improve osseointegration with a dual action. Firstly, the enrichment of 
the osteogenic progenitor cell population would increase matrix deposition at the implant interface. 
Secondly, strontium would promote osteogenic differentiation of hBMSCs loaded into TT and resident at 
the peri-implant site.  
In conclusion, we found a positive trend in matrix deposition and implant integration when titanium was 
simultaneously enriched with strontium and hBMSCs. This positive effect could be relevant in the clinical 
practice to reduce the risk of implant mobilization, with important benefits both for patients and for 
National Health Systems. We believe that, if these outcomes will be further confirmed in an orthotopic 
model, this approach may have a considerable clinical potential, representing a step forward in respect 
to the current clinical practice. 
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Chapter 10 
Arthritic synovial fluid modulates the expression of pro- 
and anti-inflammatory mediators in macrophages 
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Abstract 
Synovitis is a common trait of osteoarthritis (OA) and rheumatoid arthritis (RA), with synovium showing 
an increased presence of macrophages. Given the key role of macrophages in arthritic pathologies, we 
investigated the effect of the stimulation with OA and RA synovial fluid (SF) on the transcriptional 
expression of pro- and anti-inflammatory mediators in different macrophage subsets. 
Adherent macrophages were cultured in non-activating conditions (M0), stimulated with IFNγ and TNFα 
towards a pro-inflammatory phenotype (M1), or with IL4 towards an anti-inflammatory phenotype 
(M2). After pre-activation, macrophages were treated for 12 hours with SF from 6 donors with no joint 
disease (Ctrl SF), 10 OA donors (OA SF) and 10 RA donors (RA SF). The transcriptional expression of IL6, 
TNFα, IL1β, IL10, CCL18, CD206 and IL1Ra was then analyzed.  
Compared to Ctrl SF, IL10 was decreased in response to RA SF in M0 and M2 macrophages. OA SF also 
decreased IL10, but only in M2 macrophages. The treatment with OA SF increased IL1ra expression in all 
macrophages subsets compared to Ctrl SF. RA SF also increased IL1ra but only in M0 macrophages. IL6 
and CCL18 expression was decreased by RA SF in M2 macrophages, whereas the other genes were not 
affected by any type of SF in any macrophage subsets. 
Since IL10 was up-regulated in response to the pro-inflammatory M1 stimulation, probably as a 
feedback mechanism, the down-regulation of IL10 and the up-regulation of IL1Ra in macrophages 
treated with arthritic SF suggest that SF from OA and RA joints is a less pro-inflammatory stimulus for 
macrophages than non-arthritic SF. This may mimic the macrophage situation in the joint, where 
feedback mechanisms are induced to counteract the ongoing pro-inflammatory processes. 
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Introduction  
Osteoarthritis (OA) and rheumatoid arthritis (RA) are widespread pathologies which severely affect 
patients quality of life. Despite specific clinical features that allow a clear distinction between OA and 
RA, synovial inflammation is a common trait (1,2). Indeed, synovitis, which causes joint swelling and 
exudation in RA patients, is observed in various degrees also in OA patients, with OA synovium showing 
a mixed inflammatory infiltrate mainly consisting of macrophages (1). 
The increased number of macrophages in the synovium of OA and RA patients, together with the 
positive effect of drugs that counteract TNFα in RA patients (3) and with the promising results of 
treatments inhibiting monocyte migration in rats (4), suggests that these cells are key players in 
triggering and maintaining the inflammatory state that eventually leads to cartilage and bone disruption. 
The central role of macrophages in arthritic pathologies supports the interest in investigating their 
phenotype in response to the stimulation with pathological signals, such as the synovial fluid (SF) of OA 
and RA patients. Indeed, it is well-known that the synovial fluid from diseased joints contains increased 
levels of pro-inflammatory and chemotactic mediators (3,5,6) and it has been previously shown that SF 
from OA and RA patients affects the immunomodulatory potential of mesenchymal stem cells (5). 
Based on these considerations, the aim of the present study was to investigate the effect of synovial 
fluid obtained from OA and RA patients on the transcriptional expression of anti-inflammatory and pro-
inflammatory mediators on macrophages isolated from peripheral blood. We hypothesized that in vivo 
OA and RA synovial fluids are able to influence the phenotype of  macrophages recruited to the joint, 
modulating the transcriptional expression of genes involved in the inflammatory process. We 
investigated this by testing the effect of OA and RA SF, using SF obtained from donors without any joint 
pathology as control, on non-activated macrophages and on macrophages activated by the treatment 
with IFNγ and TNFα (M1 activation) or IL4 (M2 activation). 
 
Materials and Methods 
Monocyte isolation 
Three buffy coats of healthy donors were obtained from the blood bank (Sanquin Bloodbank, 
Rotterdam, the Netherlands). Monocytes were isolated by Ficoll density gradient (Ficoll-Paque™ PLUS, 
GE Healthcare). Briefly, 30 mL of buffy coat diluted with 0.1% PBS/BSA (1:5 ratio) were layered on the 
top of 15 mL of Ficoll. After centrifugation (15 min, 1000g), the interphase containing peripheral blood 
mononuclear cells was collected, washed in running buffer (0.5% PBS/BSA, 2 mM EDTA), labeled with 
100 μL of anti-CD14 magnetic beads (CD14 microbeads human, MACS Separation columns LS and 
MidiMACS™ Separator; all Miltenyi Biotec), and isolated according to the manufacturer’s guidelines. 
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After selection, CD14--positive viable cells were counted by Trypan Blue exclusion. 
 
CD14-positive cells culture and stimulation 
Immediately after counting, monocytes from 3 different donors were pooled together using 2x107 cells 
from each single donor. Monocytes were seeded in 48-well plates in a concentration of 5x105 cells/cm2 
and in X-vivo 15 medium (Lonza) with 20% FCS (Lonza), 0.6% fungizone (Gibco) and 0.1% gentamycine 
(Gibco), either without any further supplement (M0), or stimulated with 10 ng/mL IFNγ (recombinant 
human interferon-γ, PeproTech) and 50 ng/ml TNFα (recombinant human tumor necrosis factor-α, 
PeproTech) to obtain an M1 phenotype or with 10 ng/mL IL-4 (recombinant human interleukin 4, 
PeproTech) to obtain an M2 phenotype. After 12h of culture (37°C, 5% CO2), triplicates from each 
condition were harvested for RNA isolation and gene expression analysis.  
 
Treatment of non-stimulated and stimulated macrophages with synovial fluid from 
control and pathological donors 
Control synovial fluid samples were obtained from donors without any joint disease (Ctrl SF, n=6). 
Arthritic synovial fluid was obtained from end-stage osteoarthritic patients (OA SF, n=10) and from 
patients affected by rheumatoid arthritis (RA SF, n=10). After 12 hours of culture under M0, M1, or M2 
conditions, medium was removed and macrophages were treated with the different types of SF. Final 
concentration of SF in each well was 50%. M0, M1, and M2 stimulating conditions were maintained 
during culture with SF to evaluate the effect of each sample of synovial fluid on non-stimulated and 
stimulated macrophages. Baseline samples were prepared by culturing macrophages in M0, M1 and M2 
conditions without adding synovial fluid. All the samples were cultured for 12 hours and then harvested 
for RNA isolation and gene expression analysis. 
 
RNA isolation and qPCR 
Samples were harvested in 350 μL RLT-buffer (Qiagen) and RNA isolation was performed using the 
RNeasy Microkit (Qiagen) according to the manufacturer’s instructions. RNA concentration was 
measured using a spectrophotometer (NanoDrop ND1000 UV–VIS, Isogen Life Science B.V.,). cDNA was 
prepared using RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas) according to the 
manufacturer’s instructions. qPCR was performed by Bio-Rad CFX96 TouchTMApplied Biosystems) using 
either Taqman Universal PCR mastermix (ABI, Branchburg) or qPCR™Mastermix Plus for SYBR® Green I 
(Eurogentec). Glyceraldehyde-3-phosphate dehydrogenase was used as housekeeper gene (GAPDH, Fw: 
GTCAACGGATTTGGTCGTATTGGG; Rev: TGCCATGGGTGGAATCATATTGG; probe: Fam-
TGGCGCCCCAACCAGCC-Tamra). For gene expression analysis, the following genes were chosen: IL6 (Fw: 
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TCGAGCCCACCGGGAACGAA, Rev: GCAGGGAAGGCAGCAGGCAA), TNFα  (Fw: GCCGCATCGCCGTCTCCTAC, 
Rev: AGCGCTGAGTCGGTCACCCT), IL1β (Fw CCCTAAACAGATGAAGTGCTCCTT, Rev 
GTAGTCGGATGCCGCCAT), IL10 (Fw: ACCTGCCTAACATGCTTCGAG, Rev: CCAGCTGATCCTTCATTTGAAAG), 
CCL18 (Fw: GCACCATGGCCCTCTGCTCC, Rev: GGGCACTGGGGGCTGGTTTC), CD206 (Fw: 
TGGCCGTATGCCGGTCACTGTTA, Rev: ACTTGTGAGGTCACCGCCTTCCT), IL1ra (Fw: 
AACAGAAAGCAGGACAAGCG, Rev: CCTTCGTCAGGCATATTGGT) (all from Eurogentec,  SybrGreen). Relative 
gene expression was calculated using the 2−ΔCT method (7). 
 
Statistical analysis 
Comparison among the different types of SF was performed by One-Way ANOVA for non-parametric 
data (Kruskal-Wallis test) with Dunnett’s multiple comparison post-hoc test. Comparison between 
baseline samples (non-treated with SF) and each experimental group was performed by unpaired T-test 
with Welch’s correction (samples with non-homogeneous variance). 
 
Results 
Stimulation of macrophages for 24 hours with IFNγ and TNFα prior to treatment with synovial fluid 
resulted in the up-regulation of IL6, TNFα, and IL1β, and in the down-regulation of CD206 demonstrating 
the effective induction of the M1 phenotype was induced. IL10 was also upregulated in M1-stimulated 
cells, probably as a feedback reaction to the pro-inflammatory stimulation. On the other hand, 
stimulation of macrophages with IL4 induced the expression of CCL18, CD206 and IL1ra confirming the 
Fig. 1. Effect of different synovial fluids on non-activated macrophages (M0). (a) Representative pictures of 
macrophages cultured without SF or with Ctrl, OA, and RA SF (magnification 10X). (b) Gene expression data 
represented as aligned dot plot with mean; each dot represents an independent data corresponding to a different 
SF donor. Dotted lines indicate the average gene expression in samples cultured without SF (* P<0.05; ** P<0.01). 
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induction of an M2 phenotype (dotted lines in each graph, Fig. 1-3).  
Cell morphology changes by the treatment with SF. In particular, in the presence of OA and RA SF a 
more elongated morphology and a higher number of clusters was seen than with macrophages cultured 
in the absence of SF (Fig. 1-3). In the macrophages without M1 or M2 stimuli (Fig. 1b), TNFα expression 
was significantly down-regulated by Ctrl SF (P<0.01) and OA SF (P<0.05), whereas no effect was 
observed for RA SF. IL10 and CD206 were up-regulated in all the types of SF (P<0.01) compared to the 
baseline, whereas IL1ra was significantly down-regulated by Ctrl SF (P<0.001) but not by OA and RA SF. 
Comparing the effect of Ctrl SF to arthritic SF, we found that (Fig. 1b, lower row) IL10 expression was 
down-regulated by the treatment with RA SF (P<0.05), while IL1ra expression was increased by OA SF 
(P<0.01) and RA SF (P<0.05). No other statistically significant differences among the SF types were 
observed for the analyzed genes. 
In M1-stimulated macrophages (Fig. 2b), the treatment with all the different types of SF induced a 
significant down-regulation of TNFα (P<0.01) and up-regulation of CD206 (P<0.05) compared to 
macrophages cultured in the absence of SF. A significant increase in IL10 levels was also observed in 
macrophages treated with OA SF compared to baseline samples (P<0.001). As already observed for M0 
macrophages, the treatment with Ctrl SF reduced the expression of IL1ra compared to macrophages 
cultured in the absence of SF (P<0.01). 
Comparing the effect of Ctrl SF and arthritic SF on M1-stimulated macrophages, we found that 
macrophages treated with OA SF expressed significantly higher levels of IL1ra compared to cells treated 
with Ctrl SF (P<0.001, Fig. 2b). No significant difference among the experimental groups was observed 
Fig. 2. Effect of different synovial fluids on M1-activated macrophages. (a) Representative pictures of macrophages 
cultured in the presence of IFNγ and TNFα without SF or with Ctrl, OA, and RA SF (magnification 10X). (b) Gene 
expression data represented as aligned dot plot with mean; each dot represents an independent data 
corresponding to a different SF donor. Dotted lines indicate the average gene expression in samples cultured 
without SF (** P<0.01). 
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for the other analyzed markers. 
In M2-stimulated macrophages (Fig. 3b) we observed the significant upregulation of IL10 and down-
regulation of IL1ra in samples treated with Ctrl SF. The treatment with OA SF and RA SF significantly 
reduced the expression of IL10 (P<0.05) in comparison with Ctrl SF. Furthermore, macrophages treated 
with OA SF expressed higher levels of IL1ra than with Ctrl SF (P<0.05), whereas IL6 and CCL18 were 
significantly lower in cells treated with RA SF than when treated with Ctrl SF (P<0.005). For the other 
tested genes we did not observe any significant difference between Ctrl SF and arthritic SF. 
 
 
Discussion 
Synovitis and an increased number of macrophages residing in the synovium are common features of 
OA and RA (1,2). The key role of this cell type in the maintenance of the inflammatory state has been 
suggested by the positive effect of drugs that counteract TNFα in RA patients (3), a pro-inflammatory 
cytokine which is tipically secreted by macrophages, and with the promising results of treatments 
inhibiting monocyte migration in rats (4). It is known that SF of OA and RA patients is enriched with 
cytokines and chemokines involved in inflammatory processes and cell recruitment (3,5,6), thus here we 
evaluated the effect of SF from OA and RA patients on the transcriptional expression of different subset 
of macrophages (M0, M1, M2).  
Among the tested genes, we found that IL10 and IL1ra were the ones mostly affected by the treatment 
with SF. IL10 is a well-recognized anti-inflammatory cytokine that we found to be induced in response to 
Fig. 3. Effect of different synovial fluids on M2-activated macrophages. (a) Representative pictures of macrophages 
cultured in the presence of IL4 without SF or with Ctrl, OA, and RA SF (magnification 10X). (b) Gene expression data 
represented as aligned dot plot with mean; each dot represents an independent data corresponding to a different 
SF donor. Dotted lines indicate the average gene expression in samples cultured without SF (* P<0.05). 
Influence of arthritic synovial fluid on macrophage phenotype 
132 
stimulation with IFNγ and TNFα as a feedback mechanism to counteract the pro-inflammatory 
stimulation. A similar effect was observed in M0 and M2 macrophages cultured in the presence of Ctrl 
SF that expressed levels of IL10 similar to those of M1 macrophages without SF. On the other hand in 
M0 and M2-stimulated macrophages, the levels of IL10 were significantly decreased by OA and RA SF 
compared to Ctrl SF. Thus, unexpectedly, in our experiments the macrophages sensed the OA and RA SF 
as less pro-inflammatory than Ctrl SF. It has been shown that IL-10 protein is produced by RA and OA 
synovial membrane cultures and that it can be detected in synovial membrane biopsies from OA and RA 
patients, whereas IL-10 is not found in normal synovial membrane (8). The presence of IL-10 in OA and 
RA SF could thus explain why in our experimental set up IL10 expression was decreased in macrophages 
treated with arthritic SF compared to macrophages treated with Ctrl SF. This interpretation may appear 
in contrast with previously published results showing that IL-10 induces the transcriptional expression of 
IL10 in a dose-dependent manner in monocyte-derived macrophages (9). However, this study also 
demonstrated that in the presence of pro-inflammatory stimuli such as LPS, the treatment with IL10 
reduced the expression of its own gene. Thus, the simultaneous presence of IL10 and pro-inflammatory 
mediators in OA and RA SF could explain our results. The differences in IL10 expression observed when 
treating M0 and M2 macrophages with OA and RA SF, were lost in M1 conditions. This is probably due 
to the strong upregulation of IL10 transcription induced by the treatment with IFNγ and TNFα. 
Concerning the expression of IL1ra, we found that this gene was down-regulated by pro-inflammatory 
stimulation with IFNγ and TNFα and up-regulated by anti-inflammatory stimulation with IL4. Accordingly 
with data on IL10 expression, Ctrl SF was recognized as a pro-inflammatory environment, leading to a 
significant reduction in IL1ra transcription in unstimulated macrophages (M0) as well as in macrophages 
stimulated towards M1 and M2 phenotype. The results from macrophages treated with OA and RA SF 
support the idea that arthritic SF represents for macrophages a less pro-inflammatory environment than 
Ctrl SF. Indeed, macrophages treated with OA SF showed significantly increased levels of IL1ra in all the 
different macrophage phenotypes, even in the macrophages stimulated towards the pro-inflammatory 
M1 phenotype. In addition IL1ra levels were significantly increased in M0 macrophages treated with RA 
SF. 
In conclusion, SF from diseased OA and RA joints is a less pro-inflammatory stimulus for macrophages 
than non-arthritic SF. This may mimic the macrophage situation in the joint, where feedback 
mechanisms are induced to counteract the ongoing pro-inflammatory processes .  
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General discussion and conclusions 
Osteoarthritis (OA) is a widespread invalidating disease that implies articular cartilage and subchondral bone 
damage as well as a chronic inflammatory state of joint, eventually leading to the complete loss of joint 
functionality (1-4). With the aim of investigating basic and translational aspects related to the development of cell-
based approaches for early and late stage OA patients, in this thesis we characterized different cell sources for 
cartilage treatment and we applied multi-disciplinary approaches for the development of three-dimensional 
constructs and for the generation of bioactive implants. Furthermore, to better characterize the OA environment, 
we investigated the effect of stimuli typical of OA joint on macrophage phenotype.  
To extend cell-based therapies involving the use of articular chondrocytes (ACs) to early OA patients, the impact of 
donor age and pathological state of cartilage on cell phenotype needs to be accurately evaluated. We isolated ACs 
from a large number of aged OA patients (Chapter 3) and we found that donor age was negatively correlated with 
the proliferation rate of ACs. The sampling of the donors included in the study (75% patients older than 63 years) 
can explain the lack of correlation between age and cellular yield. In fact, according to a previous study, the most 
relevant reduction in cellular yield is observed between patients younger than 40 years and older patients, whereas 
this feature is not affected by the increasing age in older patients (5). No significant correlation was observed 
between the level of cartilage degeneration and cellular yield and proliferation rates. However, in samples with the 
highest degree of cartilage degeneration the cellular yield was reduced. These findings together with recent data 
showing that the ability of OA chondrocytes to participate to tissue homeostasis and cartilagineous matrix 
production is impaired by senescence and epigenetic modifications (6,7), suggests that further investigations are 
needed to assess the clinical relevance of autologous OA chondrocytes in aged OA patients, especially considering 
that the application of cell-based therapies to extended lesions would require a longer expansion phase to retrieve 
a sufficient number of cells, which may greatly affect the ability of ACs to recover a differentiated phenotype. 
In order to overcome the limitations of articular chondrocytes, mesenchymal stem cells have been proposed as an 
alternative cell source for the development of cell-based chondral treatments. In particular, adipose-derived MSCs 
have been proposed as candidates for musculo-skeletal applications (8-12), thanks to their multi-differentiative 
potential and to the simplicity of adipose tissue harvesting procedure. In particular, considering the development 
of cell-based therapies for knee chondral lesions, MSCs resident in the infrapatellar fat pad (IFP-MSCs) and in the 
knee subcutaneous adipose tissue (ASCs) can be considered as promising candidates thanks to their multi-
differentiative potential and to the high accessibility of these adipose depots during knee surgery (13-15). In order 
to compare these cell sources, we performed a donor-matched evaluation of the multi-lineage potential of MSCs 
derived from infrapatellar fat pad (IFP-MSCs) and knee subcutaneous adipose tissue (ASCs) (Chapter 4). Our results 
highlighted a differential commitment of IFP-MSCs and ASCs In particular, ASCs showed a superior osteogenic 
potential, whereas IFP-MSCs were characterized by a superior chondrogenic ability. In our study both cell 
populations were isolated from the same patient, eliminating the bias of inter-donor variability. Furthermore, in 
view of a future clinical application in OA patients, cells were obtained from middle-aged and aged OA donors. The 
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immunophenotype was coherent with the one reported in previous studies for IFP-MSCs and ASCs (13,14,16-18) 
and, in accordance with literature, no difference was observed between the two cell populations (13,14). 
Significantly higher levels of osteogenic markers were observed in ASCs compared to IFP-MSCs. These results were 
different from other studies reporting a similar or higher osteogenic potential of IFP-MSCs, determined on the basis 
of qualitative stainings (14,15). The use of quantitative analyses, the inclusion of a more appropriate number of 
donors, and a more careful selection of the adipose fraction of infrapatellar fat pad may explain the different result 
obtained in our study. We also demonstrated that IFP-MSCs display a superior chondrogenic commitment 
compared to ASCs, being able to extend the findings of previous studies (13,14) to a large population of OA donors 
and providing an effective demonstration of the superior chondrogenic commitment of IFP-MSCs in this category 
of patients. Hence, despite similar surface markers expression at the undifferentiated state, we found that 
different populations of MSCs display significantly different commitment towards specific cell lineages. This 
suggests that more predictive markers should be used to identify which population of MSCs is more suitable for a 
specific clinical application, as recently proposed by studies characterizing the features of specific subsets of MSCs 
(19-21). 
Since both ACs and MSCs are promising cell candidates for chondral applications, in the last decade several groups 
have focused on the co-culture of these cell types (22). The rationale of this approach relies on the intrisinc 
chondrogenic potential of ACs and MSCs, as well as on the hypothesis that co-cultured chondrocytes may exert a 
positive influence on MSCs chondrogenesis. Results from studies investigating the co-culture of ACs with bone 
marrow-derived (23-28) and adipose-derived MSCs (23,24,29,30) suggest that the outcome of the co-culture 
approach is strongly dependent on the origin and de-differentiation state of articular chondrocytes. Considering 
the application of a co-culture approach to aged OA patients, it is evident that the impact of origin and pathological 
features of chondrocytes may be particularly relevant. To resemble a possible clinical treatment for knee lesion in 
OA patients, we performed autologous co-cultures using donor-matched IFP-MSCs, ASCs and ACs obtained from 
aged OA donors (Chapter 5). In our experiments, co-cultured ACs did not exert a chondroinductive influence on 
IFP-MSCs and ASCs. A major difference between our study and others reporting MSCs chondroinduction was the 
origin of the articular chondrocytes. Indeed, the studies demonstrating a chondroinductive effect of ACs on MSCs 
employ either animal chondrocytes (26,27,30) or non expanded healthy chondrocytes (24,25), that have a superior 
chondrogenic potential compared to expanded human ACs from aged OA patients. Furthermore, to prepare 
autologous co-cultures we had to cryopreserve ACs because of the different time required to expand ACs, IFP-MSCs 
and ASCs derived from the same donor. The cryopreservation of ACs is known to reduce the expression of 
chondrogenic genes (31) and may have further impaired the chondrogenic ability of ACs used in our experiments. 
Performing autologous co-culture, it was not possible to distinguish the response of each cell type, differently from 
studies where animal ACs are co-cultured with human MSCs and specific probes are used (24). Comparing the 
global transcriptional levels of chondrogenic genes in mono-cultures and co-cultures, we did not observe a 
significant up-regulation of chondrogenic markers in IFP-MSCs/ACs and ASCs/ACs. This result differs from literature 
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data reporting a significant up-regulation of chondogenic genes in ASCs/ACs co-culture (23). In this case, the 
discrepancy can be explained both by the different origin of ACs and by the different ASCs/ACs ratio (50:50), 
supporting the idea that several factors are involved in determining the outcome of ACs and MSCs co-culture. In 
our experiments, prolonged expansion and cryopreservation as well the origin from OA aged donors had a 
dramatic effect on the chondrogenic potential of ACs, indicating that the clinical applicability of the co-culture 
approach deserves further investigation to be extended to aged patients affected by degenerative pathologies. 
Basic and translational research in the field of cartilage tissue engineering requires the use of 3D culture models, as 
pellet cultures (32-36) and scaffolds (37,38). In the last years, low-cost rapid prototyping techniques have been 
used to produce devices for the formation and culture of cell aggregates (39-43). These technologies can also be 
exploited to generate implantable multi-well scaffolds that can be used as in vitro and in vivo screening platforms 
(44). We used laser ablation and replica molding to generate multi-well devices for pellet culture and patterned 
fibrin glue scaffold (Chapter 6). The use of multi-well devices in polydimethylsiloxane (PDMS) significantly reduced 
the time required for routinary cell culture operations, which are highly time-consuming factors when handling 
several replicates in different experimental conditions. The intrinsic features of PDMS, such as high hydrophobicity 
and optical transparency (45), allowed the formation of well-defined cell aggregates and sample monitoring by 
optical microscopy during culture. The PDMS multi-well chips well supported cell viability and differentiation of ACs 
in pellets, demonstrating their suitability for chondrogenic pellet culture. Given the possibility to seed each well 
with a specific cell population and to harvest pellets from selected wells, this system presents also a great potential 
for the indirect co-culture of multiple cell types, representing a possible alternative complementary to the trans-
well system. Exploiting the same rapid prototyping techniques, we biofabricated a multi-well implantable fibrin 
glue construct, where regions with differential cell density can be easily generated. Since cell density is known to 
affect cartilagineous matrix deposition (46,47), this scaffold can be used to evaluate if high cell density regions 
work as “chondrogenic centers”, as previously proposed by other groups that have used chondrocytes aggregates 
for scaffold seeding (48,49). Furthermore, in this scaffold different cell types can be seeded within the scaffold 
structure and in the wells, suggesting that it can used for the spatially controlled co-culture of different cell types in 
alternative to standard scaffolds (25,29).  
To develop a clinically relevant strategy for the in vitro engineering of cartilagineous tissue, different factors need 
to be combined. The use of clinically approved growth factors and scaffolds is a fundamental step to get the clinical 
translability of lab research, according to the “bench to bedside” approach. Additionally, automated systems for 
the generation and culture of 3D constructs can be implemented to satisfy the high standard safety and quality 
requirements necessary to bring tissue engineering products into the clinical practice (50). Following these 
principles, in collaboration with the group supervised by Prof. Frédéric Mallein-Gerin (Institut de Biologie et Chimie 
des Proteines, Lyon, France), we used a perfusion bioreactor to improve the quality and distribution of matrix 
produced by articular chondrocytes cultured within a 3D scaffold. A collagen sponge approved for clinical use was 
used as scaffold and expansion and re-differentiation of ACs was performed using a specific cocktail of clinically 
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approved growth factors (Chapter 7). The perfusion bioreactor  used in our experiments (OPB, Oscillating Perfusion 
Bioreactor) allowed the simultaneous culture of up to 18 samples in independent chambers, providing a promising 
platform to generate in parallel several constructs. We found that cell distribution and matrix homogeneity were 
increased by perfusion culture. In particular, only samples cultured in dynamic conditions showed matrix 
deposition into the scaffold core, whereas in the inner region of sponges cultured in dynamic conditions we 
observed poor presence of cells and matrix. In dynamic conditions, the rounded morphology typical of native 
chondrocytes was restored, indicating the re-differentiation of ACs (51-54), as also suggested by the reduced 
expression of type I collagen and by the superior type II/type I collagen ratio. Both dynamic culture and the re-
differentiation cocktail were needed to induce cell rounding and the deposition of cartilagineous matrix throughout 
the collagen sponges, suggesting a synergistic action of soluble factors and culture regimen. Differently from other 
studies (55,56), we did not observe an increase in the amount of total matrix in dynamically cultured scaffolds. In 
our experimental set-up perfusion culture improved the homogeneity and quality, but not the overall quantity, of 
extracellular matrix. We tested two different perfusion protocols, shifting from a program working at costant speed 
to a program applying a slow perfusion speed in the first days of culture and repeated cycles of increasing speed in 
the following days (56-58), but we did not observe major differences between them in terms of matrix deposition. 
In this study we implemented some of the requirements for clinical translability of engineered tissue, such as the 
use of clinically approved reagents and scaffolds and the use of automated culture systems. Given the observed 
increase in the quality and homogeneity of extracellular matrix, the use of perfusion bioreactors in combination 
with optimized culture protocols holds great promises for the in vitro generation of clinically relevant engineered 
grafts, overcoming the limitations of static culture that directly correlate with the increasing size of the engineered 
tissues and providing a tool to improve automation and reproducibility of tissue engineering processes.  
Despite their great potential for the treatment of articular cartilage defects, cell-based approaches aiming at 
cartilage restoration are not clinically relevant when considering late stage OA joints with extensive lesions to 
cartilage and exposure of subchondral bone. In these patients, joint replacement is currently the only available 
clinical option and cell-based therapies can be used to overcome limitations of implant technology. In cementless 
implants the improvement of implant osseointegration is a key requirement to grant implant stability. In order to 
generate a bioactive implant with improved osseointegration we combined a macroporous titanium (Trabecular 
Titanium™, TT) with a strontium enriched hydrogel (CMCA) and bone marrow-derived MSCs (BMSCs) (Chapter 8, 
Chapter 9). Strontium was chosen as osteoinductive factors due to its positive effect on osteodeposition and for its 
intrinsic features, such as low price and high stability. BMSCs were chosen as osteoprogenitor cells, since they can 
participate to the bone healing process and can be isolated with an intra-operative approach (59,60). We found 
that the association of macroporous titanium with a biocompatible hydrogel significantly increased cell retention 
within titanium, which could be critical during and immediately after surgery whereby cells can be washed away by 
body fluids. Strontium proved to be effective in improving BMSCs osteogenic differentiation, being suitable for the 
generation of enriched osteoinductive titanium implants. We tested the performance of this composite bioactive 
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implant in an in vivo ectopic model of osseointegration. To do that, we engineered in vitro a cell-seeded bone 
scaffold in order to mimic the bone and we grafted the titanium implant either unloaded or loaded with BMSCs 
and/or Sr-enriched CMCA. The use of athymic mice in our in vivo model allowed us to use a clinically relevant cell 
source (i.e. BMSCs obtained from aged OA patients) and to clearly distinguish the effect of implanted cells and 
strontium. However, the ectopic model has limitations related to the absence of a native bone response which in in 
vivo orthotopic implants plays a key role in promoting bone deposition. In accordance with previous study 
demonstrating that the enrichment of implants with progenitor cells (59,61,62) or strontium (63,64) leads to an 
improved osseointegration, we found a positive trend in matrix deposition and implant integration when titanium 
was simultaneously enriched with BMSCs and strontium. Considering that prostheses are usually applied in aged 
patients, where the number and osteogenic potential of resident BMSCs can be reduced (65), loading the implant 
with autologous progenitor cells may represent a successful strategy to increase the population of bone-forming 
cells at the implant site. We believe that the use of bioactive implants loaded with Sr-enriched CMCA and 
autologous BMSCs obtained with an intra-operative approach would improve osseointegration with a dual action. 
Firstly, the enrichment of the osteogenic progenitor cell population would increase matrix deposition at the 
implant interface. Secondly, strontium would promote osteogenic differentiation of BMSCs loaded into TT and 
resident at the peri-implant site. The synergic action of these factors can be relevant in the clinical practice to 
reduce the risk of implant mobilization, with possible benefits for patients and for National Health Systems. If these 
outcomes will be further confirmed in an orthotopic model, this approach may have a considerable clinical 
potential, representing a step forward respect to the current clinical practice. 
Cell-based approaches have a great potential and can be exploited in different ways for the treatment of OA 
patients (66,67). However, the impact of the inflammatory state of OA joints on re-implanted cells cannot be 
neglected and deserves further investigation. The newly accepted role of cytokines and immune cells in OA 
progression (4,68,69) involves the recognition that implanted cells and/or constructs may be subjected to the same 
inflammatory stimuli that contributed to joint damage, which may negatively affect the outcome of cell-based 
approaches (70-74). In order to better evaluate the impact of OA environment on re-implanted cells or constructs, 
in vitro models mimicking the OA joint are needed. These models should comprise soluble factors present in the 
OA joint and key cell types, such as macrophages that drive the pro-inflammatory and catabolic processes in OA 
(75-77). In collaboration with the Connective Tissue Cells and Repair group supervised by Prof. Gerjo J.V.M. van 
Osch (Erasmus MC, Rotterdam, The Netherlands), we investigated the effect of OA stimuli (i.e. soluble factors 
contained in the synovial fluids of OA patients) on the phenotype of different subsets of macrophages (M0, M1, 
M2) (Chapter 10). The transcriptional expression of several pro- and anti-inflammatory mediators was analyzed in 
the presence of synovial fluid obtained from donors without any joint disease and from OA donors. We found that 
the expression of specific genes (IL10 and IL1ra) was affected by the treatment with arthritic synovial fluid, 
demonstrating that pathological environment is able to influence the phenotype of macrophages. Further 
investigations are needed to determine if the observed transcriptional changes correspond to alterations in the 
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release of soluble factors that, in the joint, may influence the tissues in direct contact with the synovial fluid and 
the fate of implanted cells or engineered grafts. On the other hand, the immunomodulatory properties of MSCs 
may also play a role in determining the outcome of cell-based approach employing MSCs as cell source. Indeed, 
MSCs potential resides not only in their multi-differentiative potential, but also in their ability to suppress pro-
inflammatory processes (78,79), as shown by the promising results obtained through local delivery of MSCs in 
preclinical models of joint disease, indicating that MSCs paracrine signalling might be more even more relevant 
than their differentiative potential in stimulating tissue repair. The immunomodulatory function of MSCs is able to 
influence also macrophage phenotype, inducing them to shift from a pro-inflammatory to an anti-inflammatory 
phenotype (80,81), an ability that may be particularly relevant when treating OA patients with MSCs-based 
approaches. Thus, the assessment of the therapeutic potency of specific subsets of MSCs should include the 
evaluation of the ability to secrete immunomodulatory paracrine factors in addition to the traditional assays based 
on the expression of specific cell-surface markers and the characterization of multi-lineage potential.   
Altogether these findings indicate the need for basic and translational studies better resembling the multi-factorial 
complexity that is found in OA joints. This complexity is reflected in the impaired phenotype of OA chondrocytes as 
well as in the inflammatory environment of joint, that may negatively affect the outcome of cell-based approaches. 
Thus, the suitability of OA articular chondrocytes for the treatment of extensive lesions in OA patients still deserves 
further investigation. Basic and translational studies should face practical issues such as the optimization of 
clinically approved protocols for in vitro expansion and re-differentiation of OA chondrocytes, which represent a 
key step towards the clinical applicability of this cell source to OA lesions given the higher number of cells required 
and the reduced chondrogenic potential of ACs from aged OA donors. In the same way, the evaluation of the 
clinical relevance of the co-culture approach should not neglect the impact of these negative features on the 
chondroinductive potential of ACs. In this field, further investigation is needed to verify whether it is possible to 
extend the promising results obtained using non-expanded healthy articular chondrocytes to co-cultures involving 
the use of expanded OA chondrocytes from aged patients. Besides articular chondrocytes, MSCs can be considered 
a promising tool for the development of novel cell-based approaches. Here, the identification of specific subsets of 
MSCs displaying a peculiar commitment should drive the selection of the most suitable cell candidate for a specific 
application. Indeed, despite common features that allow the identification of MSCs (i.e. expression of typical cell 
surface markers, multi-differentiative potential), specific populations of MSCs harvested from different anatomical 
sytes have intrinsic features that make them more or less suitable for a specific application. Hence, more predictive 
markers for the evaluation of the therapeutic potency of different populations of MSCs should be identified and 
this analysis should include the evaluation of their paracrine immunomodulatory function in a novel view of MSCs 
as potential “anti-inflammatory drugs”. The implementation of 3D culture models and automated devices for the 
production and culture of engineered grafts is also a key step in the process bringing the results obtained in tissue 
engineering labs into the clinical practice. In particular, the optimization of high-throughput 3D culture systems is 
fundamental in the basic research for the optimization of chondrogenic differentiation protocols and for the study 
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of the cross-talk between different cell types, whereas automated dynamic culture systems can be exploited to 
engineer clinically relevant grafts, overcoming the limitations of static culture and granting high quality and safety 
standards. This multidisciplinary approach can be also exploited for the cell-based improvement of existing 
therapeutic options, as we suggested for the improvement of implant osseointegration through the association of 
multiple elements comprising mesenchymal stem cells, osteoinductive factors, biocompatible hydrogels and 
macroporous titanium. Finally, the investigation of pro-inflammatory processes ongoing in the OA joints can drive 
the development of novel in vitro models to evaluate the fate of cell and engineered constructs implanted in a 
diseased environment.  
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